

### Weekly Total Prescriptions

| 2-Jul-10 | 9-Jul-10 | 16-Jul-10 | 23-Jul-10 | 30-Jul-10 | 6-Aug-10 | 13-Aug-10 | 20-Aug-10 | 27-Aug-10 |       |
|----------|----------|-----------|-----------|-----------|----------|-----------|-----------|-----------|-------|
| 24,158   | 20,973   | 22,969    | 22,960    | 22,532    | 22,515   | 22,651    | 22,613    | 22,473    |       |
| 2,364    | 2,193    | 2,284     | 2,308     | 2,280     | 2,326    | 2,276     | 2,213     | 2,322     |       |
| 38,932   | 33,905   | 36,256    | 36,508    | 35,824    | 36,261   | 35,634    | 36,541    | 35,785    |       |
| 9,701    | 8,686    | 9,341     | 9,201     | 9,066     | 9,244    | 9,478     | 9,519     | 9,145     |       |
| 37,408   | 32,071   | 33,737    | 34,402    | 33,455    | 34,392   | 32,965    | 34,230    | 33,535    |       |
| 9,571    | 8,699    | 9,169     | 9,091     | 8,870     | 9,341    | 9,228     | 9,354     | 9,189     |       |
| 31,615   | 28,074   | 29,924    | 30,061    | 29,034    | 30,577   | 30,319    | 30,398    | 29,070    |       |
| 153,749  | 134,601  | 143,680   | 144,531   | 141,061   | 144,656  | 142,551   | 144,868   | 141,519   |       |
| 7,290    | 6,169    | 6,804     | 6,779     | 6,519     | 6,476    | 6,421     | 6,354     | 6,279     |       |
| 11,562   | 10,129   | 10,579    | 10,865    | 10,449    | 10,614   | 10,580    | 10,150    | 9,216     |       |
| 6,624    | 5,701    | 6,072     | 6,241     | 5,973     | 6,307    | 6,044     | 6,291     | 6,012     |       |
| 4,210    | 3,754    | 4,030     | 3,934     | 3,949     | 4,044    | 4,058     | 4,087     | 4,035     |       |
| 29,686   | 25,753   | 27,485    | 27,819    | 26,890    | 27,441   | 27,103    | 26,882    | 25,542    |       |
| 16,868   | 14,804   | 16,165    | 16,181    | 16,013    | 16,037   | 16,204    | 15,751    | 14,610    |       |
| 2,364    | 2,193    | 2,284     | 2,308     | 2,280     | 2,325    | 2,269     | 2,092     | 2,051     |       |
| 27,370   | 23,776   | 25,677    | 25,643    | 25,374    | 25,646   | 25,006    | 25,527    | 23,270    |       |
| 9,701    | 8,686    | 9,341     | 9,201     | 9,066     | 9,243    | 9,463     | 9,254     | 8,381     |       |
| 30,784   | 26,370   | 27,665    | 28,161    | 27,482    | 28,082   | 26,829    | 26,466    | 23,102    |       |
| 9,571    | 8,699    | 9,169     | 9,091     | 8,870     | 9,340    | 9,201     | 8,982     | 7,908     |       |
| 27,405   | 24,320   | 25,894    | 26,127    | 25,083    | 26,528   | 26,166    | 23,600    | 18,678    |       |
| 124,063  | 108,848  | 116,195   | 116,712   | 114,168   | 117,201  | 115,138   | 111,672   | 98,000    |       |
|          |          |           |           |           |          | 2         | 26        | 508       | 1,584 |
|          |          |           |           |           |          | 1         | 7         | 121       | 271   |
|          |          |           |           | 1         | 1        | 48        | 864       | 3,299     |       |
|          |          |           |           |           | 1        | 15        | 265       | 764       |       |
|          |          |           |           |           | 3        | 92        | 1,473     | 4,421     |       |
|          |          |           |           |           | 1        | 27        | 372       | 1,281     |       |
|          |          |           |           | 2         | 5        | 95        | 2,711     | 6,357     |       |
| -        | -        | -         | -         | 3         | 14       | 310       | 6,314     | 17,977    |       |
| 16,868   | 14,804   | 16,165    | 16,181    | 16,013    | 16,039   | 16,230    | 16,259    | 16,194    |       |
| 2,364    | 2,193    | 2,284     | 2,308     | 2,280     | 2,326    | 2,276     | 2,213     | 2,322     |       |



| 3-Sep-10 | 10-Sep-10 | 17-Sep-10 | 24-Sep-10 | 1-Oct-10 | 8-Oct-10 | 15-Oct-10 | 22-Oct-10 | 29-Oct-10 |
|----------|-----------|-----------|-----------|----------|----------|-----------|-----------|-----------|
| 23,538   | 20,825    | 23,321    | 22,943    | 23,218   | 22,993   | 22,827    | 22,771    | 22,415    |
| 2,581    | 2,252     | 2,456     | 2,311     | 2,553    | 2,467    | 2,418     | 2,429     | 2,382     |
| 37,815   | 32,953    | 36,857    | 35,692    | 37,173   | 35,128   | 35,294    | 34,678    | 34,505    |
| 9,984    | 8,856     | 9,898     | 9,364     | 9,693    | 9,453    | 9,628     | 9,483     | 9,200     |
| 35,737   | 30,934    | 33,762    | 32,509    | 33,460   | 31,714   | 31,957    | 31,661    | 30,784    |
| 9,923    | 9,089     | 9,510     | 9,237     | 9,659    | 9,209    | 9,207     | 8,951     | 8,753     |
| 30,082   | 26,029    | 28,055    | 26,103    | 26,565   | 25,345   | 25,492    | 24,913    | 24,417    |
| 149,660  | 130,938   | 143,859   | 138,159   | 142,321  | 136,309  | 136,823   | 134,886   | 132,456   |
| 6,509    | 5,622     | 6,225     | 6,361     | 6,290    | 6,133    | 5,595     | 4,918     | 4,110     |
| 8,647    | 6,848     | 8,153     | 8,295     | 7,920    | 6,893    | 6,118     | 5,641     | 4,857     |
| 6,545    | 5,769     | 6,467     | 6,603     | 6,986    | 6,944    | 7,302     | 7,000     | 6,284     |
| 4,531    | 4,291     | 4,752     | 5,063     | 5,565    | 5,681    | 6,232     | 6,461     | 6,506     |
| 26,232   | 22,530    | 25,597    | 26,322    | 26,761   | 25,651   | 25,247    | 24,020    | 21,757    |
| 13,547   | 10,675    | 10,233    | 8,374     | 7,346    | 6,171    | 5,454     | 4,971     | 4,250     |
| 2,191    | 1,721     | 1,740     | 1,527     | 1,538    | 1,389    | 1,238     | 1,171     | 1,023     |
| 21,599   | 16,247    | 14,434    | 10,835    | 9,416    | 7,477    | 6,170     | 5,319     | 4,355     |
| 8,322    | 6,730     | 6,329     | 4,929     | 4,514    | 3,839    | 3,287     | 2,751     | 2,412     |
| 20,664   | 14,908    | 12,789    | 9,812     | 8,328    | 6,550    | 5,332     | 4,401     | 3,692     |
| 7,705    | 6,061     | 5,461     | 4,395     | 3,952    | 3,182    | 2,762     | 2,331     | 1,931     |
| 15,716   | 11,132    | 9,872     | 7,096     | 6,011    | 4,608    | 3,859     | 3,215     | 2,570     |
| 89,744   | 67,474    | 60,858    | 46,968    | 41,105   | 33,216   | 28,102    | 24,159    | 20,233    |
| 3,482    | 4,528     | 6,863     | 8,208     | 9,582    | 10,689   | 11,778    | 12,882    | 14,055    |
| 390      | 531       | 716       | 784       | 1,015    | 1,078    | 1,180     | 1,258     | 1,359     |
| 7,569    | 9,858     | 14,270    | 16,562    | 19,837   | 20,758   | 23,006    | 23,718    | 25,293    |
| 1,662    | 2,126     | 3,569     | 4,435     | 5,179    | 5,614    | 6,341     | 6,732     | 6,788     |
| 8,528    | 10,257    | 14,506    | 16,094    | 18,146   | 18,220   | 19,323    | 20,260    | 20,808    |
| 2,218    | 3,028     | 4,049     | 4,842     | 5,707    | 6,027    | 6,445     | 6,620     | 6,822     |
| 9,835    | 10,606    | 13,431    | 13,944    | 14,989   | 15,056   | 15,401    | 15,237    | 15,341    |
| 33,684   | 40,934    | 57,404    | 64,869    | 74,455   | 77,442   | 83,474    | 86,707    | 90,466    |
| 17,029   | 15,203    | 17,096    | 16,582    | 16,928   | 16,860   | 17,232    | 17,853    | 18,305    |
| 2,581    | 2,252     | 2,456     | 2,311     | 2,553    | 2,467    | 2,418     | 2,429     | 2,382     |



| 5-Nov-10 | 12-Nov-10 | 19-Nov-10 | 26-Nov-10 | 3-Dec-10 | 10-Dec-10 | 17-Dec-10 | 24-Dec-10 | 31-Dec-10 |
|----------|-----------|-----------|-----------|----------|-----------|-----------|-----------|-----------|
| 22,850   | 22,537    | 23,456    | 19,438    | 23,538   | 22,620    | 23,239    | 22,281    | 18,352    |
| 2,538    | 2,505     | 2,442     | 2,180     | 2,711    | 2,481     | 2,466     | 2,315     | 2,113     |
| 35,192   | 33,996    | 35,000    | 30,049    | 37,108   | 33,914    | 34,504    | 33,339    | 27,995    |
| 9,309    | 9,345     | 9,616     | 8,188     | 10,352   | 9,478     | 9,677     | 9,077     | 8,127     |
| 30,872   | 29,854    | 30,760    | 26,900    | 32,627   | 29,183    | 29,911    | 28,487    | 25,317    |
| 8,910    | 8,747     | 9,083     | 7,864     | 9,531    | 8,739     | 8,654     | 8,473     | 7,413     |
| 24,207   | 23,942    | 24,768    | 21,371    | 25,838   | 23,879    | 23,877    | 22,109    | 20,085    |
| 133,878  | 130,926   | 135,125   | 115,990   | 141,705  | 130,294   | 132,328   | 126,081   | 109,402   |
| 3,480    | 2,988     | 2,880     | 2,263     | 2,483    | 2,085     | 1,567     | 1,353     | 1,045     |
| 4,685    | 4,241     | 4,201     | 3,346     | 4,138    | 3,466     | 3,567     | 3,236     | 2,797     |
| 5,231    | 3,938     | 3,373     | 2,588     | 2,697    | 2,109     | 1,916     | 2,817     | 3,490     |
| 6,633    | 6,763     | 7,133     | 6,367     | 7,561    | 6,739     | 6,010     | 5,089     | 4,005     |
| 20,029   | 17,930    | 17,587    | 14,564    | 16,879   | 14,399    | 13,060    | 12,495    | 11,337    |
| 4,041    | 3,464     | 3,150     | 2,411     | 2,752    | 2,332     | 1,717     | 1,930     | 1,517     |
| 912      | 904       | 810       | 683       | 736      | 670       | 488       | 517       | 458       |
| 3,886    | 3,118     | 2,900     | 2,407     | 2,578    | 2,234     | 1,728     | 1,784     | 1,333     |
| 2,214    | 1,964     | 1,771     | 1,335     | 1,408    | 1,201     | 1,122     | 1,190     | 1,004     |
| 3,323    | 2,914     | 2,704     | 2,070     | 2,391    | 1,947     | 1,591     | 1,449     | 1,205     |
| 1,770    | 1,554     | 1,566     | 1,109     | 1,301    | 1,054     | 870       | 890       | 720       |
| 2,079    | 1,848     | 1,742     | 1,317     | 1,515    | 1,417     | 1,101     | 1,014     | 975       |
| 18,225   | 15,766    | 14,643    | 11,332    | 12,681   | 10,855    | 8,617     | 8,774     | 7,212     |
| 15,329   | 16,085    | 17,426    | 14,764    | 18,303   | 18,203    | 19,955    | 18,998    | 15,790    |
| 1,626    | 1,601     | 1,632     | 1,497     | 1,975    | 1,811     | 1,978     | 1,798     | 1,655     |
| 26,621   | 26,637    | 27,899    | 24,296    | 30,392   | 28,214    | 29,209    | 28,319    | 23,865    |
| 7,095    | 7,381     | 7,845     | 6,853     | 8,944    | 8,277     | 8,555     | 7,887     | 7,123     |
| 22,318   | 23,002    | 24,683    | 22,242    | 27,539   | 25,127    | 26,404    | 24,221    | 20,622    |
| 7,140    | 7,193     | 7,517     | 6,755     | 8,230    | 7,685     | 7,784     | 7,583     | 6,693     |
| 15,495   | 15,331    | 15,893    | 13,687    | 16,762   | 15,723    | 16,766    | 16,006    | 15,105    |
| 95,624   | 97,230    | 102,895   | 90,094    | 112,145  | 105,040   | 110,651   | 104,812   | 90,853    |
| 19,370   | 19,549    | 20,576    | 17,175    | 21,055   | 20,535    | 21,672    | 20,928    | 17,307    |
| 2,538    | 2,505     | 2,442     | 2,180     | 2,711    | 2,481     | 2,466     | 2,315     | 2,113     |



| 7-Jan-11 | 14-Jan-11 | 21-Jan-11 | 28-Jan-11 | 4-Feb-11 | 11-Feb-11 | 18-Feb-11 | 25-Feb-11 | 4-Mar-11 |
|----------|-----------|-----------|-----------|----------|-----------|-----------|-----------|----------|
| 22,404   | 21,599    | 21,655    | 20,631    | 21,487   | 21,641    | 21,137    | 20,378    | 23,229   |
| 2,590    | 2,391     | 2,348     | 2,361     | 2,397    | 2,462     | 2,471     | 2,309     | 2,702    |
| 34,434   | 32,962    | 32,331    | 30,654    | 32,355   | 33,036    | 31,922    | 30,055    | 35,637   |
| 9,871    | 9,526     | 9,164     | 8,689     | 9,428    | 9,369     | 9,184     | 8,654     | 10,448   |
| 29,970   | 28,701    | 27,923    | 26,325    | 28,379   | 28,346    | 27,402    | 26,111    | 31,060   |
| 8,931    | 8,536     | 8,390     | 7,715     | 8,531    | 8,467     | 8,473     | 7,744     | 9,440    |
| 23,157   | 22,060    | 20,698    | 19,593    | 21,340   | 20,931    | 19,578    | 18,754    | 22,514   |
| 131,357  | 125,775   | 122,509   | 115,968   | 123,917  | 124,252   | 120,167   | 114,005   | 135,030  |
| 1,076    | 902       | 911       | 851       | 808      | 696       | 648       | 590       | 612      |
| 3,487    | 3,178     | 3,092     | 2,854     | 2,934    | 2,724     | 2,311     | 1,851     | 1,660    |
| 3,887    | 4,174     | 4,254     | 3,818     | 3,766    | 3,541     | 2,994     | 2,639     | 2,628    |
| 3,897    | 3,035     | 2,283     | 1,518     | 1,178    | 991       | 683       | 487       | 456      |
| 12,347   | 11,289    | 10,540    | 9,041     | 8,686    | 7,952     | 6,636     | 5,567     | 5,356    |
| 1,841    | 1,678     | 1,630     | 1,475     | 1,582    | 1,579     | 1,467     | 1,304     | 1,444    |
| 606      | 522       | 543       | 512       | 504      | 560       | 479       | 493       | 530      |
| 1,680    | 1,616     | 1,454     | 1,391     | 1,395    | 1,452     | 1,305     | 1,233     | 1,407    |
| 1,170    | 1,048     | 1,037     | 994       | 1,020    | 977       | 925       | 865       | 1,008    |
| 1,417    | 1,335     | 1,157     | 1,058     | 1,200    | 1,143     | 1,029     | 920       | 1,086    |
| 823      | 811       | 809       | 673       | 674      | 687       | 711       | 601       | 720      |
| 1,219    | 1,078     | 1,083     | 993       | 1,125    | 948       | 889       | 810       | 899      |
| 8,756    | 8,088     | 7,713     | 7,096     | 7,500    | 7,346     | 6,805     | 6,226     | 7,094    |
| 19,487   | 19,019    | 19,114    | 18,305    | 19,097   | 19,366    | 19,022    | 18,484    | 21,173   |
| 1,984    | 1,869     | 1,805     | 1,849     | 1,893    | 1,902     | 1,992     | 1,816     | 2,172    |
| 29,267   | 28,168    | 27,785    | 26,409    | 28,026   | 28,860    | 28,306    | 26,971    | 32,570   |
| 8,701    | 8,478     | 8,127     | 7,695     | 8,408    | 8,392     | 8,259     | 7,789     | 9,440    |
| 24,666   | 23,192    | 22,512    | 21,449    | 23,413   | 23,662    | 23,379    | 22,552    | 27,346   |
| 8,108    | 7,725     | 7,581     | 7,042     | 7,857    | 7,780     | 7,762     | 7,143     | 8,720    |
| 18,041   | 17,947    | 17,332    | 17,082    | 19,037   | 18,992    | 18,006    | 17,457    | 21,159   |
| 110,254  | 106,398   | 104,256   | 99,831    | 107,731  | 108,954   | 106,726   | 102,212   | 122,580  |
| 21,328   | 20,697    | 20,744    | 19,780    | 20,679   | 20,945    | 20,489    | 19,788    | 22,617   |
| 2,590    | 2,391     | 2,348     | 2,361     | 2,397    | 2,462     | 2,471     | 2,309     | 2,702    |



| 11-Mar-11 | 18-Mar-11 | 25-Mar-11 | 1-Apr-11 | 8-Apr-11 | 15-Apr-11 | 22-Apr-11 | 29-Apr-11 | 6-May-11 |
|-----------|-----------|-----------|----------|----------|-----------|-----------|-----------|----------|
| 21,235    | 20,322    | 20,259    | 20,077   | 20,994   | 20,462    | 19,783    | 19,873    | 21,283   |
| 2,519     | 2,322     | 2,442     | 2,416    | 2,555    | 2,492     | 2,440     | 2,480     | 2,587    |
| 31,337    | 29,748    | 29,199    | 30,213   | 30,942   | 29,481    | 29,004    | 29,421    | 31,742   |
| 9,146     | 8,875     | 8,523     | 9,024    | 9,256    | 9,085     | 8,599     | 8,830     | 9,662    |
| 26,567    | 25,810    | 25,280    | 26,156   | 26,639   | 25,334    | 24,847    | 25,361    | 27,355   |
| 8,313     | 7,993     | 7,734     | 8,028    | 8,467    | 8,203     | 7,729     | 8,023     | 8,874    |
| 19,723    | 18,413    | 17,850    | 18,975   | 19,274   | 17,659    | 17,130    | 18,106    | 19,600   |
| 118,840   | 113,483   | 111,287   | 114,889  | 118,127  | 112,716   | 109,532   | 112,094   | 121,103  |
| 546       | 440       | 430       | 383      | 379      | 396       | 362       | 332       | 323      |
| 1,294     | 1,013     | 810       | 702      | 637      | 545       | 482       | 420       | 402      |
| 2,046     | 1,903     | 1,831     | 1,735    | 1,773    | 1,730     | 1,652     | 1,672     | 1,749    |
| 350       | 285       | 235       | 197      | 177      | 184       | 159       | 88        | 83       |
| 4,236     | 3,641     | 3,306     | 3,017    | 2,966    | 2,855     | 2,655     | 2,512     | 2,557    |
| 991       | 1,010     | 941       | 852      | 862      | 806       | 720       | 658       | 686      |
| 414       | 368       | 388       | 378      | 352      | 388       | 354       | 316       | 330      |
| 949       | 897       | 814       | 763      | 731      | 638       | 586       | 555       | 605      |
| 669       | 624       | 565       | 611      | 647      | 595       | 488       | 454       | 465      |
| 749       | 718       | 742       | 686      | 607      | 542       | 504       | 461       | 482      |
| 495       | 465       | 433       | 430      | 377      | 378       | 387       | 308       | 383      |
| 681       | 546       | 528       | 537      | 490      | 379       | 411       | 344       | 365      |
| 4,948     | 4,628     | 4,411     | 4,257    | 4,066    | 3,726     | 3,450     | 3,096     | 3,316    |
| 19,698    | 18,872    | 18,888    | 18,842   | 19,753   | 19,260    | 18,701    | 18,883    | 20,274   |
| 2,105     | 1,954     | 2,054     | 2,038    | 2,203    | 2,104     | 2,086     | 2,164     | 2,257    |
| 29,094    | 27,838    | 27,575    | 28,748   | 29,574   | 28,298    | 27,936    | 28,446    | 30,735   |
| 8,477     | 8,251     | 7,958     | 8,413    | 8,609    | 8,490     | 8,111     | 8,376     | 9,197    |
| 23,772    | 23,189    | 22,707    | 23,735   | 24,259   | 23,062    | 22,691    | 23,228    | 25,124   |
| 7,818     | 7,528     | 7,301     | 7,598    | 8,090    | 7,825     | 7,342     | 7,715     | 8,491    |
| 18,692    | 17,582    | 17,087    | 18,241   | 18,607   | 17,096    | 16,560    | 17,674    | 19,152   |
| 109,656   | 105,214   | 103,570   | 107,615  | 111,095  | 106,135   | 103,427   | 106,486   | 115,230  |
| 20,689    | 19,882    | 19,829    | 19,694   | 20,615   | 20,066    | 19,421    | 19,541    | 20,960   |
| 2,519     | 2,322     | 2,442     | 2,416    | 2,555    | 2,492     | 2,440     | 2,480     | 2,587    |



| 13-May-11 | 20-May-11 | 27-May-11 | 3-Jun-11 | 10-Jun-11 | 17-Jun-11 | 24-Jun-11 | 1-Jul-11 | 8-Jul-11 |
|-----------|-----------|-----------|----------|-----------|-----------|-----------|----------|----------|
| 19,945    | 20,035    | 20,679    | 18,713   | 20,161    | 19,944    | 19,897    | 21,040   | 18,187   |
| 2,536     | 2,446     | 2,564     | 2,333    | 2,585     | 2,485     | 2,473     | 2,680    | 2,419    |
| 29,273    | 28,675    | 29,834    | 28,258   | 29,188    | 28,918    | 28,805    | 31,285   | 27,058   |
| 8,984     | 8,836     | 9,188     | 8,779    | 8,993     | 9,002     | 9,037     | 9,671    | 8,573    |
| 24,931    | 24,596    | 25,742    | 24,609   | 24,794    | 24,359    | 24,832    | 26,202   | 23,329   |
| 7,878     | 7,858     | 8,324     | 7,943    | 8,134     | 7,781     | 8,079     | 8,710    | 7,614    |
| 17,455    | 17,117    | 18,250    | 17,563   | 17,575    | 17,126    | 17,619    | 18,978   | 16,346   |
| 111,002   | 109,563   | 114,581   | 108,198  | 111,430   | 109,615   | 110,742   | 118,566  | 103,526  |
| 331       | 288       | 300       | 244      | 223       | 245       | 219       | 221      | 214      |
| 371       | 344       | 339       | 308      | 293       | 277       | 256       | 275      | 238      |
| 1,653     | 1,549     | 1,674     | 1,571    | 1,640     | 1,576     | 1,641     | 1,753    | 1,454    |
| 82        | 64        | 64        | 44       | 69        | 45        | 55        | 52       | 58       |
| 2,437     | 2,245     | 2,377     | 2,167    | 2,225     | 2,143     | 2,171     | 2,301    | 1,964    |
| 575       | 526       | 449       | 435      | 394       | 375       | 360       | 389      | 294      |
| 264       | 261       | 237       | 200      | 235       | 212       | 204       | 225      | 176      |
| 429       | 417       | 365       | 351      | 312       | 342       | 281       | 280      | 268      |
| 404       | 296       | 301       | 275      | 261       | 277       | 251       | 239      | 243      |
| 330       | 311       | 289       | 239      | 240       | 227       | 216       | 180      | 201      |
| 241       | 238       | 223       | 224      | 183       | 164       | 162       | 170      | 148      |
| 260       | 227       | 202       | 212      | 179       | 152       | 143       | 162      | 111      |
| 2,503     | 2,276     | 2,066     | 1,936    | 1,804     | 1,749     | 1,617     | 1,645    | 1,441    |
| 19,039    | 19,221    | 19,930    | 18,034   | 19,544    | 19,324    | 19,318    | 20,430   | 17,679   |
| 2,272     | 2,185     | 2,327     | 2,133    | 2,350     | 2,273     | 2,269     | 2,455    | 2,243    |
| 28,473    | 27,914    | 29,130    | 27,599   | 28,583    | 28,299    | 28,268    | 30,730   | 26,552   |
| 8,580     | 8,540     | 8,887     | 8,504    | 8,732     | 8,725     | 8,786     | 9,432    | 8,330    |
| 22,948    | 22,736    | 23,779    | 22,799   | 22,914    | 22,556    | 22,975    | 24,269   | 21,674   |
| 7,637     | 7,620     | 8,101     | 7,719    | 7,951     | 7,617     | 7,917     | 8,540    | 7,466    |
| 17,113    | 16,826    | 17,984    | 17,307   | 17,327    | 16,929    | 17,421    | 18,764   | 16,177   |
| 106,062   | 105,042   | 110,138   | 104,095  | 107,401   | 105,723   | 106,954   | 114,620  | 100,121  |
| 19,614    | 19,747    | 20,379    | 18,469   | 19,938    | 19,699    | 19,678    | 20,819   | 17,973   |
| 2,536     | 2,446     | 2,564     | 2,333    | 2,585     | 2,485     | 2,473     | 2,680    | 2,419    |



| 15-Jul-11 | 22-Jul-11 | 29-Jul-11 | 5-Aug-11 | 12-Aug-11 | 19-Aug-11 | 26-Aug-11 | 2-Sep-11 | 9-Sep-11 |
|-----------|-----------|-----------|----------|-----------|-----------|-----------|----------|----------|
| 19,818    | 19,418    | 19,934    | 19,463   | 19,225    | 19,392    | 19,624    | 19,991   | 17,575   |
| 2,590     | 2,560     | 2,443     | 2,551    | 2,582     | 2,603     | 2,630     | 2,514    | 2,461    |
| 28,881    | 28,705    | 28,190    | 28,326   | 27,997    | 28,212    | 28,194    | 28,872   | 26,186   |
| 9,155     | 8,915     | 8,933     | 9,129    | 8,812     | 9,094     | 9,138     | 9,043    | 8,509    |
| 24,153    | 24,096    | 24,035    | 23,858   | 23,308    | 23,616    | 23,815    | 23,983   | 21,866   |
| 8,084     | 7,931     | 8,030     | 7,983    | 7,901     | 8,007     | 8,093     | 8,183    | 7,423    |
| 17,117    | 17,330    | 17,376    | 16,796   | 16,700    | 17,028    | 17,075    | 17,143   | 15,891   |
| 109,798   | 108,955   | 108,941   | 108,106  | 106,525   | 107,952   | 108,569   | 109,729  | 99,911   |
| 231       | 168       | 174       | 178      | 156       | 138       | 136       | 142      | 118      |
| 267       | 209       | 235       | 172      | 178       | 187       | 184       | 188      | 187      |
| 1,402     | 1,022     | 708       | 468      | 366       | 282       | 248       | 212      | 119      |
| 39        | 49        | 44        | 33       | 26        | 35        | 30        | 40       | 23       |
| 1,939     | 1,448     | 1,161     | 851      | 726       | 642       | 598       | 582      | 447      |
| 335       | 359       | 362       | 309      | 282       | 290       | 258       | 274      | 223      |
| 179       | 159       | 171       | 157      | 153       | 182       | 161       | 142      | 136      |
| 271       | 242       | 232       | 214      | 190       | 205       | 163       | 164      | 168      |
| 211       | 166       | 170       | 195      | 179       | 156       | 140       | 141      | 163      |
| 158       | 174       | 154       | 154      | 149       | 110       | 149       | 120      | 114      |
| 131       | 148       | 139       | 153      | 135       | 129       | 127       | 116      | 114      |
| 105       | 121       | 126       | 116      | 105       | 107       | 116       | 96       | 89       |
| 1,390     | 1,369     | 1,354     | 1,298    | 1,193     | 1,179     | 1,114     | 1,053    | 1,007    |
| 19,252    | 18,891    | 19,398    | 18,976   | 18,787    | 18,964    | 19,230    | 19,575   | 17,234   |
| 2,411     | 2,401     | 2,272     | 2,394    | 2,429     | 2,421     | 2,469     | 2,372    | 2,325    |
| 28,343    | 28,254    | 27,723    | 27,940   | 27,629    | 27,820    | 27,847    | 28,520   | 25,831   |
| 8,944     | 8,749     | 8,763     | 8,934    | 8,633     | 8,938     | 8,998     | 8,902    | 8,346    |
| 22,593    | 22,900    | 23,173    | 23,236   | 22,793    | 23,224    | 23,418    | 23,651   | 21,633   |
| 7,953     | 7,783     | 7,891     | 7,830    | 7,766     | 7,878     | 7,966     | 8,067    | 7,309    |
| 16,973    | 17,160    | 17,206    | 16,647   | 16,569    | 16,886    | 16,929    | 17,007   | 15,779   |
| 106,469   | 106,138   | 106,426   | 105,957  | 104,606   | 106,131   | 106,857   | 108,094  | 98,457   |
| 19,587    | 19,250    | 19,760    | 19,285   | 19,069    | 19,254    | 19,488    | 19,849   | 17,457   |
| 2,590     | 2,560     | 2,443     | 2,551    | 2,582     | 2,603     | 2,630     | 2,514    | 2,461    |



| 16-Sep-11 | 23-Sep-11 | 30-Sep-11 | 7-Oct-11 | 14-Oct-11 | 21-Oct-11 | 28-Oct-11 | 4-Nov-11 | 11-Nov-11 |
|-----------|-----------|-----------|----------|-----------|-----------|-----------|----------|-----------|
| 19,953    | 19,736    | 19,899    | 19,572   | 19,564    | 19,929    | 19,836    | 19,853   | 19,928    |
| 2,692     | 2,578     | 2,649     | 2,629    | 2,661     | 2,651     | 2,632     | 2,547    | 2,666     |
| 28,531    | 27,847    | 28,367    | 28,276   | 27,951    | 27,734    | 27,727    | 27,581   | 27,767    |
| 9,204     | 9,115     | 9,290     | 9,234    | 9,230     | 9,092     | 9,174     | 9,281    | 9,099     |
| 23,603    | 23,275    | 23,511    | 23,498   | 23,114    | 22,836    | 22,756    | 22,577   | 22,520    |
| 8,112     | 7,965     | 8,117     | 8,190    | 7,933     | 7,888     | 8,080     | 7,905    | 7,959     |
| 17,170    | 16,886    | 16,829    | 16,901   | 16,814    | 16,650    | 16,102    | 16,359   | 16,500    |
| 109,265   | 107,402   | 108,662   | 108,300  | 107,267   | 106,780   | 106,307   | 106,103  | 106,439   |
| 140       | 144       | 126       | 128      | 142       | 119       | 145       | 128      | 114       |
| 133       | 98        | 88        | 70       | 92        | 105       | 80        | 105      | 81        |
| 98        | 70        | 63        | 61       | 57        | 70        | 60        | 57       | 38        |
| 26        | 34        | 30        | 39       | 24        | 35        | 28        | 25       | 22        |
| 397       | 346       | 307       | 298      | 315       | 329       | 313       | 315      | 255       |
| 213       | 208       | 196       | 135      | 149       | 164       | 184       | 135      | 148       |
| 123       | 108       | 102       | 117      | 82        | 92        | 89        | 97       | 101       |
| 132       | 152       | 149       | 129      | 125       | 124       | 115       | 111      | 129       |
| 160       | 114       | 129       | 140      | 106       | 111       | 102       | 120      | 91        |
| 127       | 110       | 118       | 81       | 80        | 102       | 89        | 103      | 96        |
| 99        | 89        | 97        | 80       | 74        | 104       | 77        | 71       | 74        |
| 89        | 86        | 75        | 87       | 80        | 69        | 60        | 67       | 66        |
| 943       | 867       | 866       | 769      | 696       | 766       | 716       | 704      | 705       |
| 19,600    | 19,384    | 19,577    | 19,309   | 19,273    | 19,646    | 19,507    | 19,590   | 19,666    |
| 2,569     | 2,470     | 2,547     | 2,512    | 2,579     | 2,559     | 2,543     | 2,450    | 2,565     |
| 28,266    | 27,597    | 28,130    | 28,077   | 27,734    | 27,505    | 27,532    | 27,365   | 27,557    |
| 9,044     | 9,001     | 9,161     | 9,094    | 9,124     | 8,981     | 9,072     | 9,161    | 9,008     |
| 23,378    | 23,095    | 23,330    | 23,356   | 22,977    | 22,664    | 22,607    | 22,417   | 22,386    |
| 8,013     | 7,876     | 8,020     | 8,110    | 7,859     | 7,784     | 8,003     | 7,834    | 7,885     |
| 17,055    | 16,766    | 16,724    | 16,775   | 16,710    | 16,546    | 16,014    | 16,267   | 16,412    |
| 107,925   | 106,189   | 107,489   | 107,233  | 106,256   | 105,685   | 105,278   | 105,084  | 105,479   |
| 19,813    | 19,592    | 19,773    | 19,444   | 19,422    | 19,810    | 19,691    | 19,725   | 19,814    |
| 2,692     | 2,578     | 2,649     | 2,629    | 2,661     | 2,651     | 2,632     | 2,547    | 2,666     |



**18-Nov-11 25-Nov-11 2-Dec-11 9-Dec-11 16-Dec-11 23-Dec-11 30-Dec-11 6-Jan-12 13-Jan-12**

|         |        |         |         |         |         |        |         |         |
|---------|--------|---------|---------|---------|---------|--------|---------|---------|
| 20,334  | 17,564 | 21,054  | 20,327  | 20,929  | 21,348  | 16,798 | 18,468  | 20,051  |
| 2,724   | 2,382  | 2,699   | 2,779   | 2,775   | 2,752   | 2,221  | 2,628   | 2,777   |
| 28,127  | 24,712 | 29,861  | 27,956  | 28,197  | 28,920  | 24,052 | 26,716  | 27,622  |
| 9,443   | 8,248  | 10,102  | 9,503   | 9,718   | 9,556   | 8,201  | 9,211   | 9,576   |
| 22,981  | 20,401 | 24,756  | 22,664  | 23,290  | 23,514  | 20,015 | 21,896  | 23,015  |
| 8,311   | 7,270  | 8,793   | 8,027   | 8,415   | 8,353   | 7,249  | 7,929   | 8,198   |
| 16,565  | 14,661 | 17,770  | 16,431  | 16,619  | 16,714  | 14,504 | 15,951  | 16,524  |
| 108,485 | 95,238 | 115,035 | 107,687 | 109,943 | 111,157 | 93,040 | 102,799 | 107,763 |

|     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 124 | 91  | 113 | 111 | 130 | 99  | 93  | 87  | 109 |
| 92  | 93  | 82  | 80  | 75  | 74  | 59  | 86  | 49  |
| 38  | 40  | 50  | 38  | 28  | 38  | 44  | 36  | 30  |
| 26  | 16  | 17  | 17  | 13  | 26  | 22  | 21  | 15  |
| 280 | 240 | 262 | 246 | 246 | 237 | 218 | 230 | 203 |

|     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 169 | 133 | 145 | 152 | 154 | 170 | 99  | 98  | 139 |
| 91  | 78  | 80  | 61  | 92  | 61  | 60  | 69  | 69  |
| 118 | 132 | 127 | 137 | 105 | 127 | 94  | 115 | 108 |
| 106 | 101 | 119 | 104 | 108 | 104 | 83  | 101 | 98  |
| 78  | 79  | 89  | 80  | 84  | 91  | 67  | 71  | 65  |
| 83  | 59  | 73  | 67  | 65  | 68  | 67  | 72  | 80  |
| 67  | 53  | 74  | 59  | 65  | 74  | 33  | 70  | 66  |
| 712 | 635 | 707 | 660 | 673 | 695 | 503 | 596 | 625 |

|         |        |         |         |         |         |        |         |         |
|---------|--------|---------|---------|---------|---------|--------|---------|---------|
| 20,041  | 17,340 | 20,796  | 20,064  | 20,645  | 21,079  | 16,606 | 18,283  | 19,803  |
| 2,633   | 2,304  | 2,619   | 2,718   | 2,683   | 2,691   | 2,161  | 2,559   | 2,708   |
| 27,917  | 24,487 | 29,652  | 27,739  | 28,017  | 28,719  | 23,899 | 26,515  | 27,465  |
| 9,337   | 8,147  | 9,983   | 9,399   | 9,610   | 9,452   | 8,118  | 9,110   | 9,478   |
| 22,865  | 20,282 | 24,617  | 22,546  | 23,178  | 23,385  | 19,904 | 21,789  | 22,920  |
| 8,228   | 7,211  | 8,720   | 7,960   | 8,350   | 8,285   | 7,182  | 7,857   | 8,118   |
| 16,472  | 14,592 | 17,679  | 16,355  | 16,541  | 16,614  | 14,449 | 15,860  | 16,443  |
| 107,493 | 94,363 | 114,066 | 106,781 | 109,024 | 110,225 | 92,319 | 101,973 | 106,935 |

|        |        |        |        |        |        |        |        |        |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 20,210 | 17,473 | 20,941 | 20,216 | 20,799 | 21,249 | 16,705 | 18,381 | 19,942 |
| 2,724  | 2,382  | 2,699  | 2,779  | 2,775  | 2,752  | 2,221  | 2,628  | 2,777  |



**20-Jan-12 27-Jan-12 3-Feb-12 10-Feb-12 17-Feb-12 24-Feb-12 2-Mar-12 9-Mar-12 16-Mar-12**

|         |        |         |         |         |         |         |         |         |
|---------|--------|---------|---------|---------|---------|---------|---------|---------|
| 19,465  | 18,955 | 19,957  | 19,767  | 19,314  | 18,689  | 20,666  | 20,292  | 19,560  |
| 2,708   | 2,576  | 2,724   | 2,833   | 2,781   | 2,631   | 2,928   | 2,863   | 2,891   |
| 27,073  | 25,890 | 27,627  | 27,322  | 26,885  | 25,923  | 29,070  | 28,105  | 26,742  |
| 9,359   | 8,856  | 9,496   | 9,569   | 9,236   | 9,143   | 10,133  | 9,855   | 9,558   |
| 22,021  | 20,793 | 22,386  | 22,412  | 21,844  | 20,991  | 23,932  | 23,126  | 22,117  |
| 7,984   | 7,583  | 8,274   | 8,125   | 8,157   | 7,722   | 9,066   | 8,601   | 8,234   |
| 15,865  | 14,868 | 16,349  | 16,354  | 15,857  | 15,200  | 17,512  | 16,963  | 15,777  |
| 104,475 | 99,521 | 106,813 | 106,382 | 104,074 | 100,299 | 113,307 | 109,805 | 104,879 |

|     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 109 | 112 | 86  | 104 | 94  | 81  | 84  | 75  | 76  |
| 51  | 62  | 75  | 63  | 46  | 47  | 47  | 60  | 47  |
| 36  | 38  | 38  | 33  | 15  | 36  | 29  | 17  | 28  |
| 13  | 7   | 15  | 12  | 19  | 14  | 7   | 17  | 16  |
| 209 | 219 | 214 | 212 | 174 | 178 | 167 | 169 | 167 |

|     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 144 | 116 | 140 | 120 | 84  | 88  | 99  | 87  | 66  |
| 65  | 71  | 81  | 69  | 73  | 77  | 58  | 74  | 59  |
| 99  | 109 | 127 | 88  | 77  | 65  | 71  | 48  | 69  |
| 114 | 98  | 94  | 90  | 71  | 74  | 63  | 84  | 78  |
| 74  | 78  | 59  | 69  | 68  | 54  | 57  | 68  | 55  |
| 69  | 69  | 68  | 83  | 47  | 56  | 36  | 48  | 47  |
| 50  | 42  | 54  | 58  | 52  | 35  | 38  | 46  | 45  |
| 615 | 583 | 623 | 577 | 472 | 449 | 422 | 455 | 419 |

|         |        |         |         |         |        |         |         |         |
|---------|--------|---------|---------|---------|--------|---------|---------|---------|
| 19,212  | 18,727 | 19,731  | 19,543  | 19,136  | 18,520 | 20,483  | 20,130  | 19,418  |
| 2,643   | 2,505  | 2,643   | 2,764   | 2,708   | 2,554  | 2,870   | 2,789   | 2,832   |
| 26,923  | 25,719 | 27,425  | 27,171  | 26,762  | 25,811 | 28,952  | 27,997  | 26,626  |
| 9,245   | 8,758  | 9,402   | 9,479   | 9,165   | 9,069  | 10,070  | 9,771   | 9,480   |
| 21,911  | 20,677 | 22,289  | 22,310  | 21,761  | 20,901 | 23,846  | 23,041  | 22,034  |
| 7,915   | 7,514  | 8,206   | 8,042   | 8,110   | 7,666  | 9,030   | 8,553   | 8,187   |
| 15,802  | 14,819 | 16,280  | 16,284  | 15,786  | 15,151 | 17,467  | 16,900  | 15,716  |
| 103,651 | 98,719 | 105,976 | 105,593 | 103,428 | 99,672 | 112,718 | 109,181 | 104,293 |

|        |        |        |        |        |        |        |        |        |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 19,356 | 18,843 | 19,871 | 19,663 | 19,220 | 18,608 | 20,582 | 20,217 | 19,484 |
| 2,708  | 2,576  | 2,724  | 2,833  | 2,781  | 2,631  | 2,928  | 2,863  | 2,891  |



| 23-Mar-12 | 30-Mar-12 | 6-Apr-12 | 13-Apr-12 | 20-Apr-12 | 27-Apr-12 | 4-May-12 | 11-May-12 | 18-May-12 |
|-----------|-----------|----------|-----------|-----------|-----------|----------|-----------|-----------|
| 19,129    | 19,270    | 19,746   | 19,405    | 19,331    | 19,432    | 20,237   | 19,368    | 19,235    |
| 2,700     | 2,729     | 2,919    | 2,868     | 2,887     | 2,739     | 3,073    | 2,857     | 2,878     |
| 26,211    | 26,828    | 27,948   | 26,594    | 26,735    | 26,928    | 28,523   | 26,911    | 27,090    |
| 9,324     | 9,595     | 10,074   | 9,557     | 9,809     | 9,995     | 10,650   | 9,866     | 9,923     |
| 21,307    | 21,721    | 23,140   | 21,688    | 21,481    | 21,724    | 23,792   | 21,628    | 21,442    |
| 8,007     | 8,327     | 8,667    | 8,138     | 8,183     | 8,466     | 9,055    | 8,224     | 8,331     |
| 15,137    | 15,621    | 16,700   | 15,325    | 15,327    | 15,540    | 17,024   | 15,543    | 15,245    |
| 101,815   | 104,091   | 109,194  | 103,575   | 103,753   | 104,824   | 112,354  | 104,397   | 104,144   |
| 68        | 65        | 61       | 71        | 63        | 62        | 65       | 56        | 57        |
| 45        | 68        | 54       | 34        | 43        | 19        | 34       | 43        | 56        |
| 28        | 17        | 26       | 18        | 23        | 22        | 29       | 17        | 18        |
| 13        | 15        | 15       | 26        | 11        | 14        | 9        | 13        | 7         |
| 154       | 165       | 156      | 149       | 140       | 117       | 137      | 129       | 138       |
| 86        | 65        | 62       | 67        | 83        | 73        | 69       | 65        | 66        |
| 51        | 45        | 57       | 41        | 49        | 39        | 50       | 44        | 59        |
| 57        | 48        | 56       | 77        | 53        | 48        | 41       | 50        | 46        |
| 59        | 65        | 69       | 57        | 45        | 48        | 59       | 52        | 52        |
| 43        | 49        | 41       | 46        | 31        | 38        | 43       | 42        | 33        |
| 47        | 44        | 45       | 44        | 47        | 32        | 50       | 36        | 35        |
| 26        | 36        | 42       | 24        | 34        | 23        | 40       | 36        | 31        |
| 369       | 352       | 372      | 356       | 342       | 301       | 352      | 325       | 322       |
| 18,975    | 19,140    | 19,623   | 19,267    | 19,185    | 19,297    | 20,103   | 19,247    | 19,112    |
| 2,649     | 2,684     | 2,862    | 2,827     | 2,838     | 2,700     | 3,023    | 2,813     | 2,819     |
| 26,109    | 26,712    | 27,838   | 26,483    | 26,639    | 26,861    | 28,448   | 26,818    | 26,988    |
| 9,265     | 9,530     | 10,005   | 9,500     | 9,764     | 9,947     | 10,591   | 9,814     | 9,871     |
| 21,236    | 21,655    | 23,073   | 21,624    | 21,427    | 21,664    | 23,720   | 21,569    | 21,391    |
| 7,960     | 8,283     | 8,622    | 8,094     | 8,136     | 8,434     | 9,005    | 8,188     | 8,296     |
| 15,098    | 15,570    | 16,643   | 15,275    | 15,282    | 15,503    | 16,975   | 15,494    | 15,207    |
| 101,292   | 103,574   | 108,666  | 103,070   | 103,271   | 104,406   | 111,865  | 103,943   | 103,684   |
| 19,061    | 19,205    | 19,685   | 19,334    | 19,268    | 19,370    | 20,172   | 19,312    | 19,178    |
| 2,700     | 2,729     | 2,919    | 2,868     | 2,887     | 2,739     | 3,073    | 2,857     | 2,878     |



**25-May-12 1-Jun-12 8-Jun-12 15-Jun-12 22-Jun-12 29-Jun-12 6-Jul-12 13-Jul-12 20-Jul-12**

|                |               |                |                |                |                |                |                |                |
|----------------|---------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 19,950         | 17,751        | 20,090         | 19,240         | 19,435         | 19,625         | 18,121         | 19,401         | 19,361         |
| 2,994          | 2,763         | 3,077          | 2,974          | 2,961          | 2,970          | 2,993          | 3,162          | 3,096          |
| 27,611         | 25,256        | 27,667         | 26,871         | 26,516         | 27,245         | 26,077         | 27,246         | 26,885         |
| 10,478         | 9,523         | 10,178         | 10,091         | 10,138         | 10,271         | 10,151         | 10,246         | 10,267         |
| 22,187         | 21,004        | 22,503         | 21,340         | 21,546         | 21,624         | 22,079         | 21,694         | 21,663         |
| 8,732          | 8,124         | 8,464          | 8,287          | 8,493          | 8,496          | 8,532          | 8,535          | 8,620          |
| 16,101         | 15,161        | 15,903         | 15,008         | 15,583         | 15,472         | 15,707         | 15,535         | 15,554         |
| <b>108,053</b> | <b>99,582</b> | <b>107,882</b> | <b>103,811</b> | <b>104,672</b> | <b>105,703</b> | <b>103,660</b> | <b>105,819</b> | <b>105,446</b> |

|            |            |            |            |            |            |            |           |            |
|------------|------------|------------|------------|------------|------------|------------|-----------|------------|
| 60         | 45         | 63         | 70         | 58         | 44         | 39         | 46        | 48         |
| 31         | 39         | 40         | 37         | 40         | 47         | 38         | 33        | 37         |
| 23         | 18         | 23         | 17         | 13         | 8          | 15         | 9         | 11         |
| 13         | 10         | 22         | 9          | 8          | 8          | 10         | 6         | 8          |
| <b>127</b> | <b>112</b> | <b>148</b> | <b>133</b> | <b>119</b> | <b>107</b> | <b>102</b> | <b>94</b> | <b>104</b> |

|            |            |            |            |            |            |            |            |            |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| 49         | 58         | 52         | 64         | 57         | 46         | 30         | 58         | 54         |
| 39         | 53         | 60         | 51         | 40         | 29         | 36         | 40         | 46         |
| 50         | 46         | 60         | 39         | 32         | 43         | 33         | 38         | 38         |
| 83         | 53         | 39         | 39         | 62         | 44         | 37         | 30         | 39         |
| 42         | 36         | 35         | 33         | 37         | 35         | 30         | 44         | 26         |
| 33         | 37         | 35         | 37         | 40         | 30         | 37         | 25         | 44         |
| 27         | 24         | 29         | 21         | 14         | 22         | 9          | 12         | 14         |
| <b>323</b> | <b>307</b> | <b>310</b> | <b>284</b> | <b>282</b> | <b>249</b> | <b>212</b> | <b>247</b> | <b>261</b> |

|                |               |                |                |                |                |                |                |                |
|----------------|---------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 19,841         | 17,648        | 19,975         | 19,106         | 19,320         | 19,535         | 18,052         | 19,297         | 19,259         |
| 2,955          | 2,710         | 3,017          | 2,923          | 2,921          | 2,941          | 2,957          | 3,122          | 3,050          |
| 27,530         | 25,171        | 27,567         | 26,795         | 26,444         | 27,155         | 26,006         | 27,175         | 26,810         |
| 10,395         | 9,470         | 10,139         | 10,052         | 10,076         | 10,227         | 10,114         | 10,216         | 10,228         |
| 22,122         | 20,950        | 22,445         | 21,290         | 21,496         | 21,581         | 22,034         | 21,641         | 21,626         |
| 8,699          | 8,087         | 8,429          | 8,250          | 8,453          | 8,466          | 8,495          | 8,510          | 8,576          |
| 16,061         | 15,127        | 15,852         | 14,978         | 15,561         | 15,442         | 15,688         | 15,517         | 15,532         |
| <b>107,603</b> | <b>99,163</b> | <b>107,424</b> | <b>103,394</b> | <b>104,271</b> | <b>105,347</b> | <b>103,346</b> | <b>105,478</b> | <b>105,081</b> |

|        |        |        |        |        |        |        |        |        |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 19,890 | 17,706 | 20,027 | 19,170 | 19,377 | 19,581 | 18,082 | 19,355 | 19,313 |
| 2,994  | 2,763  | 3,077  | 2,974  | 2,961  | 2,970  | 2,993  | 3,162  | 3,096  |



| 27-Jul-12 | 3-Aug-12 | 10-Aug-12 | 17-Aug-12 | 24-Aug-12 | 31-Aug-12 | 7-Sep-12 | 14-Sep-12 | 21-Sep-12 |
|-----------|----------|-----------|-----------|-----------|-----------|----------|-----------|-----------|
| 19,124    | 18,880   | 18,728    | 19,146    | 18,966    | 19,382    | 18,162   | 19,493    | 19,356    |
| 3,010     | 3,096    | 3,063     | 3,163     | 2,936     | 3,119     | 2,941    | 3,272     | 3,140     |
| 26,251    | 26,490   | 26,142    | 26,661    | 26,414    | 26,829    | 25,783   | 26,819    | 26,541    |
| 10,122    | 10,252   | 10,131    | 10,474    | 10,376    | 10,354    | 9,993    | 10,591    | 10,318    |
| 21,141    | 21,700   | 21,358    | 21,459    | 21,046    | 21,720    | 20,946   | 21,565    | 21,147    |
| 8,510     | 8,484    | 8,393     | 8,628     | 8,662     | 8,553     | 8,237    | 8,635     | 8,619     |
| 15,153    | 15,102   | 15,157    | 15,418    | 15,181    | 15,189    | 15,156   | 15,301    | 15,107    |
| 103,311   | 104,004  | 102,972   | 104,949   | 103,581   | 105,146   | 101,218  | 105,676   | 104,228   |
| 33        | 45       | 41        | 33        | 41        | 22        | 35       | 25        | 18        |
| 36        | 18       | 42        | 26        | 22        | 20        | 18       | 15        | 10        |
| 10        | 8        | 3         | 10        | 7         | 8         | 5        | 6         | 1         |
| 4         | 5        | 8         | 4         | 9         | 5         | 1        | 6         | 1         |
| 83        | 76       | 94        | 73        | 79        | 55        | 59       | 52        | 30        |
| 46        | 52       | 31        | 33        | 15        | 20        | 19       | 19        | 13        |
| 26        | 23       | 22        | 24        | 14        | 23        | 20       | 27        | 15        |
| 31        | 39       | 31        | 34        | 15        | 13        | 23       | 10        | 6         |
| 48        | 24       | 37        | 37        | 29        | 40        | 31       | 34        | 40        |
| 24        | 40       | 27        | 16        | 15        | 20        | 19       | 19        | 13        |
| 29        | 35       | 27        | 22        | 11        | 3         | 8        | 13        | 8         |
| 14        | 10       | 17        | 12        | 8         | 11        | 18       | 9         | 8         |
| 218       | 223      | 192       | 178       | 107       | 130       | 138      | 131       | 103       |
| 19,045    | 18,783   | 18,656    | 19,080    | 18,910    | 19,340    | 18,108   | 19,449    | 19,325    |
| 2,984     | 3,073    | 3,041     | 3,139     | 2,922     | 3,096     | 2,921    | 3,245     | 3,125     |
| 26,184    | 26,433   | 26,069    | 26,601    | 26,377    | 26,796    | 25,742   | 26,794    | 26,525    |
| 10,074    | 10,228   | 10,094    | 10,437    | 10,347    | 10,314    | 9,962    | 10,557    | 10,278    |
| 21,107    | 21,652   | 21,328    | 21,433    | 21,024    | 21,692    | 20,922   | 21,540    | 21,133    |
| 8,481     | 8,449    | 8,366     | 8,606     | 8,651     | 8,550     | 8,229    | 8,622     | 8,611     |
| 15,135    | 15,087   | 15,132    | 15,402    | 15,164    | 15,173    | 15,137   | 15,286    | 15,098    |
| 103,010   | 103,705  | 102,686   | 104,698   | 103,395   | 104,961   | 101,021  | 105,493   | 104,095   |
| 19,091    | 18,835   | 18,687    | 19,113    | 18,925    | 19,360    | 18,127   | 19,468    | 19,338    |
| 3,010     | 3,096    | 3,063     | 3,163     | 2,936     | 3,119     | 2,941    | 3,272     | 3,140     |



**28-Sep-12 5-Oct-12 12-Oct-12 19-Oct-12 26-Oct-12 2-Nov-12 9-Nov-12 16-Nov-12 23-Nov-12**

|         |         |         |         |         |         |         |         |        |
|---------|---------|---------|---------|---------|---------|---------|---------|--------|
| 19,811  | 19,974  | 19,126  | 19,480  | 19,587  | 19,002  | 20,339  | 20,284  | 17,811 |
| 3,378   | 3,270   | 3,222   | 3,111   | 3,213   | 3,162   | 3,375   | 3,323   | 2,979  |
| 26,917  | 27,276  | 26,377  | 26,568  | 26,375  | 25,995  | 27,306  | 26,609  | 24,144 |
| 10,536  | 10,711  | 10,425  | 10,321  | 10,400  | 10,262  | 10,730  | 10,526  | 9,633  |
| 21,654  | 22,031  | 21,051  | 20,970  | 20,996  | 20,758  | 21,484  | 20,976  | 19,085 |
| 8,505   | 8,678   | 8,470   | 8,533   | 8,476   | 8,271   | 8,836   | 8,760   | 7,827  |
| 14,868  | 15,729  | 14,915  | 15,020  | 14,927  | 14,561  | 15,391  | 15,116  | 13,618 |
| 105,669 | 107,669 | 103,586 | 104,003 | 103,974 | 102,011 | 107,461 | 105,594 | 95,097 |

|    |    |    |    |    |    |    |    |    |
|----|----|----|----|----|----|----|----|----|
| 25 | 22 | 21 | 13 | 15 | 15 | 8  | 13 | 9  |
| 19 | 14 | 6  | 9  | 12 | 9  | 3  | 9  | 7  |
| 5  | 2  | 3  | 1  | -  | 3  | -  | -  | 1  |
| 4  | 3  | 2  | 2  | 2  | -  | -  | -  | -  |
| 53 | 41 | 32 | 25 | 29 | 27 | 11 | 22 | 17 |

|     |     |     |    |    |    |     |    |    |
|-----|-----|-----|----|----|----|-----|----|----|
| 14  | 6   | 9   | 8  | 5  | 7  | 21  | 22 | 5  |
| 36  | 12  | 21  | 17 | 25 | 15 | 13  | 18 | 20 |
| 21  | 28  | 8   | 12 | 16 | 7  | 8   | 4  | 6  |
| 32  | 25  | 41  | 38 | 31 | 24 | 32  | 32 | 33 |
| 10  | 13  | 5   | 6  | 4  | 6  | 3   | 6  | 8  |
| 9   | 9   | 14  | 13 | 8  | 9  | 12  | 7  | 3  |
| 5   | 13  | 10  | 3  | 7  | 5  | 13  | 10 | 4  |
| 127 | 106 | 108 | 97 | 96 | 73 | 102 | 99 | 79 |

|         |         |         |         |         |         |         |         |        |
|---------|---------|---------|---------|---------|---------|---------|---------|--------|
| 19,772  | 19,946  | 19,096  | 19,459  | 19,567  | 18,980  | 20,310  | 20,249  | 17,797 |
| 3,342   | 3,258   | 3,201   | 3,094   | 3,188   | 3,147   | 3,362   | 3,305   | 2,959  |
| 26,877  | 27,234  | 26,363  | 26,547  | 26,347  | 25,979  | 27,295  | 26,596  | 24,131 |
| 10,504  | 10,686  | 10,384  | 10,283  | 10,369  | 10,238  | 10,698  | 10,494  | 9,600  |
| 21,639  | 22,016  | 21,043  | 20,963  | 20,992  | 20,749  | 21,481  | 20,970  | 19,076 |
| 8,496   | 8,669   | 8,456   | 8,520   | 8,468   | 8,262   | 8,824   | 8,753   | 7,824  |
| 14,859  | 15,713  | 14,903  | 15,015  | 14,918  | 14,556  | 15,378  | 15,106  | 13,614 |
| 105,489 | 107,522 | 103,446 | 103,881 | 103,849 | 101,911 | 107,348 | 105,473 | 95,001 |

|        |        |        |        |        |        |        |        |        |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 19,786 | 19,952 | 19,105 | 19,467 | 19,572 | 18,987 | 20,331 | 20,271 | 17,802 |
| 3,378  | 3,270  | 3,222  | 3,111  | 3,213  | 3,162  | 3,375  | 3,323  | 2,979  |



| 30-Nov-12 | 7-Dec-12 | 14-Dec-12 | 21-Dec-12 | 28-Dec-12 | 4-Jan-13 | 11-Jan-13 | 18-Jan-13 | 25-Jan-13 |
|-----------|----------|-----------|-----------|-----------|----------|-----------|-----------|-----------|
| 20,799    | 20,914   | 20,496    | 21,521    | 16,162    | 17,966   | 19,797    | 19,703    | 17,903    |
| 3,431     | 3,492    | 3,449     | 3,573     | 2,728     | 3,096    | 3,551     | 3,341     | 3,022     |
| 27,881    | 28,197   | 27,005    | 28,340    | 22,397    | 25,104   | 26,793    | 26,177    | 23,542    |
| 11,068    | 11,293   | 10,838    | 11,296    | 9,015     | 10,247   | 10,847    | 10,667    | 9,567     |
| 22,179    | 22,137   | 21,172    | 22,042    | 18,122    | 20,382   | 21,341    | 20,543    | 18,348    |
| 8,938     | 9,076    | 8,775     | 8,955     | 7,478     | 8,333    | 8,888     | 8,631     | 7,662     |
| 15,218    | 15,980   | 14,847    | 15,667    | 13,090    | 14,542   | 15,160    | 14,947    | 12,930    |
| 109,514   | 111,089  | 106,582   | 111,394   | 88,992    | 99,670   | 106,377   | 104,009   | 92,974    |

|    |    |    |    |   |   |    |    |   |
|----|----|----|----|---|---|----|----|---|
| 8  | 6  | 5  | 3  | 4 | 1 | 4  | 8  | 2 |
| 4  | 4  | 4  | 8  | 3 |   | 3  | 3  |   |
| -  | -  | -  | 2  | 1 | 3 | 1  |    |   |
| 1  | 1  | 1  | 1  | - | 1 | 4  |    | 3 |
| 13 | 11 | 10 | 14 | 8 | 5 | 12 | 11 | 5 |

|    |    |    |    |    |     |    |    |    |
|----|----|----|----|----|-----|----|----|----|
| 11 | 8  | 18 | 10 | 4  | 5   | 7  | 8  | 6  |
| 12 | 16 | 17 | 12 | 15 | 13  | 21 | 13 | 15 |
| 8  | 8  | 4  | 5  | 6  | 12  | 7  | 3  | 5  |
| 31 | 28 | 24 | 31 | 33 | 45  | 32 | 37 | 27 |
| 3  | 6  | 10 | 5  | 5  | 10  | 3  | 8  | 9  |
| 6  | 4  | 7  | 3  | 1  | 2   | 4  | 1  | 3  |
| 6  | 11 | 6  | 7  | 6  | 13  | 3  | 4  | 8  |
| 77 | 81 | 86 | 73 | 70 | 100 | 77 | 74 | 73 |

|         |         |         |         |        |        |         |         |        |
|---------|---------|---------|---------|--------|--------|---------|---------|--------|
| 20,780  | 20,900  | 20,473  | 21,508  | 16,154 | 17,960 | 19,786  | 19,687  | 17,895 |
| 3,419   | 3,476   | 3,432   | 3,561   | 2,713  | 3,083  | 3,530   | 3,328   | 3,007  |
| 27,869  | 28,185  | 26,997  | 28,327  | 22,388 | 25,092 | 26,783  | 26,171  | 23,537 |
| 11,037  | 11,265  | 10,814  | 11,265  | 8,982  | 10,202 | 10,815  | 10,630  | 9,540  |
| 22,176  | 22,131  | 21,162  | 22,035  | 18,116 | 20,369 | 21,337  | 20,535  | 18,339 |
| 8,932   | 9,072   | 8,768   | 8,952   | 7,477  | 8,331  | 8,884   | 8,630   | 7,659  |
| 15,211  | 15,968  | 14,840  | 15,659  | 13,084 | 14,528 | 15,153  | 14,943  | 12,919 |
| 109,424 | 110,997 | 106,486 | 111,307 | 88,914 | 99,565 | 106,288 | 103,924 | 92,896 |

|        |        |        |        |        |        |        |        |        |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 20,791 | 20,908 | 20,491 | 21,518 | 16,158 | 17,965 | 19,793 | 19,695 | 17,901 |
| 3,431  | 3,492  | 3,449  | 3,573  | 2,728  | 3,096  | 3,551  | 3,341  | 3,022  |



**1-Feb-13 8-Feb-13 15-Feb-13 22-Feb-13 1-Mar-13 8-Mar-13 15-Mar-13 22-Mar-13 29-Mar-13**

|        |         |         |        |         |         |         |        |        |
|--------|---------|---------|--------|---------|---------|---------|--------|--------|
| 18,952 | 19,750  | 19,566  | 18,389 | 19,586  | 19,978  | 19,201  | 18,544 | 18,160 |
| 3,125  | 3,406   | 3,302   | 3,102  | 3,371   | 3,504   | 3,292   | 3,109  | 3,053  |
| 24,944 | 26,400  | 25,697  | 23,737 | 26,297  | 26,961  | 25,448  | 24,425 | 23,882 |
| 10,192 | 11,013  | 10,314  | 9,807  | 11,061  | 11,121  | 10,347  | 10,100 | 10,077 |
| 19,855 | 20,872  | 20,142  | 18,459 | 20,774  | 21,411  | 19,755  | 18,647 | 18,633 |
| 8,317  | 8,950   | 8,425   | 7,640  | 8,963   | 8,873   | 8,336   | 7,944  | 8,090  |
| 14,223 | 15,112  | 14,526  | 13,022 | 14,874  | 15,387  | 14,133  | 13,196 | 13,291 |
| 99,608 | 105,503 | 101,972 | 94,156 | 104,926 | 107,235 | 100,512 | 95,965 | 95,186 |

|    |    |    |    |    |    |    |    |   |
|----|----|----|----|----|----|----|----|---|
| 6  | 7  | 13 | 14 | 6  | 5  | 12 | 9  | 7 |
| 3  | 2  | -  | 1  | 5  | 3  | 3  | 6  | - |
| 3  | 1  | -  | 1  | 4  | -  | -  | -  | 1 |
| 3  | 1  | 1  | 4  | 2  | 5  | -  | -  | - |
| 15 | 11 | 14 | 20 | 17 | 13 | 15 | 15 | 8 |

|    |    |    |    |    |    |    |    |    |
|----|----|----|----|----|----|----|----|----|
| 8  | 9  | 10 | 7  | 6  | 6  | 5  | 9  | 3  |
| 6  | 15 | 9  | 13 | 5  | 8  | 6  | 5  | 9  |
| 2  | 8  | 5  | 3  | 2  | 7  | 5  | 4  | 3  |
| 37 | 29 | 24 | 25 | 28 | 3  | 6  | 4  | 4  |
| 5  | 3  | 6  | 3  | 5  | 1  | 4  | 2  | 4  |
| 3  | 5  | 5  | 5  | 2  | 6  | 1  | 5  | 3  |
| 3  | 3  | 1  | 2  | 8  | 1  |    | 5  | 7  |
| 64 | 72 | 60 | 58 | 56 | 32 | 27 | 34 | 33 |

|        |         |         |        |         |         |         |        |        |
|--------|---------|---------|--------|---------|---------|---------|--------|--------|
| 18,938 | 19,734  | 19,543  | 18,368 | 19,574  | 19,967  | 19,184  | 18,526 | 18,150 |
| 3,119  | 3,391   | 3,293   | 3,089  | 3,366   | 3,496   | 3,286   | 3,104  | 3,044  |
| 24,939 | 26,390  | 25,692  | 23,733 | 26,290  | 26,951  | 25,440  | 24,415 | 23,879 |
| 10,155 | 10,984  | 10,290  | 9,782  | 11,033  | 11,118  | 10,341  | 10,096 | 10,073 |
| 19,847 | 20,868  | 20,136  | 18,455 | 20,765  | 21,410  | 19,751  | 18,645 | 18,628 |
| 8,314  | 8,945   | 8,420   | 7,635  | 8,961   | 8,867   | 8,335   | 7,939  | 8,087  |
| 14,217 | 15,108  | 14,524  | 13,016 | 14,864  | 15,381  | 14,133  | 13,191 | 13,284 |
| 99,529 | 105,420 | 101,898 | 94,078 | 104,853 | 107,190 | 100,470 | 95,916 | 95,145 |

|        |        |        |        |        |        |        |        |        |
|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 18,946 | 19,743 | 19,553 | 18,375 | 19,580 | 19,973 | 19,189 | 18,535 | 18,153 |
| 3,125  | 3,406  | 3,302  | 3,102  | 3,371  | 3,504  | 3,292  | 3,109  | 3,053  |



**5-Apr-13 12-Apr-13 19-Apr-13 26-Apr-13 3-May-13**

**4-Jun-10 11-Jun-10**

18,826  
 3,312  
 25,656  
 10,612  
 20,195  
 8,619  
14,573  
 101,793

|           |           |           |           |          |
|-----------|-----------|-----------|-----------|----------|
| 11        | 10        | 6         | 11        | 5        |
| 2         | 2         | 5         | -         | 2        |
| 1         | 5         | 2         | 1         | -        |
| -         | -         | -         | -         | 2        |
| <u>14</u> | <u>17</u> | <u>13</u> | <u>12</u> | <u>9</u> |

|           |               |               |
|-----------|---------------|---------------|
| 6         | 100.0%        | 100.0%        |
| 7         | 100.0%        | 100.0%        |
| 4         | 100.0%        | 100.0%        |
| 2         | 100.0%        | 100.0%        |
| 5         | 100.0%        | 100.0%        |
| 7         | 100.0%        | 100.0%        |
| 1         | 100.0%        | 100.0%        |
| <u>32</u> | <u>100.0%</u> | <u>100.0%</u> |

|               |             |             |
|---------------|-------------|-------------|
| 18,809        | 0.0%        | 0.0%        |
| 3,305         | 0.0%        | 0.0%        |
| 25,650        | 0.0%        | 0.0%        |
| 10,610        | 0.0%        | 0.0%        |
| 20,189        | 0.0%        | 0.0%        |
| 8,612         | 0.0%        | 0.0%        |
| <u>14,572</u> | <u>0.0%</u> | <u>0.0%</u> |
| 101,747       | 0.0%        | 0.0%        |

18,815  
 3,312

25,654  
10,612  
20,194  
8,619  
14,573  
101,779

3.6%  
8.5%  
7.4%  
5.3%  
8.4%  
6.5%  
9.6%  
6.9%

**Share of Total OxyContin Prescriptions (Percent Conversion to I**

**18-Jun-10 25-Jun-10 2-Jul-10 9-Jul-10 16-Jul-10 23-Jul-10 30-Jul-10 6-Aug-10 13-Aug-10 20-Aug-10**

---

|        |        |        |        |        |        |        |        |       |       |
|--------|--------|--------|--------|--------|--------|--------|--------|-------|-------|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 96.9% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.7% | 94.5% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 96.7% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 97.2% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.7% | 94.7% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.7% | 96.0% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.6% | 89.7% |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.7% | 94.6% |

|      |        |        |        |        |        |        |        |        |        |
|------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.2%   | 3.1%   |
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.3%   | 5.5%   |
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.2%   | 3.3%   |
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.2%   | 2.8%   |
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.3%   | 5.3%   |
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.3%   | 4.0%   |
| 0.0% | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.0%   | 0.4%   | 10.3%  |
| 0.0% | 0.000% | 0.000% | 0.000% | 0.000% | 0.000% | 0.003% | 0.012% | 0.269% | 5.351% |



**Reformulated OxyContin)**

**27-Aug-10 3-Sep-10 10-Sep-10 17-Sep-10 24-Sep-10 1-Oct-10 8-Oct-10 15-Oct-10 22-Oct-10**

---

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 90.2% | 79.6% | 70.2% | 59.9% | 50.5% | 43.4% | 36.6% | 31.7% | 27.8% |
| 88.3% | 84.9% | 76.4% | 70.8% | 66.1% | 60.2% | 56.3% | 51.2% | 48.2% |
| 87.6% | 74.1% | 62.2% | 50.3% | 39.5% | 32.2% | 26.5% | 21.1% | 18.3% |
| 91.6% | 83.4% | 76.0% | 63.9% | 52.6% | 46.6% | 40.6% | 34.1% | 29.0% |
| 83.9% | 70.8% | 59.2% | 46.9% | 37.9% | 31.5% | 26.4% | 21.6% | 17.8% |
| 86.1% | 77.6% | 66.7% | 57.4% | 47.6% | 40.9% | 34.6% | 30.0% | 26.0% |
| 74.6% | 61.5% | 51.2% | 42.4% | 33.7% | 28.6% | 23.4% | 20.0% | 17.4% |
| 84.5% | 72.7% | 62.2% | 51.5% | 42.0% | 35.6% | 30.0% | 25.2% | 21.8% |

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 9.8%  | 20.4% | 29.8% | 40.1% | 49.5% | 56.6% | 63.4% | 68.3% | 72.2% |
| 11.7% | 15.1% | 23.6% | 29.2% | 33.9% | 39.8% | 43.7% | 48.8% | 51.8% |
| 12.4% | 25.9% | 37.8% | 49.7% | 60.5% | 67.8% | 73.5% | 78.9% | 81.7% |
| 8.4%  | 16.6% | 24.0% | 36.1% | 47.4% | 53.4% | 59.4% | 65.9% | 71.0% |
| 16.1% | 29.2% | 40.8% | 53.1% | 62.1% | 68.5% | 73.6% | 78.4% | 82.2% |
| 13.9% | 22.4% | 33.3% | 42.6% | 52.4% | 59.1% | 65.4% | 70.0% | 74.0% |
| 25.4% | 38.5% | 48.8% | 57.6% | 66.3% | 71.4% | 76.6% | 80.0% | 82.6% |

---

15.500% 27.290% 37.759% 48.540% 58.003% 64.430% 69.983% 74.814% 78.209%



**29-Oct-10 5-Nov-10 12-Nov-10 19-Nov-10 26-Nov-10 3-Dec-10 10-Dec-10 17-Dec-10 24-Dec-10**

---

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 23.2% | 20.9% | 17.7% | 15.3% | 14.0% | 13.1% | 11.4% | 7.9%  | 9.2%  |
| 42.9% | 35.9% | 36.1% | 33.2% | 31.3% | 27.1% | 27.0% | 19.8% | 22.3% |
| 14.7% | 12.7% | 10.5% | 9.4%  | 9.0%  | 7.8%  | 7.3%  | 5.6%  | 5.9%  |
| 26.2% | 23.8% | 21.0% | 18.4% | 16.3% | 13.6% | 12.7% | 11.6% | 13.1% |
| 15.1% | 13.0% | 11.2% | 9.9%  | 8.5%  | 8.0%  | 7.2%  | 5.7%  | 5.6%  |
| 22.1% | 19.9% | 17.8% | 17.2% | 14.1% | 13.7% | 12.1% | 10.1% | 10.5% |
| 14.3% | 11.8% | 10.8% | 9.9%  | 8.8%  | 8.3%  | 8.3%  | 6.2%  | 6.0%  |
| 18.3% | 16.0% | 14.0% | 12.5% | 11.2% | 10.2% | 9.4%  | 7.2%  | 7.7%  |

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 76.8% | 79.1% | 82.3% | 84.7% | 86.0% | 86.9% | 88.6% | 92.1% | 90.8% |
| 57.1% | 64.1% | 63.9% | 66.8% | 68.7% | 72.9% | 73.0% | 80.2% | 77.7% |
| 85.3% | 87.3% | 89.5% | 90.6% | 91.0% | 92.2% | 92.7% | 94.4% | 94.1% |
| 73.8% | 76.2% | 79.0% | 81.6% | 83.7% | 86.4% | 87.3% | 88.4% | 86.9% |
| 84.9% | 87.0% | 88.8% | 90.1% | 91.5% | 92.0% | 92.8% | 94.3% | 94.4% |
| 77.9% | 80.1% | 82.2% | 82.8% | 85.9% | 86.3% | 87.9% | 89.9% | 89.5% |
| 85.7% | 88.2% | 89.2% | 90.1% | 91.2% | 91.7% | 91.7% | 93.8% | 94.0% |

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 81.723% | 83.992% | 86.047% | 87.542% | 88.827% | 89.841% | 90.634% | 92.775% | 92.275% |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|



**31-Dec-10 7-Jan-11 14-Jan-11 21-Jan-11 28-Jan-11 4-Feb-11 11-Feb-11 18-Feb-11 25-Feb-11**

---

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 8.8%  | 8.6%  | 8.1%  | 7.9%  | 7.5%  | 7.7%  | 7.5%  | 7.2%  | 6.6%  |
| 21.7% | 23.4% | 21.8% | 23.1% | 21.7% | 21.0% | 22.7% | 19.4% | 21.4% |
| 5.3%  | 5.4%  | 5.4%  | 5.0%  | 5.0%  | 4.7%  | 4.8%  | 4.4%  | 4.4%  |
| 12.4% | 11.9% | 11.0% | 11.3% | 11.4% | 10.8% | 10.4% | 10.1% | 10.0% |
| 5.5%  | 5.4%  | 5.4%  | 4.9%  | 4.7%  | 4.9%  | 4.6%  | 4.2%  | 3.9%  |
| 9.7%  | 9.2%  | 9.5%  | 9.6%  | 8.7%  | 7.9%  | 8.1%  | 8.4%  | 7.8%  |
| 6.1%  | 6.3%  | 5.7%  | 5.9%  | 5.5%  | 5.6%  | 4.8%  | 4.7%  | 4.4%  |
| 7.4%  | 7.4%  | 7.1%  | 6.9%  | 6.6%  | 6.5%  | 6.3%  | 6.0%  | 5.7%  |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 91.2%   | 91.4%   | 91.9%   | 92.1%   | 92.5%   | 92.3%   | 92.5%   | 92.8%   | 93.4%   |
| 78.3%   | 76.6%   | 78.2%   | 76.9%   | 78.3%   | 79.0%   | 77.3%   | 80.6%   | 78.6%   |
| 94.7%   | 94.6%   | 94.6%   | 95.0%   | 95.0%   | 95.3%   | 95.2%   | 95.6%   | 95.6%   |
| 87.6%   | 88.1%   | 89.0%   | 88.7%   | 88.6%   | 89.2%   | 89.6%   | 89.9%   | 90.0%   |
| 94.5%   | 94.6%   | 94.6%   | 95.1%   | 95.3%   | 95.1%   | 95.4%   | 95.8%   | 96.1%   |
| 90.3%   | 90.8%   | 90.5%   | 90.4%   | 91.3%   | 92.1%   | 91.9%   | 91.6%   | 92.2%   |
| 93.9%   | 93.7%   | 94.3%   | 94.1%   | 94.5%   | 94.4%   | 95.2%   | 95.3%   | 95.6%   |
| 92.646% | 92.643% | 92.935% | 93.111% | 93.364% | 93.491% | 93.684% | 94.006% | 94.258% |



**4-Mar-11 11-Mar-11 18-Mar-11 25-Mar-11 1-Apr-11 8-Apr-11 15-Apr-11 22-Apr-11 29-Apr-11**

---

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 6.4%  | 4.8%  | 5.1%  | 4.7%  | 4.3%  | 4.2%  | 4.0%  | 3.7%  | 3.4%  |
| 19.6% | 16.4% | 15.8% | 15.9% | 15.6% | 13.8% | 15.6% | 14.5% | 12.7% |
| 4.1%  | 3.2%  | 3.1%  | 2.9%  | 2.6%  | 2.4%  | 2.2%  | 2.1%  | 1.9%  |
| 9.6%  | 7.3%  | 7.0%  | 6.6%  | 6.8%  | 7.0%  | 6.5%  | 5.7%  | 5.1%  |
| 3.8%  | 3.1%  | 3.0%  | 3.2%  | 2.8%  | 2.4%  | 2.3%  | 2.2%  | 1.9%  |
| 7.6%  | 6.0%  | 5.8%  | 5.6%  | 5.4%  | 4.5%  | 4.6%  | 5.0%  | 3.8%  |
| 4.1%  | 3.5%  | 3.0%  | 3.0%  | 2.9%  | 2.6%  | 2.2%  | 2.4%  | 1.9%  |
| 5.5%  | 4.3%  | 4.2%  | 4.1%  | 3.8%  | 3.5%  | 3.4%  | 3.2%  | 2.8%  |

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 93.6% | 95.2% | 94.9% | 95.3% | 95.7% | 95.8% | 96.0% | 96.3% | 96.6% |
| 80.4% | 83.6% | 84.2% | 84.1% | 84.4% | 86.2% | 84.4% | 85.5% | 87.3% |
| 95.9% | 96.8% | 96.9% | 97.1% | 97.4% | 97.6% | 97.8% | 97.9% | 98.1% |
| 90.4% | 92.7% | 93.0% | 93.4% | 93.2% | 93.0% | 93.5% | 94.3% | 94.9% |
| 96.2% | 96.9% | 97.0% | 96.8% | 97.2% | 97.6% | 97.7% | 97.8% | 98.1% |
| 92.4% | 94.0% | 94.2% | 94.4% | 94.6% | 95.5% | 95.4% | 95.0% | 96.2% |
| 95.9% | 96.5% | 97.0% | 97.0% | 97.1% | 97.4% | 97.8% | 97.6% | 98.1% |

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 94.529% | 95.683% | 95.787% | 95.915% | 96.195% | 96.469% | 96.608% | 96.772% | 97.175% |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|



**6-May-11 13-May-11 20-May-11 27-May-11 3-Jun-11 10-Jun-11 17-Jun-11 24-Jun-11 1-Jul-11**

---

|       |       |       |      |      |      |      |      |      |
|-------|-------|-------|------|------|------|------|------|------|
| 3.3%  | 2.9%  | 2.7%  | 2.2% | 2.4% | 2.0% | 1.9% | 1.8% | 1.9% |
| 12.8% | 10.4% | 10.7% | 9.2% | 8.6% | 9.1% | 8.5% | 8.2% | 8.4% |
| 1.9%  | 1.5%  | 1.5%  | 1.2% | 1.3% | 1.1% | 1.2% | 1.0% | 0.9% |
| 4.8%  | 4.5%  | 3.3%  | 3.3% | 3.1% | 2.9% | 3.1% | 2.8% | 2.5% |
| 1.9%  | 1.4%  | 1.3%  | 1.2% | 1.0% | 1.0% | 1.0% | 0.9% | 0.7% |
| 4.3%  | 3.1%  | 3.0%  | 2.7% | 2.8% | 2.2% | 2.1% | 2.0% | 2.0% |
| 1.9%  | 1.5%  | 1.3%  | 1.1% | 1.2% | 1.0% | 0.9% | 0.8% | 0.9% |
| 2.8%  | 2.3%  | 2.1%  | 1.8% | 1.8% | 1.7% | 1.6% | 1.5% | 1.4% |

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 96.7% | 97.1% | 97.3% | 97.8% | 97.6% | 98.0% | 98.1% | 98.2% | 98.1% |
| 87.2% | 89.6% | 89.3% | 90.8% | 91.4% | 90.9% | 91.5% | 91.8% | 91.6% |
| 98.1% | 98.5% | 98.5% | 98.8% | 98.7% | 98.9% | 98.8% | 99.0% | 99.1% |
| 95.2% | 95.5% | 96.7% | 96.7% | 96.9% | 97.1% | 96.9% | 97.2% | 97.5% |
| 98.1% | 98.6% | 98.7% | 98.8% | 99.0% | 99.0% | 99.0% | 99.1% | 99.3% |
| 95.7% | 96.9% | 97.0% | 97.3% | 97.2% | 97.8% | 97.9% | 98.0% | 98.0% |
| 98.1% | 98.5% | 98.7% | 98.9% | 98.8% | 99.0% | 99.1% | 99.2% | 99.1% |

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 97.203% | 97.694% | 97.879% | 98.159% | 98.174% | 98.348% | 98.373% | 98.511% | 98.585% |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|



**8-Jul-11 15-Jul-11 22-Jul-11 29-Jul-11 5-Aug-11 12-Aug-11 19-Aug-11 26-Aug-11 2-Sep-11**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 1.6% | 1.7% | 1.9% | 1.8% | 1.6% | 1.5% | 1.5% | 1.3% | 1.4% |
| 7.3% | 6.9% | 6.2% | 7.0% | 6.2% | 5.9% | 7.0% | 6.1% | 5.6% |
| 1.0% | 0.9% | 0.8% | 0.8% | 0.8% | 0.7% | 0.7% | 0.6% | 0.6% |
| 2.8% | 2.3% | 1.9% | 1.9% | 2.1% | 2.0% | 1.7% | 1.5% | 1.6% |
| 0.9% | 0.7% | 0.8% | 0.7% | 0.7% | 0.6% | 0.5% | 0.6% | 0.5% |
| 1.9% | 1.6% | 1.9% | 1.7% | 1.9% | 1.7% | 1.6% | 1.6% | 1.4% |
| 0.7% | 0.6% | 0.7% | 0.7% | 0.7% | 0.6% | 0.6% | 0.7% | 0.6% |
| 1.4% | 1.3% | 1.3% | 1.3% | 1.2% | 1.1% | 1.1% | 1.0% | 1.0% |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 98.4%   | 98.3%   | 98.1%   | 98.2%   | 98.4%   | 98.5%   | 98.5%   | 98.7%   | 98.6%   |
| 92.7%   | 93.1%   | 93.8%   | 93.0%   | 93.8%   | 94.1%   | 93.0%   | 93.9%   | 94.4%   |
| 99.0%   | 99.1%   | 99.2%   | 99.2%   | 99.2%   | 99.3%   | 99.3%   | 99.4%   | 99.4%   |
| 97.2%   | 97.7%   | 98.1%   | 98.1%   | 97.9%   | 98.0%   | 98.3%   | 98.5%   | 98.4%   |
| 99.1%   | 99.3%   | 99.2%   | 99.3%   | 99.3%   | 99.4%   | 99.5%   | 99.4%   | 99.5%   |
| 98.1%   | 98.4%   | 98.1%   | 98.3%   | 98.1%   | 98.3%   | 98.4%   | 98.4%   | 98.6%   |
| 99.3%   | 99.4%   | 99.3%   | 99.3%   | 99.3%   | 99.4%   | 99.4%   | 99.3%   | 99.4%   |
| 98.581% | 98.711% | 98.727% | 98.744% | 98.790% | 98.872% | 98.901% | 98.968% | 99.035% |



**9-Sep-11 16-Sep-11 23-Sep-11 30-Sep-11 7-Oct-11 14-Oct-11 21-Oct-11 28-Oct-11 4-Nov-11**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 1.3% | 1.1% | 1.1% | 1.0% | 0.7% | 0.8% | 0.8% | 0.9% | 0.7% |
| 5.5% | 4.6% | 4.2% | 3.9% | 4.5% | 3.1% | 3.5% | 3.4% | 3.8% |
| 0.6% | 0.5% | 0.5% | 0.5% | 0.5% | 0.4% | 0.4% | 0.4% | 0.4% |
| 1.9% | 1.7% | 1.3% | 1.4% | 1.5% | 1.1% | 1.2% | 1.1% | 1.3% |
| 0.5% | 0.5% | 0.5% | 0.5% | 0.3% | 0.3% | 0.4% | 0.4% | 0.5% |
| 1.5% | 1.2% | 1.1% | 1.2% | 1.0% | 0.9% | 1.3% | 1.0% | 0.9% |
| 0.6% | 0.5% | 0.5% | 0.4% | 0.5% | 0.5% | 0.4% | 0.4% | 0.4% |
| 1.0% | 0.9% | 0.8% | 0.8% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% |

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 98.7% | 98.9% | 98.9% | 99.0% | 99.3% | 99.2% | 99.2% | 99.1% | 99.3% |
| 94.5% | 95.4% | 95.8% | 96.1% | 95.5% | 96.9% | 96.5% | 96.6% | 96.2% |
| 99.4% | 99.5% | 99.5% | 99.5% | 99.5% | 99.6% | 99.6% | 99.6% | 99.6% |
| 98.1% | 98.3% | 98.7% | 98.6% | 98.5% | 98.9% | 98.8% | 98.9% | 98.7% |
| 99.5% | 99.5% | 99.5% | 99.5% | 99.7% | 99.7% | 99.6% | 99.6% | 99.5% |
| 98.5% | 98.8% | 98.9% | 98.8% | 99.0% | 99.1% | 98.7% | 99.0% | 99.1% |
| 99.4% | 99.5% | 99.5% | 99.6% | 99.5% | 99.5% | 99.6% | 99.6% | 99.6% |

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 98.988% | 99.134% | 99.190% | 99.201% | 99.288% | 99.349% | 99.280% | 99.324% | 99.335% |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|



**11-Nov-11 18-Nov-11 25-Nov-11 2-Dec-11 9-Dec-11 16-Dec-11 23-Dec-11 30-Dec-11 6-Jan-12**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 0.7% | 0.8% | 0.8% | 0.7% | 0.8% | 0.7% | 0.8% | 0.6% | 0.5% |
| 3.8% | 3.3% | 3.3% | 3.0% | 2.2% | 3.3% | 2.2% | 2.7% | 2.6% |
| 0.5% | 0.4% | 0.5% | 0.4% | 0.5% | 0.4% | 0.4% | 0.4% | 0.4% |
| 1.0% | 1.1% | 1.2% | 1.2% | 1.1% | 1.1% | 1.1% | 1.0% | 1.1% |
| 0.4% | 0.3% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.3% | 0.3% |
| 0.9% | 1.0% | 0.8% | 0.8% | 0.8% | 0.8% | 0.8% | 0.9% | 0.9% |
| 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.2% | 0.4% |
| 0.7% | 0.7% | 0.7% | 0.6% | 0.6% | 0.6% | 0.6% | 0.5% | 0.6% |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 99.3%   | 99.2%   | 99.2%   | 99.3%   | 99.2%   | 99.3%   | 99.2%   | 99.4%   | 99.5%   |
| 96.2%   | 96.7%   | 96.7%   | 97.0%   | 97.8%   | 96.7%   | 97.8%   | 97.3%   | 97.4%   |
| 99.5%   | 99.6%   | 99.5%   | 99.6%   | 99.5%   | 99.6%   | 99.6%   | 99.6%   | 99.6%   |
| 99.0%   | 98.9%   | 98.8%   | 98.8%   | 98.9%   | 98.9%   | 98.9%   | 99.0%   | 98.9%   |
| 99.6%   | 99.7%   | 99.6%   | 99.6%   | 99.6%   | 99.6%   | 99.6%   | 99.7%   | 99.7%   |
| 99.1%   | 99.0%   | 99.2%   | 99.2%   | 99.2%   | 99.2%   | 99.2%   | 99.1%   | 99.1%   |
| 99.6%   | 99.6%   | 99.6%   | 99.6%   | 99.6%   | 99.6%   | 99.6%   | 99.8%   | 99.6%   |
| 99.336% | 99.342% | 99.332% | 99.384% | 99.386% | 99.386% | 99.373% | 99.458% | 99.419% |



**13-Jan-12 20-Jan-12 27-Jan-12 3-Feb-12 10-Feb-12 17-Feb-12 24-Feb-12 2-Mar-12 9-Mar-12**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 0.7% | 0.7% | 0.6% | 0.7% | 0.6% | 0.4% | 0.5% | 0.5% | 0.4% |
| 2.5% | 2.4% | 2.8% | 3.0% | 2.4% | 2.6% | 2.9% | 2.0% | 2.6% |
| 0.4% | 0.4% | 0.4% | 0.5% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% |
| 1.0% | 1.2% | 1.1% | 1.0% | 0.9% | 0.8% | 0.8% | 0.6% | 0.9% |
| 0.3% | 0.3% | 0.4% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% |
| 1.0% | 0.9% | 0.9% | 0.8% | 1.0% | 0.6% | 0.7% | 0.4% | 0.6% |
| 0.4% | 0.3% | 0.3% | 0.3% | 0.4% | 0.3% | 0.2% | 0.2% | 0.3% |
| 0.6% | 0.6% | 0.6% | 0.6% | 0.5% | 0.5% | 0.4% | 0.4% | 0.4% |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 99.3%   | 99.3%   | 99.4%   | 99.3%   | 99.4%   | 99.6%   | 99.5%   | 99.5%   | 99.6%   |
| 97.5%   | 97.6%   | 97.2%   | 97.0%   | 97.6%   | 97.4%   | 97.1%   | 98.0%   | 97.4%   |
| 99.6%   | 99.6%   | 99.6%   | 99.5%   | 99.7%   | 99.7%   | 99.7%   | 99.8%   | 99.8%   |
| 99.0%   | 98.8%   | 98.9%   | 99.0%   | 99.1%   | 99.2%   | 99.2%   | 99.4%   | 99.1%   |
| 99.7%   | 99.7%   | 99.6%   | 99.7%   | 99.7%   | 99.7%   | 99.7%   | 99.8%   | 99.7%   |
| 99.0%   | 99.1%   | 99.1%   | 99.2%   | 99.0%   | 99.4%   | 99.3%   | 99.6%   | 99.4%   |
| 99.6%   | 99.7%   | 99.7%   | 99.7%   | 99.6%   | 99.7%   | 99.8%   | 99.8%   | 99.7%   |
| 99.419% | 99.410% | 99.413% | 99.416% | 99.457% | 99.546% | 99.552% | 99.627% | 99.585% |



**16-Mar-12 23-Mar-12 30-Mar-12 6-Apr-12 13-Apr-12 20-Apr-12 27-Apr-12 4-May-12 11-May-12**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 0.3% | 0.5% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% | 0.3% | 0.3% |
| 2.0% | 1.9% | 1.6% | 2.0% | 1.4% | 1.7% | 1.4% | 1.6% | 1.5% |
| 0.3% | 0.2% | 0.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.1% | 0.2% |
| 0.8% | 0.6% | 0.7% | 0.7% | 0.6% | 0.5% | 0.5% | 0.6% | 0.5% |
| 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% | 0.2% | 0.2% |
| 0.6% | 0.6% | 0.5% | 0.5% | 0.5% | 0.6% | 0.4% | 0.6% | 0.4% |
| 0.3% | 0.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.1% | 0.2% | 0.2% |
| 0.4% | 0.4% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 99.7%   | 99.5%   | 99.7%   | 99.7%   | 99.7%   | 99.6%   | 99.6%   | 99.7%   | 99.7%   |
| 98.0%   | 98.1%   | 98.4%   | 98.0%   | 98.6%   | 98.3%   | 98.6%   | 98.4%   | 98.5%   |
| 99.7%   | 99.8%   | 99.8%   | 99.8%   | 99.7%   | 99.8%   | 99.8%   | 99.9%   | 99.8%   |
| 99.2%   | 99.4%   | 99.3%   | 99.3%   | 99.4%   | 99.5%   | 99.5%   | 99.4%   | 99.5%   |
| 99.8%   | 99.8%   | 99.8%   | 99.8%   | 99.8%   | 99.9%   | 99.8%   | 99.8%   | 99.8%   |
| 99.4%   | 99.4%   | 99.5%   | 99.5%   | 99.5%   | 99.4%   | 99.6%   | 99.4%   | 99.6%   |
| 99.7%   | 99.8%   | 99.8%   | 99.7%   | 99.8%   | 99.8%   | 99.9%   | 99.8%   | 99.8%   |
| 99.600% | 99.637% | 99.661% | 99.659% | 99.656% | 99.670% | 99.713% | 99.686% | 99.688% |



**18-May-12 25-May-12 1-Jun-12 8-Jun-12 15-Jun-12 22-Jun-12 29-Jun-12 6-Jul-12 13-Jul-12**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 0.3% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.3% |
| 2.1% | 1.3% | 1.9% | 1.9% | 1.7% | 1.4% | 1.0% | 1.2% | 1.3% |
| 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.2% | 0.1% | 0.1% |
| 0.5% | 0.8% | 0.6% | 0.4% | 0.4% | 0.6% | 0.4% | 0.4% | 0.3% |
| 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.2% |
| 0.4% | 0.4% | 0.5% | 0.4% | 0.4% | 0.5% | 0.4% | 0.4% | 0.3% |
| 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% |

|       |       |       |       |       |       |       |       |       |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 99.7% | 99.8% | 99.7% | 99.7% | 99.7% | 99.7% | 99.8% | 99.8% | 99.7% |
| 97.9% | 98.7% | 98.1% | 98.1% | 98.3% | 98.6% | 99.0% | 98.8% | 98.7% |
| 99.8% | 99.8% | 99.8% | 99.8% | 99.9% | 99.9% | 99.8% | 99.9% | 99.9% |
| 99.5% | 99.2% | 99.4% | 99.6% | 99.6% | 99.4% | 99.6% | 99.6% | 99.7% |
| 99.8% | 99.8% | 99.8% | 99.8% | 99.8% | 99.8% | 99.8% | 99.9% | 99.8% |
| 99.6% | 99.6% | 99.5% | 99.6% | 99.6% | 99.5% | 99.6% | 99.6% | 99.7% |
| 99.8% | 99.8% | 99.8% | 99.8% | 99.9% | 99.9% | 99.9% | 99.9% | 99.9% |

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 99.690% | 99.701% | 99.691% | 99.712% | 99.726% | 99.730% | 99.764% | 99.795% | 99.766% |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|



**20-Jul-12 27-Jul-12 3-Aug-12 10-Aug-12 17-Aug-12 24-Aug-12 31-Aug-12 7-Sep-12 14-Sep-12**

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 0.3%    | 0.2%    | 0.3%    | 0.2%    | 0.2%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    |
| 1.5%    | 0.9%    | 0.7%    | 0.7%    | 0.8%    | 0.5%    | 0.7%    | 0.7%    | 0.8%    |
| 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.0%    | 0.1%    | 0.0%    |
| 0.4%    | 0.5%    | 0.2%    | 0.4%    | 0.4%    | 0.3%    | 0.4%    | 0.3%    | 0.3%    |
| 0.1%    | 0.1%    | 0.2%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    |
| 0.5%    | 0.3%    | 0.4%    | 0.3%    | 0.3%    | 0.1%    | 0.0%    | 0.1%    | 0.2%    |
| 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    |
| 0.2%    | 0.2%    | 0.2%    | 0.2%    | 0.2%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    |
| 99.7%   | 99.8%   | 99.7%   | 99.8%   | 99.8%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   |
| 98.5%   | 99.1%   | 99.3%   | 99.3%   | 99.2%   | 99.5%   | 99.3%   | 99.3%   | 99.2%   |
| 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 100.0%  | 99.9%   | 100.0%  |
| 99.6%   | 99.5%   | 99.8%   | 99.6%   | 99.6%   | 99.7%   | 99.6%   | 99.7%   | 99.7%   |
| 99.9%   | 99.9%   | 99.8%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   |
| 99.5%   | 99.7%   | 99.6%   | 99.7%   | 99.7%   | 99.9%   | 100.0%  | 99.9%   | 99.8%   |
| 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   |
| 99.752% | 99.789% | 99.785% | 99.813% | 99.830% | 99.897% | 99.876% | 99.864% | 99.876% |



**21-Sep-12 28-Sep-12 5-Oct-12 12-Oct-12 19-Oct-12 26-Oct-12 2-Nov-12 9-Nov-12 16-Nov-12**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% |
| 0.5% | 1.1% | 0.4% | 0.7% | 0.5% | 0.8% | 0.5% | 0.4% | 0.5% |
| 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| 0.4% | 0.3% | 0.2% | 0.4% | 0.4% | 0.3% | 0.2% | 0.3% | 0.3% |
| 0.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 0.1% | 0.1% | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% |
| 0.1% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 99.9%   | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 99.9%   | 99.9%   |
| 99.5%   | 98.9%   | 99.6%   | 99.3%   | 99.5%   | 99.2%   | 99.5%   | 99.6%   | 99.5%   |
| 100.0%  | 99.9%   | 99.9%   | 100.0%  | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  |
| 99.6%   | 99.7%   | 99.8%   | 99.6%   | 99.6%   | 99.7%   | 99.8%   | 99.7%   | 99.7%   |
| 99.9%   | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 99.9%   | 99.9%   | 99.9%   | 99.8%   | 99.8%   | 99.9%   | 99.9%   | 99.9%   | 99.9%   |
| 99.9%   | 100.0%  | 99.9%   | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 99.9%   | 99.9%   |
| 99.901% | 99.880% | 99.902% | 99.896% | 99.907% | 99.908% | 99.928% | 99.905% | 99.906% |



**23-Nov-12 30-Nov-12 7-Dec-12 14-Dec-12 21-Dec-12 28-Dec-12 4-Jan-13 11-Jan-13 18-Jan-13**

---

|      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|
| 0.0% | 0.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 0.7% | 0.3% | 0.5% | 0.5% | 0.3% | 0.5% | 0.4% | 0.6% | 0.4% |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 0.3% | 0.3% | 0.2% | 0.2% | 0.3% | 0.4% | 0.4% | 0.3% | 0.3% |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 0.0% | 0.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 100.0%  | 99.9%   | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 99.3%   | 99.7%   | 99.5%   | 99.5%   | 99.7%   | 99.5%   | 99.6%   | 99.4%   | 99.6%   |
| 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 99.7%   | 99.7%   | 99.8%   | 99.8%   | 99.7%   | 99.6%   | 99.6%   | 99.7%   | 99.7%   |
| 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 100.0%  | 99.9%   | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 100.0%  | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 99.9%   | 100.0%  | 100.0%  |
| 99.917% | 99.930% | 99.927% | 99.919% | 99.934% | 99.921% | 99.900% | 99.928% | 99.929% |



**25-Jan-13 1-Feb-13 8-Feb-13 15-Feb-13 22-Feb-13 1-Mar-13 8-Mar-13 15-Mar-13 22-Mar-13**

---

|         |         |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 0.0%    | 0.0%    | 0.0%    | 0.1%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    |
| 0.5%    | 0.2%    | 0.4%    | 0.3%    | 0.4%    | 0.1%    | 0.2%    | 0.2%    | 0.2%    |
| 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    |
| 0.3%    | 0.4%    | 0.3%    | 0.2%    | 0.3%    | 0.3%    | 0.0%    | 0.1%    | 0.0%    |
| 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    |
| 0.0%    | 0.0%    | 0.1%    | 0.1%    | 0.1%    | 0.0%    | 0.1%    | 0.0%    | 0.1%    |
| 0.1%    | 0.0%    | 0.0%    | 0.0%    | 0.0%    | 0.1%    | 0.0%    | 0.0%    | 0.0%    |
| 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.1%    | 0.0%    | 0.0%    | 0.0%    |
| 100.0%  | 100.0%  | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 99.5%   | 99.8%   | 99.6%   | 99.7%   | 99.6%   | 99.9%   | 99.8%   | 99.8%   | 99.8%   |
| 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 99.7%   | 99.6%   | 99.7%   | 99.8%   | 99.7%   | 99.7%   | 100.0%  | 99.9%   | 100.0%  |
| 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 100.0%  |
| 100.0%  | 100.0%  | 99.9%   | 99.9%   | 99.9%   | 100.0%  | 99.9%   | 100.0%  | 99.9%   |
| 99.9%   | 100.0%  | 100.0%  | 100.0%  | 100.0%  | 99.9%   | 100.0%  | 100.0%  | 100.0%  |
| 99.921% | 99.936% | 99.932% | 99.941% | 99.938% | 99.947% | 99.970% | 99.973% | 99.965% |



**29-Mar-13 5-Apr-13 12-Apr-13**

---

|      |      |
|------|------|
| 0.0% | 0.0% |
| 0.3% | 0.2% |
| 0.0% | 0.0% |
| 0.0% | 0.0% |
| 0.0% | 0.0% |
| 0.0% | 0.1% |
| 0.1% | 0.0% |
| 0.0% | 0.0% |

|         |         |
|---------|---------|
| 100.0%  | 100.0%  |
| 99.7%   | 99.8%   |
| 100.0%  | 100.0%  |
| 100.0%  | 100.0%  |
| 100.0%  | 100.0%  |
| 100.0%  | 99.9%   |
| 99.9%   | 100.0%  |
| 99.965% | 99.969% |

**Produced Natively**

|           | Total          |                |          |         |                        | % of Budget Achieved vs. True Rx's |                                | % of TRx |                        | Total Rx        |                | Total NRx       |                | Total RRx       |                | True Rx     |            | Trial Card Redemptions |       | % Chg vs. Prior Period |                 |                |         |                |               |                        |    |
|-----------|----------------|----------------|----------|---------|------------------------|------------------------------------|--------------------------------|----------|------------------------|-----------------|----------------|-----------------|----------------|-----------------|----------------|-------------|------------|------------------------|-------|------------------------|-----------------|----------------|---------|----------------|---------------|------------------------|----|
|           | 2012 Budget Rx | 2013 Budget Rx | Total Rx | True Rx | Trial Card Redemptions | Weekly True Rx Vs Budget           | Cumulative % True Rx vs Budget | True Rx  | Trial Card Redemptions | 1.75mg Total Rx | 3.5mg Total Rx | 1.75mg Total Rx | 3.5mg Total Rx | 1.75mg Total Rx | 3.5mg Total Rx | 1.75mg True | 3.5mg True | 1.75mg                 | 3.5mg | Total Rx               | 1.75mg Total Rx | 3.5mg Total Rx | True Rx | 1.75mg True Rx | 3.5mg True Rx | Trial Card Redemptions |    |
|           |                |                |          |         |                        |                                    |                                |          |                        |                 |                |                 |                |                 |                |             |            |                        |       |                        |                 |                |         |                |               |                        |    |
| 6-Apr-12  | 69             |                | 92       | 88      | 4                      | 128.0%                             | 128.0%                         | 96%      | 4%                     | 53              | 39             | 53              | 39             | 0               | 0              | 50          | 38         | 3                      | 1     | NA                     | NA              | NA             | NA      | NA             | NA            | NA                     | NA |
| 13-Apr-12 | 104            |                | 410      | 392     | 18                     | 376.7%                             | 277.8%                         | 96%      | 4%                     | 227             | 183            | 227             | 183            | 0               | 0              | 218         | 174        | 9                      | 9     | 345.7%                 | 328.3%          | 369.2%         | 345.5%  | 336.0%         | 357.9%        | 350.0%                 |    |
| 20-Apr-12 | 183            |                | 468      | 406     | 62                     | 221.5%                             | 248.8%                         | 87%      | 13%                    | 256             | 212            | 253             | 212            | 3               | 0              | 225         | 181        | 31                     | 31    | 14.1%                  | 12.8%           | 15.8%          | 3.6%    | 3.2%           | 4.0%          | 244.4%                 |    |
| 27-Apr-12 | 322            |                | 461      | 400     | 61                     | 124.1%                             | 189.5%                         | 87%      | 13%                    | 254             | 207            | 251             | 205            | 3               | 2              | 226         | 174        | 28                     | 33    | -1.5%                  | -0.8%           | -2.4%          | -1.5%   | 0.4%           | -3.9%         | -1.6%                  |    |
| 4-May-12  | 519            |                | 551      | 466     | 85                     | 89.8%                              | 146.3%                         | 85%      | 15%                    | 306             | 245            | 306             | 240            | 0               | 5              | 266         | 200        | 40                     | 45    | 19.5%                  | 20.5%           | 18.4%          | 16.5%   | 17.7%          | 14.9%         | 39.3%                  |    |
| 11-May-12 | 924            |                | 581      | 482     | 99                     | 52.2%                              | 105.3%                         | 83%      | 17%                    | 329             | 252            | 320             | 242            | 9               | 10             | 279         | 203        | 50                     | 49    | 5.4%                   | 7.5%            | 2.9%           | 3.4%    | 4.9%           | 1.5%          | 16.5%                  |    |
| 18-May-12 | 1,171          |                | 577      | 474     | 103                    | 40.5%                              | 82.3%                          | 82%      | 18%                    | 303             | 274            | 290             | 249            | 13              | 25             | 249         | 225        | 54                     | 49    | -0.7%                  | -7.9%           | 8.7%           | -1.7%   | -10.8%         | 10.8%         | 4.0%                   |    |
| 25-May-12 | 1,334          |                | 644      | 539     | 105                    | 40.4%                              | 70.2%                          | 84%      | 16%                    | 330             | 314            | 309             | 296            | 21              | 18             | 281         | 258        | 49                     | 56    | 11.6%                  | 8.9%            | 14.6%          | 13.7%   | 12.9%          | 14.7%         | 1.9%                   |    |
| 1-Jun-12  | 1,423          |                | 561      | 494     | 67                     | 34.7%                              | 61.8%                          | 88%      | 12%                    | 295             | 266            | 270             | 245            | 25              | 21             | 256         | 238        | 39                     | 28    | -12.9%                 | -10.6%          | -15.3%         | -8.3%   | -8.9%          | -7.8%         | -36.2%                 |    |
| 8-Jun-12  | 2,153          |                | 801      | 678     | 123                    | 31.5%                              | 53.9%                          | 85%      | 15%                    | 409             | 392            | 365             | 346            | 44              | 46             | 339         | 339        | 70                     | 53    | 42.8%                  | 38.6%           | 47.4%          | 37.2%   | 32.4%          | 42.4%         | 83.6%                  |    |
| 15-Jun-12 | 2,246          |                | 760      | 657     | 103                    | 29.2%                              | 48.6%                          | 86%      | 14%                    | 393             | 367            | 362             | 325            | 31              | 42             | 333         | 324        | 60                     | 43    | -5.1%                  | -3.9%           | -6.4%          | -3.1%   | -1.8%          | -4.4%         | -16.3%                 |    |
| 22-Jun-12 | 2,406          |                | 840      | 720     | 120                    | 29.9%                              | 45.1%                          | 86%      | 14%                    | 462             | 378            | 426             | 332            | 36              | 46             | 405         | 315        | 57                     | 63    | 10.5%                  | 17.6%           | 3.0%           | 9.6%    | 21.6%          | -2.8%         | 16.5%                  |    |
| 29-Jun-12 | 2,683          |                | 842      | 728     | 114                    | 27.1%                              | 42.0%                          | 86%      | 14%                    | 443             | 399            | 395             | 346            | 48              | 53             | 372         | 356        | 71                     | 43    | 0.2%                   | -4.1%           | 5.6%           | 1.1%    | -8.1%          | 13.0%         | -5.0%                  |    |
| 6-Jul-12  | 2,488          |                | 715      | 646     | 69                     | 26.0%                              | 39.8%                          | 90%      | 10%                    | 367             | 348            | 325             | 281            | 42              | 67             | 333         | 313        | 34                     | 35    | -15.1%                 | -17.2%          | -12.8%         | -11.3%  | -10.5%         | -12.1%        | -39.5%                 |    |
| 13-Jul-12 | 3,222          |                | 904      | 808     | 96                     | 25.1%                              | 37.5%                          | 89%      | 11%                    | 417             | 487            | 343             | 405            | 74              | 82             | 368         | 440        | 49                     | 47    | 26.4%                  | 13.6%           | 39.9%          | 25.1%   | 10.5%          | 40.6%         | 39.1%                  |    |
| 20-Jul-12 | 3,606          |                | 894      | 789     | 105                    | 21.9%                              | 35.3%                          | 88%      | 12%                    | 451             | 443            | 387             | 358            | 64              | 85             | 403         | 386        | 48                     | 57    | -1.1%                  | 8.2%            | -9.0%          | -2.4%   | 9.5%           | -12.3%        | 9.4%                   |    |
| 27-Jul-12 | 3,926          |                | 939      | 818     | 121                    | 20.8%                              | 33.3%                          | 87%      | 13%                    | 458             | 481            | 403             | 398            | 55              | 83             | 391         | 427        | 67                     | 54    | 5.0%                   | 1.6%            | 8.6%           | 3.7%    | -3.0%          | 10.6%         | 15.2%                  |    |
| 3-Aug-12  | 4,452          |                | 907      | 785     | 122                    | 17.6%                              | 31.2%                          | 87%      | 13%                    | 461             | 446            | 392             | 367            | 69              | 79             | 393         | 392        | 68                     | 54    | -3.4%                  | 0.7%            | -7.3%          | -4.0%   | 0.5%           | -8.2%         | 0.8%                   |    |
| 10-Aug-12 | 4,679          |                | 1,063    | 954     | 109                    | 20.4%                              | 29.9%                          | 90%      | 10%                    | 510             | 553            | 458             | 446            | 52              | 107            | 458         | 496        | 52                     | 57    | 17.2%                  | 10.6%           | 24.0%          | 21.5%   | 16.5%          | 26.5%         | -10.7%                 |    |
| 17-Aug-12 | 4,809          |                | 1,094    | 977     | 117                    | 20.3%                              | 28.8%                          | 89%      | 11%                    | 545             | 549            | 471             | 427            | 74              | 122            | 479         | 498        | 66                     | 51    | 2.9%                   | 6.9%            | -0.7%          | 2.4%    | 4.6%           | 0.4%          | 7.3%                   |    |
| 24-Aug-12 | 5,086          |                | 1,102    | 967     | 135                    | 19.0%                              | 27.8%                          | 88%      | 12%                    | 547             | 555            | 459             | 444            | 88              | 111            | 466         | 501        | 81                     | 54    | 0.7%                   | 0.4%            | 1.1%           | -1.0%   | -2.7%          | 0.6%          | 15.4%                  |    |
| 31-Aug-12 | 5,166          |                | 1,093    | 975     | 118                    | 18.9%                              | 26.9%                          | 89%      | 11%                    | 539             | 554            | 433             | 426            | 106             | 128            | 479         | 496        | 60                     | 58    | -0.8%                  | -1.5%           | -0.2%          | 0.8%    | 2.8%           | -1.0%         | -12.6%                 |    |
| 7-Sep-12  | 4,357          |                | 974      | 873     | 101                    | 20.0%                              | 26.4%                          | 90%      | 10%                    | 465             | 509            | 372             | 382            | 93              | 127            | 412         | 461        | 53                     | 48    | -10.9%                 | -13.7%          | -8.1%          | -10.5%  | -14.0%         | -7.1%         | -14.4%                 |    |
| 14-Sep-12 | 5,453          |                | 1,194    | 1,078   | 116                    | 19.8%                              | 25.8%                          | 90%      | 10%                    | 590             | 604            | 489             | 468            | 101             | 136            | 539         | 539        | 51                     | 65    | 22.6%                  | 26.9%           | 18.7%          | 23.5%   | 30.8%          | 16.9%         | 14.9%                  |    |



NRx, RRx and TRx by Strength  
 Distribution of Rx's by Strength  
 Distribution of NRx, RRx and TRx by Strength  
 Weekly Growth in Intermezzo TRx's

Data includes retail pharmacy, mail order and LTC channels


| Week #       | Week Ending | Intermezzo New, Refill and Total Prescriptions by Strength |               |               |               |              |               |               |               |               |
|--------------|-------------|------------------------------------------------------------|---------------|---------------|---------------|--------------|---------------|---------------|---------------|---------------|
|              |             | Total                                                      |               | 1.75mg        |               | 3.5mg        |               |               |               |               |
|              |             | NRx                                                        | TRx           | NRx           | TRx           | NRx          | TRx           |               |               |               |
| Week 1*      | 6-Apr-12    | 92                                                         | 0             | 53            | 0             | 39           | 0             |               |               |               |
| Week 2       | 13-Apr-12   | 410                                                        | 0             | 227           | 0             | 183          | 0             |               |               |               |
| Week 3       | 20-Apr-12   | 465                                                        | 3             | 253           | 3             | 212          | 0             |               |               |               |
| Week 4       | 27-Apr-12   | 456                                                        | 5             | 251           | 3             | 205          | 2             |               |               |               |
| Week 5       | 4-May-12    | 546                                                        | 5             | 306           | 0             | 240          | 5             |               |               |               |
| Week 6       | 11-May-12   | 562                                                        | 19            | 320           | 9             | 242          | 10            |               |               |               |
| Week 7       | 18-May-12   | 539                                                        | 38            | 290           | 13            | 249          | 25            |               |               |               |
| Week 8       | 25-May-12   | 605                                                        | 39            | 309           | 21            | 296          | 18            |               |               |               |
| Week 9       | 1-Jun-12    | 515                                                        | 46            | 279           | 25            | 245          | 21            |               |               |               |
| Week 10      | 8-Jun-12    | 711                                                        | 90            | 401           | 44            | 346          | 46            |               |               |               |
| Week 11      | 15-Jun-12   | 687                                                        | 73            | 365           | 31            | 325          | 42            |               |               |               |
| Week 12      | 22-Jun-12   | 758                                                        | 82            | 426           | 36            | 332          | 46            |               |               |               |
| Week 13      | 29-Jun-12   | 741                                                        | 101           | 395           | 48            | 346          | 53            |               |               |               |
| Week 14      | 6-Jul-12    | 606                                                        | 109           | 325           | 42            | 281          | 67            |               |               |               |
| Week 15      | 13-Jul-12   | 748                                                        | 156           | 343           | 74            | 417          | 82            |               |               |               |
| Week 16      | 20-Jul-12   | 745                                                        | 149           | 387           | 64            | 358          | 85            |               |               |               |
| Week 17      | 27-Jul-12   | 801                                                        | 138           | 403           | 55            | 398          | 83            |               |               |               |
| Week 18      | 3-Aug-12    | 759                                                        | 148           | 392           | 69            | 367          | 79            |               |               |               |
| Week 19      | 10-Aug-12   | 904                                                        | 159           | 458           | 52            | 446          | 107           |               |               |               |
| Week 20      | 17-Aug-12   | 898                                                        | 196           | 471           | 74            | 447          | 122           |               |               |               |
| Week 21      | 24-Aug-12   | 903                                                        | 199           | 459           | 88            | 444          | 111           |               |               |               |
| Week 22      | 31-Aug-12   | 859                                                        | 234           | 433           | 106           | 547          | 128           |               |               |               |
| Week 23      | 7-Sep-12    | 754                                                        | 220           | 372           | 93            | 382          | 127           |               |               |               |
| Week 24      | 14-Sep-12   | 957                                                        | 237           | 489           | 101           | 509          | 136           |               |               |               |
| Week 25      | 21-Sep-12   | 972                                                        | 306           | 461           | 129           | 511          | 177           |               |               |               |
| Week 26      | 28-Sep-12   | 1,141                                                      | 279           | 478           | 124           | 663          | 155           |               |               |               |
| Week 27      | 5-Oct-12    | 915                                                        | 297           | 436           | 128           | 564          | 169           |               |               |               |
| Week 28      | 12-Oct-12   | 1,017                                                      | 267           | 485           | 107           | 592          | 160           |               |               |               |
| Week 29      | 19-Oct-12   | 981                                                        | 288           | 452           | 120           | 572          | 168           |               |               |               |
| Week 30      | 26-Oct-12   | 1,026                                                      | 277           | 453           | 44            | 597          | 233           |               |               |               |
| Week 31      | 2-Nov-12    | 997                                                        | 301           | 475           | 115           | 518          | 186           |               |               |               |
| Week 32      | 9-Nov-12    | 1,043                                                      | 340           | 467           | 151           | 576          | 189           |               |               |               |
| Week 33      | 16-Nov-12   | 1,019                                                      | 328           | 467           | 138           | 513          | 207           |               |               |               |
| Week 34      | 23-Nov-12   | 810                                                        | 299           | 369           | 116           | 485          | 141           |               |               |               |
| Week 35      | 30-Nov-12   | 955                                                        | 353           | 466           | 133           | 599          | 220           |               |               |               |
| Week 36      | 7-Dec-12    | 1,046                                                      | 339           | 483           | 132           | 563          | 207           |               |               |               |
| Week 37      | 14-Dec-12   | 1,040                                                      | 449           | 521           | 188           | 709          | 261           |               |               |               |
| Week 38      | 21-Dec-12   | 1,137                                                      | 397           | 537           | 169           | 706          | 228           |               |               |               |
| Week 39      | 28-Dec-12   | 654                                                        | 341           | 307           | 144           | 347          | 197           |               |               |               |
| Week 40      | 4-Jan-13    | 663                                                        | 322           | 289           | 127           | 374          | 195           |               |               |               |
| Week 41      | 11-Jan-13   | 916                                                        | 374           | 417           | 147           | 564          | 227           |               |               |               |
| Week 42      | 18-Jan-13   | 1,151                                                      | 381           | 553           | 144           | 697          | 237           |               |               |               |
| Week 43      | 25-Jan-13   | 1,187                                                      | 340           | 625           | 122           | 747          | 218           |               |               |               |
| Week 44      | 1-Feb-13    | 1,417                                                      | 365           | 741           | 141           | 882          | 224           |               |               |               |
| Week 45      | 8-Feb-13    | 1,461                                                      | 369           | 730           | 126           | 856          | 243           |               |               |               |
| Week 46      | 15-Feb-13   | 1,479                                                      | 408           | 779           | 157           | 936          | 251           |               |               |               |
| Week 47      | 22-Feb-13   | 1,493                                                      | 414           | 783           | 155           | 938          | 259           |               |               |               |
| Week 48      | 1-Mar-13    | 1,534                                                      | 429           | 804           | 177           | 981          | 252           |               |               |               |
| Week 49      | 8-Mar-13    | 1,474                                                      | 474           | 744           | 166           | 910          | 308           |               |               |               |
| Week 50      | 15-Mar-13   | 1,442                                                      | 443           | 747           | 176           | 923          | 267           |               |               |               |
| Week 51      | 22-Mar-13   | 1,416                                                      | 523           | 739           | 228           | 967          | 295           |               |               |               |
| Week 52      | 29-Mar-13   | 1,401                                                      | 513           | 695           | 183           | 878          | 330           |               |               |               |
| Week 53      | 5-Apr-13    | 1,280                                                      | 449           | 692           | 177           | 869          | 272           |               |               |               |
| Week 54      | 12-Apr-13   | 1,367                                                      | 490           | 666           | 197           | 863          | 293           |               |               |               |
| Week 55      | 19-Apr-13   | 1,305                                                      | 464           | 678           | 189           | 867          | 275           |               |               |               |
| Week 56      | 26-Apr-13   | 1,228                                                      | 520           | 748           | 209           | 803          | 311           |               |               |               |
| Week 57      | 3-May-13    | 1,252                                                      | 538           | 790           | 223           | 863          | 315           |               |               |               |
| Week 58      | 10-May-13   | 1,183                                                      | 511           | 694           | 210           | 764          | 301           |               |               |               |
| Week 59      | 17-May-13   | 1,177                                                      | 518           | 695           | 202           | 773          | 316           |               |               |               |
| Week 60      | 24-May-13   | 1,114                                                      | 495           | 609           | 187           | 725          | 308           |               |               |               |
| Week 61      | 31-May-13   | 927                                                        | 506           | 480           | 175           | 655          | 331           |               |               |               |
| Week 62      | 7-Jun-13    | 1,097                                                      | 486           | 503           | 191           | 694          | 295           |               |               |               |
| Week 63      | 14-Jun-13   | 1,066                                                      | 561           | 529           | 214           | 743          | 347           |               |               |               |
| Week 64      | 21-Jun-13   | 1,046                                                      | 517           | 499           | 204           | 703          | 313           |               |               |               |
| Week 65      | 28-Jun-13   | 966                                                        | 495           | 462           | 180           | 672          | 315           |               |               |               |
| Week 66      | 5-Jul-13    | 853                                                        | 469           | 408           | 186           | 594          | 283           |               |               |               |
| Week 67      | 12-Jul-13   | 985                                                        | 518           | 503           | 206           | 656          | 322           |               |               |               |
| Week 68      | 19-Jul-13   | 1,016                                                      | 517           | 533           | 209           | 678          | 316           |               |               |               |
| Week 69      | 26-Jul-13   | 1,017                                                      | 521           | 538           | 214           | 718          | 327           |               |               |               |
| Week 70      | 2-Aug-13    | 989                                                        | 494           | 460           | 197           | 657          | 297           |               |               |               |
| Week 71      | 9-Aug-13    | 965                                                        | 517           | 482           | 214           | 673          | 306           |               |               |               |
| Week 72      | 16-Aug-13   | 945                                                        | 488           | 458           | 178           | 636          | 310           |               |               |               |
| Week 73      | 23-Aug-13   | 901                                                        | 498           | 418           | 179           | 597          | 319           |               |               |               |
| Week 74      | 30-Aug-13   | 1,056                                                      | 512           | 568           | 207           | 688          | 331           |               |               |               |
| Week 75      | 6-Sep-13    | 958                                                        | 476           | 439           | 174           | 613          | 302           |               |               |               |
| Week 76      | 13-Sep-13   | 1,065                                                      | 456           | 521           | 192           | 695          | 323           |               |               |               |
| Week 77      | 20-Sep-13   | 1,022                                                      | 536           | 494           | 206           | 700          | 330           |               |               |               |
| Week 78      | 27-Sep-13   | 1,000                                                      | 492           | 458           | 182           | 640          | 310           |               |               |               |
| Week 79      | 4-Oct-13    | 1,007                                                      | 515           | 467           | 180           | 647          | 335           |               |               |               |
| <b>TOTAL</b> | <b>2013</b> | <b>36,902</b>                                              | <b>14,424</b> | <b>64,735</b> | <b>22,603</b> | <b>7,278</b> | <b>29,881</b> | <b>23,218</b> | <b>11,636</b> | <b>34,854</b> |
| <b>YTD</b>   | <b>2013</b> | <b>36,902</b>                                              | <b>14,424</b> | <b>64,735</b> | <b>22,603</b> | <b>7,278</b> | <b>29,881</b> | <b>23,218</b> | <b>11,636</b> | <b>34,854</b> |

| Week #  | Week Ending | Distribution of Total Intermezzo Prescriptions by Strength |        |        |       |        |       |
|---------|-------------|------------------------------------------------------------|--------|--------|-------|--------|-------|
|         |             | Total                                                      |        | 1.75mg |       | 3.5mg  |       |
|         |             | NRx                                                        | TRx    | NRx    | TRx   | NRx    | TRx   |
| Week 1* | 6-Apr-12    | 100.0%                                                     | 100.0% | 100.0% | 57.6% | 0.0%   | 57.6% |
| Week 2  | 13-Apr-12   | 100.0%                                                     | 100.0% | 100.0% | 55.4% | 0.0%   | 55.4% |
| Week 3  | 20-Apr-12   | 100.0%                                                     | 100.0% | 100.0% | 54.4% | 100.0% | 54.7% |
| Week 4  | 27-Apr-12   | 100.0%                                                     | 100.0% | 100.0% | 55.0% | 60.0%  | 55.1% |
| Week 5  | 4-May-12    | 100.0%                                                     | 100.0% | 100.0% | 56.0% | 0.0%   | 55.5% |
| Week 6  | 11-May-12   | 100.0%                                                     | 100.0% | 100.0% | 56.9% | 47.4%  | 56.6% |
| Week 7  | 18-May-12   | 100.0%                                                     | 100.0% | 100.0% | 53.8% | 34.2%  | 52.5% |
| Week 8  | 25-May-12   | 100.0%                                                     | 100.0% | 100.0% | 51.1% | 53.8%  | 51.2% |
| Week 9  | 1-Jun-12    | 100.0%                                                     | 100.0% | 100.0% | 52.4% | 54.3%  | 52.6% |
| Week 10 | 8-Jun-12    | 100.0%                                                     | 100.0% | 100.0% | 51.3% | 48.9%  | 51.1% |
| Week 11 | 15-Jun-12   | 100.0%                                                     | 100.0% | 100.0% | 52.7% | 42.5%  | 51.7% |
| Week 12 | 22-Jun-12   | 100.0%                                                     | 100.0% | 100.0% | 56.2% | 43.9%  | 55.0% |
| Week 13 | 29-Jun-12   | 100.0%                                                     | 100.0% | 100.0% | 53.3% | 47.5%  | 52.6% |
| Week 14 | 6-Jul-12    | 100.0%                                                     | 100.0% | 100.0% | 53.6% | 38.5%  | 51.3% |
| Week 15 | 13-Jul-12   | 100.0%                                                     | 100.0% | 100.0% | 45.9% | 47.4%  | 46.1% |
| Week 16 | 20-Jul-12   | 100.0%                                                     | 100.0% | 100.0% | 51.9% | 43.0%  | 50.4% |
| Week 17 | 27-Jul-12   | 100.0%                                                     | 100.0% | 100.0% | 50.3% | 39.9%  | 48.8% |
| Week 18 | 3-Aug-12    | 100.0%                                                     | 100.0% | 100.0% | 51.6% | 46.6%  | 50.8% |
| Week 19 | 10-Aug-12   | 100.0%                                                     | 100.0% | 100.0% | 50.7% | 32.7%  | 48.0% |
| Week 20 | 17-Aug-12   | 100.0%                                                     | 100.0% | 100.0% | 52.4% | 37.8%  | 49.8% |
| Week 21 | 24-Aug-12   | 100.0%                                                     | 100.0% | 100.0% | 50.8% | 44.2%  | 49.6% |
| Week 22 | 31-Aug-12   | 100.0%                                                     | 100.0% | 100.0% | 50.4% | 45.3%  | 49.3% |
| Week 23 | 7-Sep-12    | 100.0%                                                     | 100.0% | 100.0% | 49.3% | 42.3%  | 47.7% |
| Week 24 | 14-Sep-12   | 100.0%                                                     | 100.0% | 100.0% | 51.1% | 42.6%  | 49.4% |
| Week 25 | 21-Sep-12   | 100.0%                                                     | 100.0% | 100.0% | 47.4% | 42.2%  | 46.2% |
| Week 26 | 28-Sep-12   | 100.0%                                                     | 100.0% | 100.0% | 41.9% | 44.4%  | 42.4% |
| Week 27 | 5-Oct-12    | 100.0%                                                     | 100.0% | 100.0% | 47.7% | 43.1%  | 46.5% |
| Week 28 | 12-Oct-12   | 100.0%                                                     | 100.0% | 100.0% | 47.7% | 40.1%  | 46.1% |
| Week 29 | 19-Oct-12   | 100.0%                                                     | 100.0% | 100.0% | 46.1% | 41.7%  | 45.1% |
| Week 30 | 26-Oct-12   | 100.0%                                                     | 100.0% | 100.0% | 53.9% | 15.9%  | 45.8% |
| Week 31 | 2-Nov-12    | 100.0%                                                     | 100.0% | 100.0% | 48.0% | 38.2%  | 45.8% |
| Week 32 | 9-Nov-12    | 100.0%                                                     | 100.0% | 100.0% | 44.8% | 44.4%  | 44.7% |
| Week 33 | 16-Nov-12   | 100.0%                                                     | 100.0% | 100.0% | 49.7% | 42.1%  | 47.8% |
| Week 34 | 23-Nov-12   | 100.0%                                                     | 100.0% | 100.0% | 45.6% | 38.8%  | 43.7% |
| Week 35 | 30-Nov-12   | 100.0%                                                     | 100.0% | 100.0% | 48.8% | 37.7%  | 45.8% |
| Week 36 | 7-Dec-12    | 100.0%                                                     | 100.0% | 100.0% | 46.2% | 38.9%  | 44.4% |
| Week 37 | 14-Dec-12   | 100.0%                                                     | 100.0% | 100.0% | 50.1% | 41.9%  | 47.6% |
| Week 38 | 21-Dec-12   | 100.0%                                                     | 100.0% | 100.0% | 47.2% | 42.6%  | 46.0% |
| Week 39 | 28-Dec-12   | 100.0%                                                     | 100.0% | 100.0% | 46.9% | 42.4%  | 45.3% |
| Week 40 | 4-Jan-13    | 100.0%                                                     | 100.0% | 100.0% | 43.6% | 39.4%  | 42.2% |
| Week 41 | 11-Jan-13   | 100.0%                                                     | 100.0% | 100.0% | 45.5% | 39.3%  | 43.7% |
| Week 42 | 18-Jan-13   | 100.0%                                                     | 100.0% | 100.0% | 48.0% | 37.8%  | 45.5% |
| Week 43 | 25-Jan-13   | 100.0%                                                     | 100.0% | 100.0% | 52.7% | 35.9%  | 48.9% |
| Week 44 | 1-Feb-13    | 100.0%                                                     | 100.0% | 100.0% | 52.3% | 38.6%  | 49.5% |
| Week 45 | 8-Feb-13    | 100.0%                                                     | 100.0% | 100.0% | 50.0% | 34.1%  | 46.8% |
| Week 46 | 15-Feb-13   | 100.0%                                                     | 100.0% | 100.0% | 52.7% | 38.5%  | 49.6% |
| Week 47 | 22-Feb-13   | 100.0%                                                     | 100.0% | 100.0% | 52.4% | 37.4%  | 49.2% |
| Week 48 | 1-Mar-13    | 100.0%                                                     | 100.0% | 100.0% | 52.4% | 41.3%  | 50.0% |
| Week 49 | 8-Mar-13    | 100.0%                                                     | 100.0% | 100.0% | 50.5% | 35.0%  | 46.7% |
| Week 50 | 15-Mar-13   | 100.0%                                                     | 100.0% | 100.0% | 51.8% | 39.7%  | 49.0% |
| Week 51 | 22-Mar-13   | 100.0%                                                     | 100.0% | 100.0% | 52.2% | 43.6%  | 49.9% |
| Week 52 | 29-Mar-13   | 100.0%                                                     | 100.0% | 100.0% | 49.6% | 35.7%  | 45.9% |
| Week 53 | 5-Apr-13    | 100.0%                                                     | 100.0% | 100.0% | 54.1% | 39.4%  | 50.3% |
| Week 54 | 12-Apr-13   | 100.0%                                                     | 100.0% | 100.0% | 48.7% | 40.2%  | 46.5% |
| Week 55 | 19-Apr-13   | 100.0%                                                     | 100.0% | 100.0% | 52.0% | 40.7%  | 49.0% |
| Week 56 | 26-Apr-13   | 100.0%                                                     | 100.0% | 100.0% | 48.4% | 40.2%  | 45.9% |
| Week 57 | 3-May-13    | 100.0%                                                     | 100.0% | 100.0% | 51.1% | 41.4%  | 48.2% |
| Week 58 | 10-May-13   | 100.0%                                                     | 100.0% | 100.0% | 46.8% | 41.1%  | 45.1% |
| Week 59 | 17-May-13   | 100.0%                                                     | 100.0% | 100.0% | 48.5% | 39.0%  | 45.6% |
| Week 60 | 24-May-13   | 100.0%                                                     | 100.0% | 100.0% | 48.3% | 37.8%  | 45.1% |
| Week 61 | 31-May-13   | 100.0%                                                     | 100.0% | 100.0% | 51.8% | 34.6%  | 45.7% |
| Week 62 | 7-Jun-13    | 100.0%                                                     | 100.0% | 100.0% | 45.9% | 39.3%  | 43.8% |
| Week 63 | 14-Jun-13   | 100.0%                                                     | 100.0% | 100.0% | 49.6% | 38.1%  | 45.7% |
| Week 64 | 21-Jun-13   | 100.0%                                                     | 100.0% | 100.0% | 47.7% | 35.5%  | 45.0% |
| Week 65 | 28-Jun-13   | 100.0%                                                     | 100.0% | 100.0% | 50.9% | 36.4%  | 46.0% |
| Week 66 | 5-Jul-13    | 100.0%                                                     | 100.0% | 100.0% | 47.8% | 39.7%  | 44.9% |
| Week 67 | 12-Jul-13   | 100.0%                                                     | 100.0% | 100.0% | 46.7% | 37.8%  | 43.6% |
| Week 68 | 19-Jul-13   | 100.0%                                                     | 100.0% | 100.0% | 46.9% | 38.9%  | 44.2% |
| Week 69 | 26-Jul-13   | 100.0%                                                     | 100.0% | 100.0% | 51.5% | 37.2%  | 46.7% |
| Week 70 | 2-Aug-13    | 100.0%                                                     | 100.0% | 100.0% | 46.5% |        |       |

# Intermezzo True Rx's (Source: IMS NPA/McKesson) 2013



# Intermezzo True Rx's (Source: IMS NPA/McKesson) 2012




2012  
Budget Rx  
Total Rx


TRXs (absolute)

6-Apr-12 6-May-12 6-Jun-12 6-Jul-12 6-Aug-12 6-Sep-12 6-Oct-12 6-Nov-12 6-Dec-12 6-Jan-13


### Total TRx, True Rx and Trial Card Redemptions (Source: IMS NPA/McKesson)




## True Rx vs. Trial Card Redemptions (Source: IMS NPA/McKesson)




**Intermezzo Total Rxs by Dosage Strength  
Week ending October 4, 2013  
(Source: IMS NPA)**




**Intermezzo Total NRx vs. Total RRx  
Week ending October 4, 2013  
(Source: IMS NPA)**



## Intermezzo Total Rx Share of Insomnia



## Intermezzo True Rx Share of Insomnia Ma



Source: IMS NPA Data

Data includes retail pharmacy, mail order and LTC channels

Numbers are absolute

|                                    | 23-Mar-12 | 30-Mar-12 | 6-Apr-12      | 13-Apr-12     |
|------------------------------------|-----------|-----------|---------------|---------------|
| <b>Total Market TRx</b>            | 1,370,896 | 1,384,239 | 1,432,279     | 1,369,297     |
| Intermezzo Total                   | -         | 0         | 92            | 410           |
| Intermezzo True                    |           |           | 88            | 392           |
| <b>Share of Market (Total TRx)</b> |           |           | <b>0.006%</b> | <b>0.030%</b> |
| <b>Share of Market (True TRx)</b>  |           |           | <b>0.006%</b> | <b>0.029%</b> |

| 20-Apr-12     | 27-Apr-12     | 4-May-12      | 11-May-12     | 18-May-12     | 25-May-12     |
|---------------|---------------|---------------|---------------|---------------|---------------|
| 1,375,370     | 1,382,029     | 1,465,269     | 1,372,778     | 1,358,917     | 1,377,379     |
| 468           | 461           | 551           | 581           | 577           | 644           |
| 406           | 400           | 466           | 482           | 474           | 539           |
| <b>0.034%</b> | <b>0.033%</b> | <b>0.038%</b> | <b>0.042%</b> | <b>0.042%</b> | <b>0.047%</b> |
| <b>0.030%</b> | <b>0.029%</b> | <b>0.032%</b> | <b>0.035%</b> | <b>0.035%</b> | <b>0.039%</b> |

| 1-Jun-12      | 8-Jun-12      | 15-Jun-12     | 22-Jun-12     | 29-Jun-12     | 6-Jul-12      | 13-Jul-12     |
|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| 1,308,074     | 1,406,687     | 1,355,575     | 1,354,480     | 1,386,497     | 1,324,286     | 1,403,405     |
| 561           | 801           | 760           | 840           | 842           | 715           | 904           |
| 494           | 678           | 657           | 720           | 728           | 646           | 808           |
| <b>0.043%</b> | <b>0.057%</b> | <b>0.056%</b> | <b>0.062%</b> | <b>0.061%</b> | <b>0.054%</b> | <b>0.064%</b> |
| <b>0.038%</b> | <b>0.048%</b> | <b>0.048%</b> | <b>0.053%</b> | <b>0.053%</b> | <b>0.049%</b> | <b>0.058%</b> |

| 20-Jul-12     | 27-Jul-12     | 3-Aug-12      | 10-Aug-12     | 17-Aug-12     | 24-Aug-12     |
|---------------|---------------|---------------|---------------|---------------|---------------|
| 1,369,334     | 1,324,286     | 1,369,334     | 1,324,286     | 1,369,334     | 1,377,799     |
| 894           | 939           | 907           | 1,063         | 1,094         | 1,102         |
| 789           | 818           | 785           | 954           | 977           | 967           |
| <b>0.065%</b> | <b>0.071%</b> | <b>0.066%</b> | <b>0.080%</b> | <b>0.080%</b> | <b>0.080%</b> |
| <b>0.058%</b> | <b>0.062%</b> | <b>0.057%</b> | <b>0.072%</b> | <b>0.071%</b> | <b>0.070%</b> |

| 31-Aug-12     | 7-Sep-12      | 14-Sep-12     | 21-Sep-12     | 28-Sep-12     |
|---------------|---------------|---------------|---------------|---------------|
| 1,415,168     | 1,359,788     | 1,416,839     | 1,394,006     | 1,407,414     |
| 1,093         | 974           | 1,194         | 1,278         | 1,265         |
| 975           | 873           | 1,078         | 1,144         | 1,158         |
| <b>0.077%</b> | <b>0.072%</b> | <b>0.084%</b> | <b>0.092%</b> | <b>0.090%</b> |
| <b>0.069%</b> | <b>0.064%</b> | <b>0.076%</b> | <b>0.082%</b> | <b>0.082%</b> |

| 5-Oct-12      | 12-Oct-12     | 19-Oct-12     | 26-Oct-12     | 2-Nov-12      |
|---------------|---------------|---------------|---------------|---------------|
| 1,461,046     | 1,385,829     | 1,391,512     | 1,389,095     | 1,378,667     |
| 1,212         | 1,284         | 1,269         | 1,303         | 1,298         |
| 1,086         | 1,187         | 1,150         | 1,179         | 1,183         |
| <b>0.083%</b> | <b>0.093%</b> | <b>0.091%</b> | <b>0.094%</b> | <b>0.094%</b> |
| <b>0.074%</b> | <b>0.086%</b> | <b>0.083%</b> | <b>0.085%</b> | <b>0.086%</b> |

| 9-Nov-12      | 16-Nov-12     | 23-Nov-12     | 30-Nov-12     | 7-Dec-12      |
|---------------|---------------|---------------|---------------|---------------|
| 1,409,855     | 1,391,492     | 1,208,449     | 1,482,181     | 1,470,840     |
| 1,383         | 1,347         | 1,109         | 1,308         | 1,385         |
| 1,270         | 1,221         | 1,026         | 1,208         | 1,264         |
| <b>0.098%</b> | <b>0.097%</b> | <b>0.092%</b> | <b>0.088%</b> | <b>0.094%</b> |
| <b>0.090%</b> | <b>0.088%</b> | <b>0.085%</b> | <b>0.082%</b> | <b>0.086%</b> |

| 14-Dec-12     | 21-Dec-12     | 28-Dec-12     | 4-Jan-13      | 11-Jan-13     |
|---------------|---------------|---------------|---------------|---------------|
| 1,417,828     | 1,444,247     | 1,170,577     | 1,356,237     | 1,475,389     |
| 1,489         | 1,534         | 995           | 985           | 1,290         |
| 1,377         | 1,430         | 943           | 918           | 1,205         |
| <b>0.105%</b> | <b>0.106%</b> | <b>0.085%</b> | <b>0.073%</b> | <b>0.087%</b> |
| <b>0.097%</b> | <b>0.099%</b> | <b>0.081%</b> | <b>0.068%</b> | <b>0.082%</b> |

| 18-Jan-13     | 25-Jan-13     | 1-Feb-13      | 8-Feb-13      | 15-Feb-13     |
|---------------|---------------|---------------|---------------|---------------|
| 1,422,268     | 1,317,001     | 1,399,365     | 1,435,241     | 1,378,842     |
| 1,532         | 1,527         | 1,782         | 1,830         | 1,887         |
| 1,377         | 1,354         | 1,568         | 1,606         | 1,638         |
| <b>0.108%</b> | <b>0.116%</b> | <b>0.127%</b> | <b>0.128%</b> | <b>0.137%</b> |
| <b>0.097%</b> | <b>0.103%</b> | <b>0.112%</b> | <b>0.112%</b> | <b>0.119%</b> |

| 22-Feb-13     | 1-Mar-13      | 8-Mar-13      | 15-Mar-13     | 22-Mar-13     |
|---------------|---------------|---------------|---------------|---------------|
| 1,334,165     | 1,439,081     | 1,454,057     | 1,390,065     | 1,372,433     |
| 1,907         | 1,963         | 1,948         | 1,885         | 1,939         |
| 1,631         | 1,664         | 1,675         | 1,602         | 1,665         |
| <b>0.143%</b> | <b>0.136%</b> | <b>0.134%</b> | <b>0.136%</b> | <b>0.141%</b> |
| <b>0.122%</b> | <b>0.116%</b> | <b>0.115%</b> | <b>0.115%</b> | <b>0.121%</b> |

| 29-Mar-13     | 5-Apr-13      | 12-Apr-13     | 19-Apr-13     | 26-Apr-13     |
|---------------|---------------|---------------|---------------|---------------|
| 1,341,216     | 1,403,587     | 1,369,962     | 1,344,785     | 1,348,514     |
| 1,914         | 1,729         | 1,857         | 1,769         | 1,748         |
| 1,632         | 1,492         | 1,627         | 1,559         | 1,497         |
| <b>0.143%</b> | <b>0.123%</b> | <b>0.136%</b> | <b>0.132%</b> | <b>0.130%</b> |
| <b>0.122%</b> | <b>0.106%</b> | <b>0.119%</b> | <b>0.116%</b> | <b>0.111%</b> |

| 3-May-13      | 10-May-13     | 17-May-13     | 24-May-13     | 31-May-13     |
|---------------|---------------|---------------|---------------|---------------|
| 1,420,123     | 1,369,002     | 1,338,281     | 1,353,362     | 1,263,602     |
| 1,790         | 1,694         | 1,695         | 1,609         | 1,433         |
| 1,569         | 1,507         | 1,528         | 1,445         | 1,302         |
| <b>0.126%</b> | <b>0.124%</b> | <b>0.127%</b> | <b>0.119%</b> | <b>0.113%</b> |
| <b>0.110%</b> | <b>0.110%</b> | <b>0.114%</b> | <b>0.107%</b> | <b>0.103%</b> |

| 7-Jun-13      | 14-Jun-13     | 21-Jun-13     | 28-Jun-13     | 5-Jul-13      |
|---------------|---------------|---------------|---------------|---------------|
| 1,416,696     | 1,345,466     | 1,329,143     | 1,324,936     | 1,295,506     |
| 1,583         | 1,627         | 1,563         | 1,461         | 1,322         |
| 1,419         | 1,499         | 1,414         | 1,325         | 1,201         |
| <b>0.112%</b> | <b>0.121%</b> | <b>0.118%</b> | <b>0.110%</b> | <b>0.102%</b> |
| <b>0.100%</b> | <b>0.111%</b> | <b>0.106%</b> | <b>0.100%</b> | <b>0.093%</b> |

| 12-Jul-13     | 19-Jul-13     | 26-Jul-13     | 2-Aug-13      | 9-Aug-13      |
|---------------|---------------|---------------|---------------|---------------|
| 1,391,722     | 1,335,269     | 1,325,989     | 1,350,570     | 1,345,158     |
| 1,503         | 1,533         | 1,538         | 1,483         | 1,482         |
| 1,362         | 1,427         | 1,393         | 1,316         | 1,315         |
| <b>0.108%</b> | <b>0.115%</b> | <b>0.116%</b> | <b>0.110%</b> | <b>0.110%</b> |
| <b>0.098%</b> | <b>0.107%</b> | <b>0.105%</b> | <b>0.097%</b> | <b>0.098%</b> |

| 16-Aug-13     | 23-Aug-13     | 30-Aug-13     | 6-Sep-13      | 13-Sep-13     |
|---------------|---------------|---------------|---------------|---------------|
| 1,335,599     | 1,330,365     | 1,364,376     | 1,307,012     | 1,359,286     |
| 1,433         | 1,399         | 1,568         | 1,434         | 1,521         |
| 1,269         | 1,239         | 1,398         | 1,273         | 1,362         |
| <b>0.107%</b> | <b>0.105%</b> | <b>0.115%</b> | <b>0.110%</b> | <b>0.112%</b> |
| <b>0.095%</b> | <b>0.093%</b> | <b>0.102%</b> | <b>0.097%</b> | <b>0.100%</b> |

| 20-Sep-13     | 27-Sep-13     | 4-Oct-13      | 1/1 Week Growth |
|---------------|---------------|---------------|-----------------|
| 1,335,075     | 1,336,103     | 1,394,330     | 4.4%            |
| 1,558         | 1,492         | 1,522         | 2.0%            |
| 1,397         | 1,369         | 1,353         | -1.2%           |
| <b>0.117%</b> | <b>0.112%</b> | <b>0.109%</b> |                 |
| <b>0.105%</b> | <b>0.102%</b> | <b>0.097%</b> |                 |



**Intermezzo Total Rxs for the week ending**

| Strength     | <u>NRx</u>   | <u>RRx</u> | <u>TRxs</u>  |
|--------------|--------------|------------|--------------|
| 1.75mg       | 467          | 180        | 647          |
| 3.5mg        | 540          | 335        | 875          |
| <b>Total</b> | <b>1,007</b> | <b>515</b> | <b>1,522</b> |

**Distribution of Total New versus Refill Rxs for Intermezzo**

| Strength     | <u>NRx</u>   | <u>RRx</u>   | <u>TRxs</u>   |
|--------------|--------------|--------------|---------------|
| 1.75mg       | 72.2%        | 27.8%        | 100.0%        |
| 3.5mg        | 61.7%        | 38.3%        | 100.0%        |
| <b>Total</b> | <b>66.2%</b> | <b>33.8%</b> | <b>100.0%</b> |

**Distribution of Intermezzo Total Rxs by Strength**

| Strength     | <u>NRx</u>    | <u>RRx</u>    | <u>TRx</u>    |
|--------------|---------------|---------------|---------------|
| 1.75mg       | 46.4%         | 35.0%         | 42.5%         |
| 3.5mg        | 53.6%         | 65.0%         | 57.5%         |
| <b>Total</b> | <b>100.0%</b> | <b>100.0%</b> | <b>100.0%</b> |

October 4, 2013

| <u>Trial Card Redemptions</u> | <u>"True" Rx</u> |
|-------------------------------|------------------|
| 82                            | 565              |
| 87                            | 788              |
| <b>169</b>                    | <b>1,353</b>     |

**Intermezzo**<sup>®</sup>  
 (ZOLPIDEM TARTRATE) sublingual tablet   
 1.75 mg | 3.5 mg

Data includes retail pharmacy, mail order and LT

|           | Total          |                               |          |         | % of Budget Achieved vs. True Rx's |                                |
|-----------|----------------|-------------------------------|----------|---------|------------------------------------|--------------------------------|
|           | 2012 Budget Rx | 2013 Mid-Year Update Forecast | Total Rx | True Rx | Weekly True Rx Vs Budget           | Cumulative % True Rx vs Budget |
| 6-Apr-12  |                |                               | 92       |         |                                    |                                |
| 13-Apr-12 |                |                               | 410      |         |                                    |                                |
| 20-Apr-12 |                |                               | 468      |         |                                    |                                |
| 27-Apr-12 |                |                               | 461      |         |                                    |                                |
| 4-May-12  |                |                               | 551      |         |                                    |                                |
| 11-May-12 |                |                               | 581      |         |                                    |                                |
| 18-May-12 |                |                               | 577      |         |                                    |                                |
| 25-May-12 |                |                               | 644      |         |                                    |                                |
| 1-Jun-12  |                |                               | 561      |         |                                    |                                |
| 8-Jun-12  |                |                               | 801      |         |                                    |                                |
| 15-Jun-12 |                |                               | 760      |         |                                    |                                |
| 22-Jun-12 |                |                               | 840      |         |                                    |                                |
| 29-Jun-12 |                |                               | 842      |         |                                    |                                |
| 6-Jul-12  |                |                               | 715      |         |                                    |                                |
| 13-Jul-12 |                |                               | 904      |         |                                    |                                |
| 20-Jul-12 |                |                               | 894      |         |                                    |                                |
| 27-Jul-12 |                |                               | 939      |         |                                    |                                |
| 3-Aug-12  |                |                               | 907      |         |                                    |                                |
| 10-Aug-12 |                |                               | 1,063    |         |                                    |                                |
| 17-Aug-12 |                |                               | 1,094    |         |                                    |                                |
| 24-Aug-12 |                |                               | 1,102    |         |                                    |                                |
| 31-Aug-12 |                |                               | 1,093    |         |                                    |                                |
| 7-Sep-12  |                |                               | 974      |         |                                    |                                |
| 14-Sep-12 |                |                               | 1,194    |         |                                    |                                |
| 21-Sep-12 |                |                               | 1,278    |         |                                    |                                |
| 28-Sep-12 |                |                               | 1,265    |         |                                    |                                |
| 5-Oct-12  |                |                               | 1,212    |         |                                    |                                |
| 12-Oct-12 |                |                               | 1,284    |         |                                    |                                |
| 19-Oct-12 |                |                               | 1,269    |         |                                    |                                |
| 26-Oct-12 |                |                               | 1,303    |         |                                    |                                |
| 2-Nov-12  |                |                               | 1,298    |         |                                    |                                |
| 9-Nov-12  |                |                               | 1,383    |         |                                    |                                |
| 16-Nov-12 |                |                               | 1,347    |         |                                    |                                |
| 23-Nov-12 |                |                               | 1,109    |         |                                    |                                |
| 30-Nov-12 |                |                               | 1,308    |         |                                    |                                |

|           |  |       |       |       |  |        |        |
|-----------|--|-------|-------|-------|--|--------|--------|
| 7-Dec-12  |  |       | 1,385 |       |  |        |        |
| 14-Dec-12 |  |       | 1,489 |       |  |        |        |
| 21-Dec-12 |  |       | 1,534 |       |  |        |        |
| 28-Dec-12 |  |       | 995   |       |  |        |        |
| 4-Jan-13  |  | 918   | 985   | 918   |  | 100.0% | 100.0% |
| 11-Jan-13 |  | 1,205 | 1,290 | 1,205 |  | 100.0% | 100.0% |
| 18-Jan-13 |  | 1,377 | 1,532 | 1,377 |  | 100.0% | 100.0% |
| 25-Jan-13 |  | 1,354 | 1,527 | 1,354 |  | 100.0% | 100.0% |
| 1-Feb-13  |  | 1,568 | 1,782 | 1,568 |  | 100.0% | 100.0% |
| 8-Feb-13  |  | 1,606 | 1,830 | 1,606 |  | 100.0% | 100.0% |
| 15-Feb-13 |  | 1,638 | 1,887 | 1,638 |  | 100.0% | 100.0% |
| 22-Feb-13 |  | 1,631 | 1,907 | 1,631 |  | 100.0% | 100.0% |
| 1-Mar-13  |  | 1,664 | 1,963 | 1,664 |  | 100.0% | 100.0% |
| 8-Mar-13  |  | 1,675 | 1,948 | 1,675 |  | 100.0% | 100.0% |
| 15-Mar-13 |  | 1,602 | 1,885 | 1,602 |  | 100.0% | 100.0% |
| 22-Mar-13 |  | 1,665 | 1,939 | 1,665 |  | 100.0% | 100.0% |
| 29-Mar-13 |  | 1,632 | 1,914 | 1,632 |  | 100.0% | 100.0% |
| 5-Apr-13  |  | 1,492 | 1,729 | 1,492 |  | 100.0% | 100.0% |
| 12-Apr-13 |  | 1,627 | 1,857 | 1,627 |  | 100.0% | 100.0% |
| 19-Apr-13 |  | 1,559 | 1,769 | 1,559 |  | 100.0% | 100.0% |
| 26-Apr-13 |  | 1,497 | 1,748 | 1,497 |  | 100.0% | 100.0% |
| 3-May-13  |  | 1,569 | 1,790 | 1,569 |  | 100.0% | 100.0% |
| 10-May-13 |  | 1,507 | 1,694 | 1,507 |  | 100.0% | 100.0% |
| 17-May-13 |  | 1,528 | 1,695 | 1,528 |  | 100.0% | 100.0% |
| 24-May-13 |  | 1,445 | 1,609 | 1,445 |  | 100.0% | 100.0% |
| 31-May-13 |  | 1,302 | 1,433 | 1,302 |  | 100.0% | 100.0% |
| 7-Jun-13  |  | 1,500 | 1,583 | 1,419 |  | 94.6%  | 99.8%  |
| 14-Jun-13 |  | 1,433 | 1,627 | 1,499 |  | 104.6% | 100.0% |
| 21-Jun-13 |  | 1,422 | 1,563 | 1,414 |  | 99.5%  | 99.9%  |
| 28-Jun-13 |  | 1,410 | 1,461 | 1,325 |  | 94.0%  | 99.7%  |
| 5-Jul-13  |  | 1,399 | 1,322 | 1,201 |  | 85.9%  | 99.2%  |
| 12-Jul-13 |  | 1,387 | 1,503 | 1,362 |  | 98.2%  | 99.2%  |
| 19-Jul-13 |  | 1,376 | 1,533 | 1,427 |  | 103.7% | 99.3%  |
| 26-Jul-13 |  | 1,365 | 1,538 | 1,393 |  | 102.1% | 99.4%  |
| 2-Aug-13  |  | 1,354 | 1,483 | 1,316 |  | 97.2%  | 99.4%  |
| 9-Aug-13  |  | 1,343 | 1,482 | 1,315 |  | 97.9%  | 99.3%  |
| 16-Aug-13 |  | 1,332 | 1,433 | 1,269 |  | 95.3%  | 99.2%  |
| 23-Aug-13 |  | 1,321 | 1,399 | 1,239 |  | 93.8%  | 99.1%  |
| 30-Aug-13 |  | 1,310 | 1,568 | 1,398 |  | 106.7% | 99.3%  |
| 6-Sep-13  |  | 1,299 | 1,434 | 1,273 |  | 98.0%  | 99.2%  |
| 13-Sep-13 |  | 1,289 | 1,521 | 1,362 |  | 105.7% | 99.4%  |
| 20-Sep-13 |  | 1,278 | 1,558 | 1,397 |  | 109.3% | 99.6%  |
| 27-Sep-13 |  | 1,268 | 1,492 | 1,369 |  | 108.0% | 99.8%  |
| 4-Oct-13  |  | 1,258 | 1,522 | 1,353 |  | 107.6% | 100.0% |
| 11-Oct-13 |  | 1,247 |       |       |  |        |        |
| 18-Oct-13 |  | 1,237 |       |       |  |        |        |
| 25-Oct-13 |  | 1,227 |       |       |  |        |        |







|     |    |  |  |
|-----|----|--|--|
| 0%  | 0% |  |  |
| 0%  | 0% |  |  |
| 0%  | 0% |  |  |
| 0%  | 0% |  |  |
| 93% | 0% |  |  |
| 93% | 0% |  |  |
| 90% | 0% |  |  |
| 89% | 0% |  |  |
| 88% | 0% |  |  |
| 88% | 0% |  |  |
| 87% | 0% |  |  |
| 86% | 0% |  |  |
| 85% | 0% |  |  |
| 86% | 0% |  |  |
| 85% | 0% |  |  |
| 86% | 0% |  |  |
| 85% | 0% |  |  |
| 86% | 0% |  |  |
| 88% | 0% |  |  |
| 88% | 0% |  |  |
| 86% | 0% |  |  |
| 88% | 0% |  |  |
| 89% | 0% |  |  |
| 90% | 0% |  |  |
| 90% | 0% |  |  |
| 91% | 0% |  |  |
| 90% | 0% |  |  |
| 92% | 0% |  |  |
| 90% | 0% |  |  |
| 91% | 0% |  |  |
| 91% | 0% |  |  |
| 91% | 0% |  |  |
| 93% | 0% |  |  |
| 91% | 0% |  |  |
| 89% | 0% |  |  |
| 89% | 0% |  |  |
| 89% | 0% |  |  |
| 89% | 0% |  |  |
| 89% | 0% |  |  |
| 89% | 0% |  |  |
| 90% | 0% |  |  |
| 90% | 0% |  |  |
| 92% | 0% |  |  |
| 89% | 0% |  |  |
|     |    |  |  |
|     |    |  |  |
|     |    |  |  |



# Intermezzo True Rx's (Source: IMS NP)



# A/McKesson) 2013



Message

**From:** Mahony, Edward [REDACTED]  
**Sent:** 10/18/2013 2:30:56 PM  
**To:** Boer, Peter [REDACTED]; Lewent, Judy [REDACTED]; Pickett, Cecil [REDACTED]; Costa, Paulo [REDACTED]; Snyderman, Ralph [REDACTED]; Sackler, Dr Raymond R [REDACTED]; Sackler, Dr Richard [REDACTED]; Sackler, Jonathan [REDACTED]; Sackler, Dr Kathe [REDACTED]; Sackler, Mortimer D.A. [REDACTED]; Sackler, Dame Theresa [REDACTED]; Sackler Lefcourt, Ilene [REDACTED]; Sackler, Beverly [REDACTED]; Sackler, David [REDACTED]; Baker, Stuart D. [REDACTED]; Stewart, John H. (US) [REDACTED]; Gasdia, Russell [REDACTED]; Baumgartner, Todd [REDACTED]; Lundie, David [REDACTED]; Damas, Raul [REDACTED];  
**CC:** [REDACTED]; Lowne, Jon [REDACTED];  
**BCC:** Stewart, John H. (US) [REDACTED]  
**Subject:** FW: September 2013 Financial Statements  
**Attachments:** Financial Statements 09 30 2013.xlsm; September 2013 Financial Statement Cover Memo Final.docx

Colleagues,

Attached for your information are the Purdue September 2013 financial statements.

We are happy to supply a hard copy upon request.

Ed

**Purdue U.S.  
Financial Statements  
September 2013**

Page Number

|    |                                       |
|----|---------------------------------------|
| 1  | Financial Reporting Scorecard         |
| 2  | Profit and Loss Statement             |
| 3  | P&L Ratios                            |
| 4  | Balance Sheet                         |
| 5  | Balance Sheet Notes                   |
| 6  | Statement of Cash Flows               |
| 7  | Sales Summary Gross to Net by Product |
| 8  | Gross Sales Summary by Product        |
| 9  | Sales Variance to Mid Year Update     |
| 10 | Brand P&L's                           |
| 11 | General & Administrative Summary      |
| 12 | Legal Fees Summary                    |
| 13 | Research & Development Summary        |
| 14 | Other US                              |
| 15 | Headcount                             |

Purdue US - Financial Reporting Scorecard

*Expressed in 000's*

|                                                    | September YTD   |                          |                 |                 | 2013 YTD Actual versus   |                  |                  | Full Year            |              |              |
|----------------------------------------------------|-----------------|--------------------------|-----------------|-----------------|--------------------------|------------------|------------------|----------------------|--------------|--------------|
|                                                    | 2013 YTD Actual | 2013 YTD Mid Year Update | 2013 YTD Budget | 2012 YTD Actual | 2013 YTD Mid Year Update | 2013 YTD Budget  | 2012 YTD Actual  | 2013 Mid Year Update | 2013 Budget  | 2012 Actual  |
| Net Revenues                                       | \$ 1,498,905    | \$ 1,570,771             | \$ 1,810,118    | \$ 1,597,815    | -4.8%                    | -20.8%           | -6.6%            | \$ 2,107,208         | \$ 2,410,349 | \$ 2,200,922 |
| Operating Profit Margin                            | \$ 629,525      | \$ 682,594               | \$ 824,353      | \$ 737,393      | -8.4%                    | -30.9%           | -17.1%           | \$ 930,262           | \$ 1,137,004 | \$ 1,007,776 |
| EBITDA                                             | \$ 684,976      | \$ 727,497               | \$ 772,013      | \$ 740,911      | -6.2%                    | -12.7%           | -8.2%            | \$ 948,266           | \$ 1,066,877 | \$ 1,038,561 |
| Net Profit Before Tax                              | \$ 660,946      | \$ 703,493               | \$ 748,038      | \$ 719,333      | -6.4%                    | -13.2%           | -8.8%            | \$ 916,261           | \$ 1,034,911 | \$ 1,010,856 |
| Owner's Equity                                     | \$ 568,463      | \$ 608,939               | \$ 895,486      | \$ 649,271      | -7.1%                    | -57.5%           | -14.2%           | \$ 590,000           | \$ 705,232   | \$ 671,725   |
| Non-tax Distributions                              | \$ 399,920      | \$ 231,650               | \$ 239,600      | \$ 242,543      | 42.1%                    | 40.1%            | 39.4%            | \$ 575,600           | \$ 538,100   | \$ 471,643   |
| Days Sales Outstanding                             | 34.6            | 35.0                     | 35.0            | 34.3            | <i>on target</i>         | <i>on target</i> | <i>on target</i> | 35.0                 | 35.0         | 33.2         |
| Accounts Receivable Outstanding > 90 Days Past Due | < 1%            | < 1%                     | < 1%            | < 1%            | <i>on target</i>         | <i>on target</i> | <i>on target</i> | < 1%                 | < 1%         | < 1%         |
| Capital Spending                                   | \$ 19,095       | \$ 26,250                | \$ 26,250       | \$ 22,948       | -37.5%                   | -37.5%           | -20.2%           | \$ 35,000            | \$ 35,000    | \$ 30,467    |
| Unrestricted Cash on Hand                          | \$ 868,981      | \$ 796,384               | \$ 978,605      | \$ 795,291      | 8.4%                     | -12.6%           | 8.5%             | \$ 576,056           | \$ 600,000   | \$ 755,593   |
| Available Liquidity                                | \$ 868,981      | \$ 796,384               | \$ 978,605      | \$ 795,291      | 8.4%                     | -12.6%           | 8.5%             | \$ 576,056           | \$ 600,000   | \$ 755,593   |
| Available Liquidity - Average Months Sales         | 5.2             | 4.6                      | 4.9             | 4.5             | +0.5 months              | +0.3 months      | +0.7 months      | 3.3                  | 3.0          | 4.1          |
| Headcount                                          | 1,702           | 1,777                    | 1,784           | 1,664           | - 75 heads               | -82 heads        | +38 heads        | 1,777                | 1,784        | 1,666        |

**PURDUE US - Profit and Loss Statement**  
 Period Ended September 30, 2013  
 Expressed in 000's

|                                                               | September YTD       |              |                          |              | 2013 YTD Actual versus |              |                     | Full Year    |                          |                     |                     |                      |              |                     |              |                     |              |
|---------------------------------------------------------------|---------------------|--------------|--------------------------|--------------|------------------------|--------------|---------------------|--------------|--------------------------|---------------------|---------------------|----------------------|--------------|---------------------|--------------|---------------------|--------------|
|                                                               | 2013 YTD Actual     | % Sales      | 2013 YTD Mid Year Update | % Sales      | 2013 YTD Budget        | % Sales      | 2012 YTD Actual     | % Sales      | 2013 YTD Mid Year Update | 2013 YTD Budget     | 2012 YTD Actual     | 2013 Mid Year Update | % Sales      | 2013 Budget         | % Sales      | 2012 Actual         | % Sales      |
| <b>GROSS BRANDED PRODUCT SALES</b>                            | <b>\$ 2,017,880</b> |              | <b>\$ 2,110,171</b>      |              | <b>\$ 2,409,221</b>    |              | <b>\$ 2,187,586</b> |              | <b>\$ (92,291)</b>       | <b>\$ (391,341)</b> | <b>\$ (169,706)</b> | <b>\$ 2,821,387</b>  |              | <b>\$ 3,228,472</b> |              | <b>\$ 3,004,905</b> |              |
| Fee for Service                                               | (40,907)            | 2.0%         | (43,498)                 | 2.1%         | (48,774)               | 2.0%         | (55,947)            | 2.6%         | 2,591                    | 7,867               | 15,040              | (57,957)             | 2.1%         | (65,338)            | 2.0%         | (69,313)            | 2.3%         |
| Discounts and Allowances                                      | (35,036)            | 1.7%         | (43,323)                 | 2.1%(2)      | (51,899)               | 2.2%         | (76,186)            | 3.5%         | 8,287                    | 16,863              | 41,150              | (54,066)             | 1.9%         | (88,198)            | 2.7%         | (134,032)           | 4.5%         |
| Patient Savings Card Discount                                 | (33,136)            | 1.6%         | (31,547)                 | 1.5%         | (25,439)               | 1.1%         | (17,257)            | 0.8%         | (1,589)                  | (7,697)             | (15,879)            | (41,334)             | 1.5%         | (34,537)            | 1.1%         | (25,104)            | 0.8%         |
| Rebates on Branded Sales                                      | (368,199)           | 18.2%        | (365,026)                | 17.3%        | (424,861)              | 17.6%        | (392,664)           | 17.9%        | (3,173)                  | 56,662              | 24,465              | (488,581)            | 17.3%        | (554,896)           | 17.2%        | (517,606)           | 17.2%        |
| Proposed Regulation Adjustment for Medicaid Rebates (1)       | (45,094)            | 2.2%         | (57,244)                 | 2.7%         | (49,368)               | 2.0%         | (49,878)            | 2.3%         | 12,150                   | 4,274               | 4,784               | (73,892)             | 2.6%         | (76,805)            | 2.4%         | (60,383)            | 2.0%         |
| Other                                                         | 3,397               |              | 1,238                    |              | 1,238                  |              | 2,161               |              | 2,159                    | 2,159               | 1,236               | 1,651                |              | 1,651               |              | 2,455               |              |
| <b>NET REVENUES</b>                                           | <b>1,498,905</b>    |              | <b>1,570,771</b>         |              | <b>1,810,118</b>       |              | <b>1,597,815</b>    |              | <b>(71,866)</b>          | <b>(311,213)</b>    | <b>(98,910)</b>     | <b>2,107,208</b>     |              | <b>2,410,349</b>    |              | <b>2,200,922</b>    |              |
| Cost of Goods Sold                                            | (103,205)           | 5.1%         | (111,497)                | 5.3%         | (122,076)              | 5.1%         | (106,709)           | 4.9%         | 8,292                    | 18,871              | 3,504               | (149,240)            | 5.3%         | (162,211)           | 5.0%         | (148,475)           | 4.9%         |
| Royalty Expense                                               | (92,706)            | 4.6%         | (95,457)                 | 4.5%         | (109,491)              | 4.5%         | (94,393)            | 4.3%         | 2,751                    | 16,785              | 1,687               | (122,339)            | 4.3%         | (131,575)           | 4.1%         | (120,268)           | 4.0%         |
| Shipping and Warehousing                                      | (8,066)             | 0.4%         | (8,488)                  | 0.4%         | (8,340)                | 0.3%         | (8,961)             | 0.4%         | 422                      | 274                 | 895                 | (11,356)             | 0.4%         | (10,807)            | 0.3%         | (11,814)            | 0.4%         |
| <b>TOTAL COST OF GOODS SOLD</b>                               | <b>(203,977)</b>    |              | <b>(215,442)</b>         |              | <b>(239,907)</b>       |              | <b>(210,063)</b>    |              | <b>11,465</b>            | <b>35,930</b>       | <b>6,086</b>        | <b>(282,935)</b>     |              | <b>(304,593)</b>    |              | <b>(280,557)</b>    |              |
| <b>GROSS PROFIT</b>                                           | <b>1,294,928</b>    |              | <b>1,355,329</b>         |              | <b>1,570,211</b>       |              | <b>1,387,752</b>    |              | <b>(60,401)</b>          | <b>(275,283)</b>    | <b>(92,824)</b>     | <b>1,824,273</b>     |              | <b>2,105,756</b>    |              | <b>1,920,365</b>    |              |
| General and Administrative (incl Legal Dept, excl Legal Fees) | (112,407)           | 7.5%         | (118,849)                | 7.6%         | (120,626)              | 6.7%         | (112,102)           | 7.0%         | 6,442                    | 8,219               | (305)               | (155,762)            | 7.4%         | (157,762)           | 6.5%         | (151,635)           | 6.9%         |
| Research and Development                                      | (225,420)           | 15.0%        | (235,915)                | 15.0%        | (292,856)              | 16.2%        | (232,469)           | 14.5%        | 10,495                   | 67,436              | 7,049               | (327,247)            | 15.5%        | (377,347)           | 15.7%        | (312,513)           | 14.2%        |
| Research and Development Other - Milestones and Alliances     | (10,472)            |              | (10,029)                 |              | (5,019)                |              | (1,567)             |              | (443)                    | (5,453)             | (8,905)             | (10,952)             |              | (6,692)             |              | (2,284)             |              |
| Sales and Promotion                                           | (210,034)           | 14.0%        | (220,472)                | 14.0%        | (236,075)              | 13.0%        | (223,145)           | 14.0%        | 10,438                   | 26,041              | 13,111              | (288,313)            | 13.7%        | (309,913)           | 12.9%        | (303,110)           | 13.8%        |
| Health Care Reform Fee                                        | (22,710)            | 1.5%         | (23,850)                 | 1.5%         | (23,850)               | 1.3%         | (22,951)            | 1.4%         | 1,140                    | 1,140               | 241                 | (31,800)             | 1.5%         | (31,800)            | 1.3%         | (31,251)            | 1.4%         |
| Other US                                                      | (241)               |              | (366)                    |              | (3,583)                |              | 618                 |              | 125                      | 3,342               | (859)               | (102)                |              | (4,603)             |              | (17,641)            |              |
| <b>OPERATING EXPENSES</b>                                     | <b>(627,937)</b>    |              | <b>(647,378)</b>         |              | <b>(717,150)</b>       |              | <b>(622,016)</b>    |              | <b>19,441</b>            | <b>89,213</b>       | <b>(5,921)</b>      | <b>(860,051)</b>     |              | <b>(929,692)</b>    |              | <b>(867,577)</b>    |              |
| <b>OPERATING MARGIN BEFORE INCENTIVES AND SETTLEMEN</b>       | <b>666,991</b>      |              | <b>707,951</b>           |              | <b>853,061</b>         |              | <b>765,736</b>      |              | <b>(40,960)</b>          | <b>(186,070)</b>    | <b>(98,745)</b>     | <b>964,222</b>       |              | <b>1,176,064</b>    |              | <b>1,052,788</b>    |              |
| Incentive Bonus                                               | (35,279)            | 2.4%         | (26,635)                 | 1.7%         | (31,886)               | 1.8%         | (30,585)            | 1.9%         | (8,644)                  | (3,393)             | (4,694)             | (35,618)             | 1.7%         | (42,618)            | 1.8%         | (34,285)            | 1.6%         |
| Insurance Income                                              | 427                 |              | 3,178                    |              | 3,178                  |              | 2,076               |              | (2,751)                  | (2,751)             | (1,649)             | 3,558                |              | 3,558               |              | 3,520               |              |
| <b>Redacted</b>                                               |                     |              |                          |              |                        |              |                     |              |                          |                     |                     |                      |              |                     |              |                     |              |
| <b>OPERATING PROFIT MARGIN</b>                                | <b>629,525</b>      | <b>42.0%</b> | <b>682,594</b>           | <b>43.5%</b> | <b>824,353</b>         | <b>45.5%</b> | <b>737,393</b>      | <b>46.2%</b> | <b>(53,089)</b>          | <b>(194,828)</b>    | <b>(107,868)</b>    | <b>930,262</b>       | <b>44.1%</b> | <b>1,137,004</b>    | <b>47.2%</b> | <b>1,007,776</b>    | <b>45.8%</b> |
| Royalty Income - ex US                                        | 35,775              |              | 30,519                   |              | 30,519                 |              | 64,586              |              | 5,256                    | 5,256               | (28,811)(3)         | 40,692               |              | 40,692              |              | 83,961              |              |
| Ex US Expenses                                                | (116,116)           |              | (123,665)                |              | (95,698)               |              | (71,281)            |              | 7,549                    | (20,418)            | (44,835)            | (164,889)(4)         |              | (127,600)           |              | (65,063)            |              |
| Other ex US Expenses                                          | (11,081)            |              | (8,448)                  |              | (9,048)                |              | (11,051)            |              | (2,633)                  | (2,033)             | (30)                | (11,601)             |              | (12,401)            |              | (15,026)            |              |
| Gain on Infinity Stock                                        | 124,581             |              | 124,581                  |              | -                      |              | -                   |              | -                        | 124,581             | 124,581             | 124,581              |              | -                   |              | -                   |              |
| One Time Charges / Other Items                                | (1,861)             |              | (2,217)                  |              | (2,217)                |              | (1,594)             |              | 356                      | 356                 | (267)               | (2,956)              |              | (2,956)             |              | (2,146)             |              |
| Interest Income (Expense), net                                | 123                 |              | 129                      |              | 129                    |              | 1,280               |              | (6)                      | (6)                 | (1,157)             | 172                  |              | 172                 |              | 1,354               |              |
| <b>TOTAL OTHER ITEMS</b>                                      | <b>31,421</b>       |              | <b>20,899</b>            |              | <b>(76,315)</b>        |              | <b>(18,060)</b>     |              | <b>10,522</b>            | <b>107,736</b>      | <b>49,481</b>       | <b>(14,001)</b>      |              | <b>(102,093)</b>    |              | <b>3,080</b>        |              |
| <b>PROFIT BEFORE TAX</b>                                      | <b>660,946</b>      |              | <b>703,493</b>           |              | <b>748,038</b>         |              | <b>719,333</b>      |              | <b>(42,547)</b>          | <b>(87,092)</b>     | <b>(58,387)</b>     | <b>916,261</b>       |              | <b>1,034,911</b>    |              | <b>1,010,856</b>    |              |
| Tax Provision for Corporations                                | (2,645)             |              | (2,337)                  |              | (2,337)                |              | (5,128)             |              | (308)                    | (308)               | 2,483               | (4,674)              |              | (4,674)             |              | (2,548)             |              |
| <b>PROFIT AFTER TAX</b>                                       | <b>\$ 658,301</b>   | <b>43.9%</b> | <b>\$ 701,156</b>        | <b>44.6%</b> | <b>\$ 745,701</b>      | <b>41.2%</b> | <b>\$ 714,205</b>   | <b>44.7%</b> | <b>\$ (42,855)</b>       | <b>\$ (87,400)</b>  | <b>\$ (55,904)</b>  | <b>\$ 911,587</b>    | <b>43.3%</b> | <b>\$ 1,030,237</b> | <b>42.7%</b> | <b>\$ 1,008,308</b> | <b>45.8%</b> |

(1) The Proposed Rule was issued in Q1 2012, which when finalized could result in a higher rebate rate on the new formulation of OxyContin.

(2) Discounts and Allowances as a % of sales is below the mid year update due to trade inventory reduction higher than forecast results in VCB accrual reversals (\$2.6 million) and a favorable Intermezzo pull through adjustment to recognize the difference between demand and Purdue factory sales

(3) Decrease from prior year is due to a lower royalty rate at the end of 2012 upon patent expiration.

(4) The 2013 mid year update includes \$80.3 million of cash funding to Pearl Therapeutics of which \$30.3 million was included as an Ex-US expense and \$50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 mid year update.

PURDUE US - Profit and Loss Statement Ratios

|                                                               | ACTUAL        |               |               |               |               |               | 2013                    |                    |
|---------------------------------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|-------------------------|--------------------|
|                                                               | 2007          | 2008          | 2009          | 2010          | 2011          | 2012          | Sept 2013<br>YTD Actual | MID YEAR<br>UPDATE |
| <b>GROSS BRANDED PRODUCT SALES</b>                            | 100%          | 100%          | 100%          | 100%          | 100%          | 100%          | 100%                    | 100%               |
| Fee for Service                                               | -2.1%         | -1.5%         | -2.2%         | -2.5%         | -2.5%         | -2.3%         | -2.0%                   | -2.1%              |
| Discounts and Allowances                                      | -3.5%         | -3.1%         | -2.2%         | -1.6%         | -1.9%         | -4.5% (1)     | -1.7%                   | -1.9%              |
| Patient Savings Card Discount                                 | 0.0%          | -0.5%         | -0.6%         | -0.5%         | -0.5%         | -0.8%         | -1.6%                   | -1.5%              |
| Rebates on Branded Sales                                      | -12.4%        | -13.4%        | -15.1%        | -19.9%        | -18.4%        | -17.2%        | -18.2%                  | -17.3%             |
| Proposed Regulation Adjustment for Medicaid Rebates           | 0.0%          | 0.0%          | 0.0%          | -1.3%         | -2.3%         | -2.0%         | -2.2%                   | -2.6%              |
| Other                                                         | 8.2% (2)      | 0.9%          | 1.5%          | 1.2%          | 0.4%          | 0.1%          | 0.2%                    | 0.1%               |
| <b>NET REVENUES</b>                                           | <b>82.0%</b>  | <b>81.5%</b>  | <b>79.9%</b>  | <b>74.3%</b>  | <b>74.4%</b>  | <b>73.2%</b>  | <b>74.3%</b>            | <b>74.6%</b>       |
| Cost of Goods Sold                                            | -8.5% (3)     | -5.9%         | -5.6%         | -5.2%         | -5.6%         | -4.9%         | -5.1%                   | -5.3%              |
| Royalty Expense                                               | -0.4%         | -0.1%         | -0.4%         | -2.3% (4)     | -3.9%         | -4.0%         | -4.6%                   | -4.3%              |
| Shipping and Warehousing                                      | -0.9%         | -0.5%         | -0.5%         | -0.5%         | -0.4%         | -0.4%         | -0.4%                   | -0.4%              |
| <b>TOTAL COST OF GOODS SOLD</b>                               | <b>-9.8%</b>  | <b>-6.5%</b>  | <b>-6.4%</b>  | <b>-7.9%</b>  | <b>-9.9%</b>  | <b>-9.3%</b>  | <b>-10.1%</b>           | <b>-10.0%</b>      |
| <b>GROSS PROFIT</b>                                           | <b>72.2%</b>  | <b>75.0%</b>  | <b>73.5%</b>  | <b>66.3%</b>  | <b>64.5%</b>  | <b>63.9%</b>  | <b>64.2%</b>            | <b>64.6%</b>       |
| General and Administrative (incl Legal Dept, excl Legal Fees) | -11.7%        | -6.0%         | -5.4%         | -5.9%         | -6.6%         | -6.9%         | -7.5%                   | -7.4%              |
| Research and Development                                      | -11.0%        | -3.8%         | -3.5%         | -7.1%         | -12.1%        | -14.2%        | -15.0%                  | -15.5%             |
| Research and Development Other - Milestones and Alliances     | -0.5%         | -0.4%         | -2.5%         | -0.4%         | 0.0%          | -0.1%         | -0.7%                   | -0.5%              |
| Sales and Promotion                                           | -11.9%        | -6.5%         | -6.5%         | -8.4%         | -10.3%        | -13.8%        | -14.0%                  | -13.7%             |
| Health Care Reform Fee                                        | 0.0%          | 0.0%          | 0.0%          | 0.0%          | -1.2%         | -1.4%         | -1.5%                   | -1.5%              |
| Other US                                                      | -0.7%         | -0.7%         | -0.4%         | 0.7%          | -0.1%         | -0.8%         | 8.3%                    | 5.9%               |
| <b>OPERATING EXPENSES</b>                                     | <b>-42.4%</b> | <b>-23.1%</b> | <b>-23.1%</b> | <b>-23.3%</b> | <b>-33.0%</b> | <b>-39.4%</b> | <b>-33.6%</b>           | <b>-34.9%</b>      |
| <b>OPERATING MARGIN BEFORE INCENTIVES AND SETTLEMENTS</b>     | <b>29.8%</b>  | <b>51.9%</b>  | <b>50.4%</b>  | <b>43.1%</b>  | <b>53.8%</b>  | <b>47.8%</b>  | <b>44.5%</b>            | <b>45.8%</b>       |
| Incentive Bonus                                               | -4.3%         | -1.5%         | -1.4%         | -1.7%         | -1.5%         | -1.6%         | -2.4%                   | -1.7%              |
| Insurance Income                                              | 3.5%          | 0.6%          | 0.4%          | 0.7%          | 1.4%          | 0.2%          | 0.0%                    | 0.2%               |
| <b>TOTAL INCENTIVES AND SETTLEMENTS</b>                       | <b>-1.0%</b>  | <b>-3.1%</b>  | <b>-2.7%</b>  | <b>-1.7%</b>  | <b>-0.4%</b>  | <b>-2.0%</b>  | <b>-2.5%</b>            | <b>-1.6%</b>       |
| <b>OPERATING PROFIT MARGIN</b>                                | <b>28.8%</b>  | <b>48.8%</b>  | <b>47.8%</b>  | <b>41.3%</b>  | <b>53.4%</b>  | <b>45.8%</b>  | <b>42.0%</b>            | <b>44.1%</b>       |
| Royalty Income - ex US                                        | 6.6%          | 3.4%          | 3.2%          | 3.7%          | 4.1%          | 3.8%          | 2.4%                    | 1.9%               |
| Ex US Expenses                                                | -0.7%         | -6.0%         | -5.1%         | -5.7%         | -5.8%         | -3.0%         | -7.7%                   | -7.8%              |
| Other Ex US Expenses                                          | n/a           | n/a           | n/a           | n/a           | n/a           | -0.7%         | -0.7%                   | -0.6%              |
| One Time Charges / Other Items                                | -0.2%         | -0.1%         | 0.0%          | -1.1%         | -0.1%         | -0.1%         | -0.1%                   | -0.1%              |
| Interest Income (Expense), net                                | 3.4%          | 0.7%          | 0.0%          | 0.0%          | 0.0%          | 0.1%          | 0.0%                    | 0.0%               |
| <b>TOTAL OTHER ITEMS</b>                                      | <b>9.1%</b>   | <b>-2.0%</b>  | <b>-1.8%</b>  | <b>-3.1%</b>  | <b>-1.8%</b>  | <b>0.1%</b>   | <b>-6.2%</b>            | <b>-6.6%</b>       |
| <b>PROFIT BEFORE TAX</b>                                      | <b>37.9%</b>  | <b>46.9%</b>  | <b>45.9%</b>  | <b>38.2%</b>  | <b>51.6%</b>  | <b>45.9%</b>  | <b>44.1%</b>            | <b>43.5%</b>       |

Income statement  
line items as a  
percent of  
gross sales

Income statement  
line items as a  
percent of  
net sales

(1) 2012 Discounts and Allowances ratio is higher than history due to an increase in OxyContin return reserves.

(2) 2007 Other ratio is higher than history due to the termination of the OxyContin AG distribution agreement during 2007.

(3) 2007 Cost of Goods Sold was higher due to a higher sales mix of lower margin products. OxyContin gross sales were 89% of gross sales in 2007 versus 92% of gross sales in 2012 and the 2013 mid year update.

(4) Starting mid 2010 royalties on the new OxyContin formula became due.

PURDUE US - Balance Sheet

Expressed in 000's

|                                                       | Footnotes | September 30, 2013<br>Actual | December 31, 2013<br>Mid Year Update | December 31, 2013<br>Budget | December 31, 2012<br>Actual |
|-------------------------------------------------------|-----------|------------------------------|--------------------------------------|-----------------------------|-----------------------------|
| <b>ASSETS</b>                                         |           |                              |                                      |                             |                             |
| <b>CURRENT ASSETS</b>                                 |           |                              |                                      |                             |                             |
| Cash and cash equivalents                             |           | \$ 868,981                   | \$ 576,056                           | \$ 600,000                  | \$ 755,593                  |
| Accounts receivable                                   | (1)       | 131,218                      | 136,623                              | 150,613                     | 187,137                     |
| Due from associated companies                         | (2)       | 21,390                       | 13,673                               | 13,673                      | 31,819                      |
| Other receivables                                     | (3)       | 8,472                        | 7,250                                | 8,350                       | 2,957                       |
| Inventories                                           | (4)       | 69,024                       | 42,881                               | 42,881                      | 50,631                      |
| Prepaid expenses and other assets                     | (5)       | 17,164                       | 23,670                               | 28,670                      | 22,144                      |
| Restricted cash - current                             | (6)       | 23,883                       | 4,800                                | -                           | 23,927                      |
| <b>TOTAL CURRENT ASSETS</b>                           |           | <b>1,140,132</b>             | <b>804,953</b>                       | <b>844,187</b>              | <b>1,074,208</b>            |
| Property and equipment, net                           | (7)       | 149,529                      | 159,119                              | 163,447                     | 149,483                     |
| Investments in associated companies                   | (8)       | 28,200                       | 69,111                               | 14,936                      | 7,871                       |
| Due from associated companies                         |           | 2,750                        | 3,250                                | 3,250                       | 3,000                       |
| Restricted cash - long term                           | (6)       | 21,056                       | 21,700                               | 21,700                      | 17,205                      |
| Goodwill                                              |           | 23,396                       | 23,396                               | 23,396                      | 23,396                      |
| Product rights, trademarks and other intangibles, net | (9)       | 168,119                      | 166,409                              | 165,982                     | 173,249                     |
| Other assets                                          | (10)      | 21,536                       | 21,247                               | 21,247                      | 22,523                      |
| Investment in Infinity common stock                   | (11)      | -                            | -                                    | 138,772                     | 189,545                     |
| Deferred income taxes                                 |           | 19,788                       | 17,425                               | 17,425                      | 19,788                      |
| <b>TOTAL ASSETS</b>                                   |           | <b>\$ 1,574,506</b>          | <b>\$ 1,286,610</b>                  | <b>\$ 1,414,342</b>         | <b>\$ 1,680,268</b>         |
| <b>LIABILITIES AND EQUITY</b>                         |           |                              |                                      |                             |                             |
| <b>CURRENT LIABILITIES</b>                            |           |                              |                                      |                             |                             |
| Accounts payable                                      |           | 72,986                       | 81,600                               | 94,100                      | 71,181                      |
| Accrued expenses and taxes payable                    | (12)      | 672,137                      | 360,628                              | 360,628                     | 694,721                     |
| Due to associated companies                           |           | 12,775                       | 13,000                               | 13,000                      | 12,392                      |
| <b>TOTAL CURRENT LIABILITIES</b>                      |           | <b>757,898</b>               | <b>455,228</b>                       | <b>467,728</b>              | <b>778,294</b>              |
| Other liabilities                                     |           | 248,145                      | 241,382                              | 241,382                     | 230,249                     |
| <b>TOTAL LIABILITIES</b>                              |           | <b>1,006,043</b>             | <b>696,610</b>                       | <b>709,110</b>              | <b>1,008,543</b>            |
| <b>EQUITY</b>                                         |           |                              |                                      |                             |                             |
| Capital stock - common                                |           | 9                            | 9                                    | 9                           | 9                           |
| Additional paid in capital                            |           | 1,982                        | 1,982                                | 1,982                       | 1,982                       |
| Subscription receivable                               |           | (999)                        | (999)                                | (999)                       | (999)                       |
| Accumulated other comprehensive income                |           | (139,935)                    | (128,436)                            | (128,436)                   | (139,935)                   |
| Unrealized gain on Infinity stock                     | (11)      | -                            | -                                    | 60,232                      | 97,469                      |
| Retained earnings and partners' capital               |           | 707,406                      | 717,444                              | 772,444                     | 713,199                     |
| <b>TOTAL EQUITY</b>                                   | (13)      | <b>568,463</b>               | <b>590,000</b>                       | <b>705,232</b>              | <b>671,725</b>              |
| <b>TOTAL LIABILITIES AND EQUITY</b>                   |           | <b>\$ 1,574,506</b>          | <b>\$ 1,286,610</b>                  | <b>\$ 1,414,342</b>         | <b>\$ 1,680,268</b>         |

**PURDUE US - Balance Sheet Footnotes**

*Expressed in 000's*

- (1) Accounts receivable is \$55.9 million lower than prior year end primarily due to lower September sales as compared to December.  
 (2) Decrease from prior year end is primarily due to a lower Ex-US royalty receivable due to lower sales and royalty rates upon patent expiration in 2012.  
 (3) Increase from prior year end of \$5.5 million in other receivables balance is primarily due an increase in net amount receivables from Express Scripts related to IPAP program (\$5.1 million).  
 (4) Increase from prior year end of \$18.4 million in inventory balance is due to higher Oxycodone API (\$15.4 million) driven by accelerated receipts from Rhodes Tech which increased capacity for new product validations, higher finished goods for Dilaudid (\$0.9 million) and Slow-Mag (\$0.9 million) due to timing of third party receipts, and higher Morphine Sulfate API (\$1.3 million) primarily driven by depleted 2012 year end levels.  
 (5) The balance in the prepaids fluctuates according to payment patterns on major contracts, larger items include: prepaid software (\$5.6 million), prepaid REMS security deposit (\$1.2 million) and prepaid S&P (\$4.1 million).  
 (6) All remaining settlements have been paid out from the Qualified Settlement Trust (QST). As of September 30, the entire balance of \$23.9 million of the QST is classified as current reflecting the fact that the balance of the QST is expected to be returned to Purdue in 2014. In October, \$7.0 million was returned to Purdue. Long term restricted cash relates to cash collateralized insurance letters of credit.

(7) Change in Property and equipment is as follows:

|                      |                 |
|----------------------|-----------------|
| Balance @ 01/01/13   | 149,483         |
| Capital expenditures | 19,095          |
| Loss on disposals    | (26)            |
| Depreciation         | <u>(19,023)</u> |
| Balance @ 09/30/13   | <u>149,529</u>  |

(8) Investments represent cash investments net of losses in Lucien, Germany, Japan, and Other.

|                                                   |               |
|---------------------------------------------------|---------------|
| Balance @ 01/01/13                                | 7,871         |
| Cash investments in Lucien, Japan, and Other, net | 114,366       |
| Equity losses in Lucien, Japan, and Other         | (114,366)     |
| 15% of Germany income                             | 241           |
| Cash investment in Germany                        | <u>20,088</u> |
| Balance @ 09/30/13                                | <u>28,200</u> |

The 2013 mid year update includes \$80.3 million of cash funding to Pearl Therapeutics of which \$30.3 million was included as an Ex-US expense and \$50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 mid year update.

(9) The balance as of September 30, 2013 consists of:

|                                                |                |
|------------------------------------------------|----------------|
| Dilaudid product rights                        | 85,085         |
| Shire assets (Colace, PeriColace and Slow-mag) | 64,917         |
| Grunenthal milestones (OxyContin)              | 15,500         |
| Abbott/McGinity patent (OxyContin)             | 2,175          |
| Butrans milestone                              | <u>442</u>     |
| Total                                          | <u>168,119</u> |

- (10) Other assets balance of \$21.5 million includes the payments made by Purdue (covering UBS free rent related to floors 2-8, commission and closing costs) to OSR in prior years (\$13.6 million) which are being amortized over the lease term of floors 9 and 10 and a \$6 million lease deposit paid to OSR to be returned in 2016.  
 (11) On April 9, 2013 Purdue distributed 5,416,565 shares of Infinity stock to its owners who then sold the shares for \$40 per share (\$216.7 million).  
 (12) Accrued expenses and taxes payable of \$672.1 million includes \$168.6 million in accrued rebates, \$369.2 million in accrued Medicaid and Medicaid Part D (\$197.9 million relating to the proposed CMS rule), **Redacted** and \$35.5 million in salaries and bonuses. The decrease from prior year end of \$22.6 million is primarily due to decrease in wholesaler inventory rebates (\$34.1 million) as a result of decreased estimates of trade inventory, offset by increase in rebate and Medicaid accruals of \$11.9 million due to timing.

(13) Equity rollforward:

|                                        |                |
|----------------------------------------|----------------|
| Balance @ 01/01/13                     | 671,725        |
| Cash contributions                     | 784            |
| Cash distributions (tax and non-tax)   | (448,215)      |
| Infinity Distribution                  | (216,663)      |
| Realized gain on Infinity Distribution | (97,469)       |
| Net Income                             | <u>658,301</u> |
| Balance @ 09/30/13                     | <u>568,463</u> |

**PURDUE US - Statement of Cash Flows**

*Expressed in 000's*

|                                                                                   | <u>September 30, 2013</u><br>Actual | <u>December 31, 2013</u><br>Mid Year Update | <u>December 31, 2013</u><br>Budget | <u>December 31, 2012</u><br>Actual |
|-----------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|------------------------------------|------------------------------------|
| <b>Operating activities</b>                                                       |                                     |                                             |                                    |                                    |
| Net income                                                                        | \$ 658,301                          | \$ 911,586                                  | \$ 1,030,237                       | \$ 1,008,308                       |
| Adjustments to reconcile net income to net cash provided by operating activities: |                                     |                                             |                                    |                                    |
| Depreciation and amortization                                                     | 24,153                              | 32,177                                      | 32,138                             | 29,059                             |
| Distribution of Infinity stock                                                    | 216,663                             | 216,663                                     | -                                  | -                                  |
| Gain on Investment in Infinity                                                    | (124,581)                           | (124,581)                                   | -                                  | (24,742)                           |
| Impairment of intangible asset                                                    | -                                   | -                                           | -                                  | 20,000                             |
| Deferred income taxes                                                             | -                                   | 2,363                                       | -                                  | (2,600)                            |
| Loss on unconsolidated, associated companies                                      | 114,125                             | 163,066                                     | 128,621                            | 101,005                            |
| Loss on disposal of assets                                                        | 26                                  | 27                                          | -                                  | 27                                 |
| Changes to working capital                                                        | 16,212                              | (271,230)                                   | (212,281)(1)                       | 88,604                             |
| Long-term assets and liabilities                                                  | 18,877                              | 23,903                                      | 27,431                             | 22,730                             |
| <b>Total cash provided by operating activities</b>                                | <b>923,776</b>                      | <b>953,974</b>                              | <b>1,006,146</b>                   | <b>1,242,391</b>                   |
| <b>Investing activities</b>                                                       |                                     |                                             |                                    |                                    |
| Capital expenditures                                                              | (19,095)                            | (35,000)                                    | (35,000)                           | (30,467)                           |
| Purchase of product marketing rights and other intangible:                        | -                                   | -                                           | -                                  | (29,982)                           |
| Restricted cash, net                                                              | (3,807)                             | 14,632                                      | 22,472                             | 17,337                             |
| Investments in associated companies, net                                          | (134,454)                           | (224,306)(2)                                | (134,605)                          | (89,089)                           |
| Investment in Infinity stock                                                      | -                                   | -                                           | -                                  | (27,500)                           |
| <b>Total cash used in investing activities</b>                                    | <b>(157,356)</b>                    | <b>(244,674)</b>                            | <b>(147,133)</b>                   | <b>(159,701)</b>                   |
| <b>Financing activities</b>                                                       |                                     |                                             |                                    |                                    |
| Payments from associates, net                                                     | 11,062                              | 18,504                                      | 6,792                              | (2,703)                            |
| Capital contributions                                                             | 784                                 | -                                           | -                                  | -                                  |
| Distributions to partners for required tax payments                               | (264,958)                           | (331,772)                                   | (444,000)                          | (459,245)                          |
| Distributions to partners non-tax                                                 | (183,257)                           | (358,906)                                   | (538,077)                          | (471,643)                          |
| Distribution of Infinity stock                                                    | (216,663)                           | (216,663)                                   | -                                  | -                                  |
| <b>Total cash used in financing activities</b>                                    | <b>(653,032)</b>                    | <b>(888,837)</b>                            | <b>(975,285)</b>                   | <b>(933,591)</b>                   |
| <b>Increase (decrease) in cash and cash equivalents</b>                           | <b>113,388</b>                      | <b>(179,537)</b>                            | <b>(116,272)</b>                   | <b>149,099</b>                     |
| Cash and cash equivalents:                                                        |                                     |                                             |                                    |                                    |
| Unrestricted cash at the beginning of the period                                  | 755,593                             | 755,593                                     | 716,271                            | 606,494                            |
| <b>Unrestricted cash at the end of the period</b>                                 | <b>\$ 868,981</b>                   | <b>\$ 576,056</b>                           | <b>\$ 599,999</b>                  | <b>\$ 755,593</b>                  |

(1) Budget assumes payout of Medicaid rebates related to the CMS proposed rule of \$183 million. The current expectation is the payment will be made in 2014.

(2) The 2013 mid year update includes \$80.3 million of cash funding to Pearl Therapeutics of which \$30.3 million was included as an Ex-US expense and \$50 million was included as an investment relating to the purchase of Pearl stock. Since the Pearl transaction did not close, there will be variances in these line items versus the 2013 mid year update.

**Sales Summary Gross to Net by Product**

*Expressed in 000's*

|                                                     | September YTD       |                          |                     |                     | 2013 YTD Actual versus   |                     |                     | Full Year            |                     |                     |
|-----------------------------------------------------|---------------------|--------------------------|---------------------|---------------------|--------------------------|---------------------|---------------------|----------------------|---------------------|---------------------|
|                                                     | 2013 YTD Actual     | 2013 YTD Mid Year Update | 2013 YTD Budget     | 2012 YTD Actual     | 2013 YTD Mid Year Update | 2013 YTD Budget     | 2012 YTD Actual     | 2013 Mid Year Update | 2013 Budget         | 2012 Actual         |
| <b>OxyContin</b>                                    |                     |                          |                     |                     |                          |                     |                     |                      |                     |                     |
| Gross Sales                                         | \$ 1,840,242        | \$ 1,913,216             | \$ 2,184,831        | \$ 2,026,175        | \$ (72,974)              | \$ (344,589)        | \$ (185,933)        | \$ 2,553,108         | \$ 2,916,463        | \$ 2,777,064        |
| Fee for Service                                     | (38,096)            | (40,172)                 | (44,880)            | (52,744)            | 2,076                    | 6,784               | 14,648              | (53,399)             | (59,887)            | (65,876)            |
| Sales Discounts and Allowances                      | (36,374)            | (39,358)                 | (46,828)            | (72,149)            | 2,984                    | 10,454              | 35,775              | (44,826)             | (72,658)            | (116,425)           |
| Savings Cards Discounts                             | (26,293)            | (24,411)                 | (17,117)            | (12,654)            | (1,882)                  | (9,176)(2)          | (13,639)(1)         | (31,522)             | (22,813)            | (18,330)            |
| Rebates                                             | (357,430)           | (352,417)                | (411,897)           | (386,111)           | (5,013)                  | 54,467              | 28,681              | (471,555)            | (547,870)           | (509,597)           |
| Proposed Regulation Adjustment for Medicaid Rebates | (45,094)            | (57,244)                 | (49,368)            | (49,878)            | 12,150                   | 4,274               | 4,784               | (73,892)             | (65,584)            | (60,383)            |
| <b>OxyContin Net Sales</b>                          | <b>1,336,955</b>    | <b>1,399,614</b>         | <b>1,614,741</b>    | <b>1,452,639</b>    | <b>(62,659)</b>          | <b>(277,786)</b>    | <b>(115,684)</b>    | <b>1,877,914</b>     | <b>2,147,651</b>    | <b>2,006,453</b>    |
| % net to gross                                      | 73%                 | 73%                      | 74%                 | 72%                 |                          |                     |                     | 74%                  | 74%                 | 72%                 |
| <b>Butrans</b>                                      |                     |                          |                     |                     |                          |                     |                     |                      |                     |                     |
| Gross Sales                                         | \$ 100,772          | \$ 114,983               | \$ 114,983          | \$ 77,678           | (14,211)                 | \$ (14,211)         | \$ 23,094           | \$ 160,025           | \$ 160,025          | \$ 112,887          |
| Fee for Service                                     | (2,124)             | (2,487)                  | (2,470)             | (2,136)             | 363                      | 346                 | 12                  | (3,448)              | (3,432)             | (2,693)             |
| Sales Discounts and Allowances                      | (1,956)             | (2,446)                  | (2,663)             | (1,462)             | 490                      | 707                 | (494)               | (6,609)              | (6,826)             | (13,726)            |
| Savings Cards Discounts                             | (5,880)             | (6,040)                  | (6,219)             | (4,326)             | 160                      | 339                 | (1,554)             | (8,392)              | (8,574)             | (6,198)             |
| Rebates                                             | (8,894)             | (10,504)                 | (10,457)            | (4,464)             | 1,610                    | 1,563               | (4,430)             | (14,326)             | (14,341)            | (6,139)             |
| <b>Butrans Net Sales</b>                            | <b>81,918</b>       | <b>93,506</b>            | <b>93,174</b>       | <b>65,290</b>       | <b>(11,588)</b>          | <b>(11,256)</b>     | <b>16,628</b>       | <b>127,250</b>       | <b>126,852</b>      | <b>84,131</b>       |
| % net to gross                                      | 81%                 | 81%                      | 81%                 | 84%                 |                          |                     |                     | 80%                  | 79%                 | 75%                 |
| <b>Intermezzo</b>                                   |                     |                          |                     |                     |                          |                     |                     |                      |                     |                     |
| Gross Sales                                         | \$ 7,449            | \$ 11,003                | \$ 38,438           | \$ 14,104           | (3,554)                  | \$ (30,989)         | \$ (6,655)          | \$ 13,893            | \$ 57,622           | \$ 16,556           |
| Fee for Service                                     | (203)               | (219)                    | (765)               | (359)               | 16                       | 562                 | 156                 | (276)                | (1,147)             | (352)               |
| Sales Discounts and Allowances                      | 3,580               | (15)                     | (769)               | (8,244)             | 3,595(3)                 | 4,349               | 11,824              | (1,096)              | (6,914)             | (9,908)             |
| Savings Cards Discounts                             | (962)               | (1,096)                  | (2,103)             | (277)               | 134                      | 1,141               | (685)               | (1,421)              | (3,150)             | (576)               |
| Rebates                                             | (552)               | (635)                    | (1,337)             | (266)               | 83                       | 785                 | (286)               | (728)                | (2,365)             | (138)               |
| <b>Intermezzo Net Sales</b>                         | <b>9,312</b>        | <b>9,038</b>             | <b>33,464</b>       | <b>4,958</b>        | <b>274</b>               | <b>(24,152)</b>     | <b>4,354</b>        | <b>10,372</b>        | <b>44,046</b>       | <b>5,582</b>        |
| % net to gross                                      | 125%                | 82%                      | 87%                 | 35%                 |                          |                     |                     | 75%                  | 76%                 | 34%                 |
| <b>Total for All Products</b>                       |                     |                          |                     |                     |                          |                     |                     |                      |                     |                     |
| Gross Sales                                         | \$ 2,017,880        | \$ 2,110,171             | 2,409,221           | \$ 2,187,586        | (92,291)                 | \$ (391,341)        | \$ (169,706)        | \$ 2,821,387         | \$ 3,228,472        | \$ 3,004,905        |
| Fee for Service                                     | (40,907)            | (43,498)                 | (48,774)            | (55,947)            | 2,591                    | 7,867               | 15,040              | (57,957)             | (65,338)            | (69,313)            |
| Sales Discounts and Allowances                      | (35,036)            | (43,323)                 | (51,899)            | (76,186)            | 8,287                    | 16,863              | 41,150              | (54,066)             | (88,198)            | (134,032)           |
| Savings Cards Discounts                             | (33,136)            | (31,547)                 | (25,439)            | (17,257)            | (1,589)                  | (7,697)             | (15,879)            | (41,334)             | (34,537)            | (25,104)            |
| Rebates                                             | (368,199)           | (365,026)                | (424,861)           | (392,664)           | (3,173)                  | 56,662              | 24,465              | (488,581)            | (566,117)           | (517,606)           |
| Proposed Regulation Adjustment for Medicaid Rebates | (45,094)            | (57,244)                 | (49,368)            | (49,878)            | 12,150                   | 4,274               | 4,784               | (73,892)             | (65,584)            | (60,383)            |
| Other                                               | 3,397               | 1,238                    | 1,238               | 2,161               | 2,159                    | 2,159               | 1,236               | 1,651                | 1,651               | 2,455               |
| <b>Total Net Sales</b>                              | <b>\$ 1,498,905</b> | <b>\$ 1,570,771</b>      | <b>\$ 1,810,118</b> | <b>\$ 1,597,815</b> | <b>\$ (71,866)</b>       | <b>\$ (313,372)</b> | <b>\$ (100,146)</b> | <b>\$ 2,107,208</b>  | <b>\$ 2,410,349</b> | <b>\$ 2,200,922</b> |
| % net to gross                                      | 74%                 | 74%                      | 75%                 | 73%                 |                          |                     |                     | 75%                  | 75%                 | 73%                 |

(1) The increase in year-to-date September 2013 actual expense versus prior year-to-date actual is due to (1) higher redemption rates largely due to the fact that the eVoucher program only initiated in March 2012 and the 65 and over age limit on the eVoucher program was lifted in 2013 and (2) the card limit was increased from \$70 to \$90 which increased the average cost per redemption.

(2) The variance to budget, which was adjusted for in the mid year update, primarily relates to the lifting of the age limit of 65 on the eVoucher program.

(3) Due to favorable Intermezzo pull through adjustment to recognize the difference between demand and Purdue factory sales. The mid year update assumed demand would equal Purdue sales. Year to date factory sales were lower than demand by \$3.6 million.

Gross Sales Summary by Product

Expressed in 000's

|                                              | September YTD       |                          |                     | 2013 YTD Actual versus |                          |                     | Full Year          |                      |                     |                     |
|----------------------------------------------|---------------------|--------------------------|---------------------|------------------------|--------------------------|---------------------|--------------------|----------------------|---------------------|---------------------|
|                                              | 2013 YTD Actual     | 2013 YTD Mid Year Update | 2013 YTD Budget     | 2012 YTD Actual        | 2013 YTD Mid Year Update | 2012 YTD Budget     | 2012 YTD Actual    | 2013 Mid Year Update | 2013 Budget         | 2012 Actual         |
| 10 mg                                        | \$ 104,192          | \$ 105,702               | \$ 117,590          | \$ 110,338             | \$ (1,510)               | \$ (13,398)         | \$ (6,146)         | \$ 142,460           | \$ 156,987          | \$ 152,741          |
| 15 mg                                        | 27,636              | 26,193                   | 28,332              | 24,012                 | 1,443                    | (696)               | 3,624              | 35,840               | 37,814              | 33,992              |
| 20 mg                                        | 266,699             | 281,821                  | 314,577             | 293,406                | (15,122)                 | (47,878)            | (26,707)           | 377,709              | 419,948             | 402,472             |
| 30 mg                                        | 154,824             | 157,532                  | 177,889             | 146,878                | (2,708)                  | (23,065)            | 7,946              | 214,549              | 237,429             | 205,335             |
| 40 mg                                        | 392,065             | 417,523                  | 466,161             | 451,287                | (25,458)                 | (74,096)            | (59,222)           | 555,777              | 622,343             | 618,704             |
| 60 mg                                        | 241,811             | 250,339                  | 291,312             | 246,457                | (8,528)                  | (49,501)            | (4,646)            | 338,266              | 388,817             | 340,746             |
| 80 mg                                        | 653,015             | 674,106                  | 788,970             | 753,797                | (21,091)                 | (135,955)           | (100,782)          | 888,506              | 1,053,124           | 1,023,074           |
| <b>Gross OxyContin Sales</b>                 | <b>1,840,242</b>    | <b>1,913,216</b>         | <b>2,184,831</b>    | <b>2,026,175</b>       | <b>(72,974)</b>          | <b>(344,589)</b>    | <b>(185,933)</b>   | <b>2,553,107</b>     | <b>2,916,462</b>    | <b>2,777,064</b>    |
| Dilaudid Tablets                             | \$ 7,624            | \$ 8,915                 | \$ 8,915            | \$ 10,546              | \$ (1,291)               | \$ (1,291)          | \$ (2,922)         | \$ 11,856            | \$ 11,856           | \$ 14,191           |
| Dilaudid Ampules                             | 2,376               | 3,350                    | 3,350               | 5,716                  | (974)                    | (974)               | (3,340)            | 4,328                | 4,328               | 8,272               |
| Dilaudid Vials                               | 763                 | 619                      | 619                 | 1,023                  | 144                      | 144                 | (260)              | 797                  | 797                 | 1,306               |
| <b>Gross Dilaudid Sales</b>                  | <b>10,763</b>       | <b>12,884</b>            | <b>12,884</b>       | <b>17,285</b>          | <b>(2,121)</b>           | <b>(2,121)</b>      | <b>(6,522)</b>     | <b>16,981</b>        | <b>16,981</b>       | <b>23,769</b>       |
| Betadine First Aid                           | \$ 3,138            | \$ 3,022                 | \$ 3,022            | \$ 3,083               | \$ 116                   | \$ 116              | \$ 55              | \$ 4,027             | \$ 4,027            | \$ 4,118            |
| Betadine Hospital                            | 3,556               | 3,302                    | 3,302               | 3,398                  | 254                      | 254                 | 158                | 4,401                | 4,401               | 4,653               |
| Betadine Veterinary                          | 732                 | 619                      | 619                 | 688                    | 113                      | 113                 | 44                 | 830                  | 830                 | 850                 |
| <b>Gross Betadine Sales</b>                  | <b>7,426</b>        | <b>6,943</b>             | <b>6,943</b>        | <b>7,169</b>           | <b>483</b>               | <b>483</b>          | <b>257</b>         | <b>9,258</b>         | <b>9,258</b>        | <b>9,621</b>        |
| Colace                                       | \$ 18,310           | \$ 19,252                | \$ 19,252           | \$ 18,272              | \$ (942)                 | \$ (942)            | \$ 38              | \$ 25,669            | \$ 25,669           | \$ 25,891           |
| Peri-Colace                                  | 3,136               | 3,531                    | 3,531               | 3,264                  | (395)                    | (395)               | (128)              | 4,708                | 4,708               | 4,403               |
| <b>Gross Colace / Peri-Colace Sales</b>      | <b>21,446</b>       | <b>22,783</b>            | <b>22,783</b>       | <b>21,536</b>          | <b>(1,337)</b>           | <b>(1,337)</b>      | <b>(90)</b>        | <b>30,377</b>        | <b>30,377</b>       | <b>30,294</b>       |
| Senokot-S                                    | \$ 8,685            | \$ 7,234                 | \$ 7,234            | \$ 8,222               | \$ 1,451                 | \$ 1,451            | \$ 463             | \$ 9,648             | \$ 9,648            | \$ 11,220           |
| Senokot                                      | 7,462               | 6,947                    | 6,947               | 7,253                  | 515                      | 515                 | 209                | 9,263                | 9,263               | 10,000              |
| <b>Gross Senokot Sales</b>                   | <b>16,147</b>       | <b>14,181</b>            | <b>14,181</b>       | <b>15,475</b>          | <b>1,966</b>             | <b>1,966</b>        | <b>672</b>         | <b>18,911</b>        | <b>18,911</b>       | <b>21,220</b>       |
| Butrans                                      | \$ 100,772          | \$ 114,983               | \$ 114,983          | \$ 77,678              | \$ (14,211)              | \$ (14,211)         | \$ 23,094          | \$ 160,025           | \$ 160,025          | \$ 112,887          |
| Intermezzo                                   | 7,449               | 11,003                   | 38,438              | 14,104                 | (3,554)                  | (30,989)            | (6,655)            | 13,892               | 57,622              | 16,556              |
| MS Contin                                    | 8,627               | 8,798                    | 8,798               | 9,548                  | (171)                    | (171)               | (921)              | 11,642               | 11,642              | 12,974              |
| Ryzolt                                       | (1,172)             | -                        | -                   | (6,781)                | (1,172)                  | (1,172)             | 5,609              | -                    | -                   | (6,924)             |
| Slow-Mag                                     | 4,572               | 3,974                    | 3,974               | 4,047                  | 598                      | 598                 | 525                | 5,316                | 5,316               | 5,554               |
| Betasept                                     | 1,615               | 1,406                    | 1,406               | 1,424                  | 209                      | 209                 | 191                | 1,878                | 1,878               | 1,971               |
| Discontinued Products                        | (7)                 | -                        | -                   | (74)                   | (7)                      | (7)                 | 67                 | -                    | -                   | (81)                |
| <b>GROSS BRANDED SALES</b>                   | <b>2,017,880</b>    | <b>2,110,171</b>         | <b>2,409,221</b>    | <b>2,187,586</b>       | <b>(92,291)</b>          | <b>(391,341)</b>    | <b>(169,706)</b>   | <b>2,821,387</b>     | <b>3,228,472</b>    | <b>3,004,905</b>    |
| Fee for Service                              | (40,907)            | (43,498)                 | (48,774)            | (55,947)               | 2,591                    | 7,867               | 15,040             | (57,957)             | (65,338)            | (69,313)            |
| Discounts and Allowances                     | (35,036)            | (43,323)                 | (51,899)            | (76,186)               | 8,287                    | 16,863              | 41,150             | (54,066)             | (88,198)            | (134,032)           |
| Savings Card Discount                        | (33,136)            | (31,547)                 | (25,439)            | (17,257)               | (1,589)                  | (7,697)             | (15,879)           | (41,334)             | (34,537)            | (25,104)            |
| Rebates                                      | (368,199)           | (365,026)                | (424,861)           | (392,664)              | (3,173)                  | 56,662              | 24,465             | (488,581)            | (566,117)           | (517,606)           |
| Proposed Regulation Adj for Medicaid Rebates | (45,094)            | (57,244)                 | (49,368)            | (49,878)               | 12,150                   | 4,274               | 4,784              | (73,892)             | (65,584)            | (60,383)            |
| Other                                        | 3,397               | 1,238                    | 1,238               | 2,161                  | 2,159                    | 2,159               | 1,236              | 1,651                | 1,651               | 2,455               |
| <b>NET BRANDED SALES</b>                     | <b>\$ 1,498,905</b> | <b>\$ 1,570,771</b>      | <b>\$ 1,810,118</b> | <b>\$ 1,597,815</b>    | <b>\$ (71,866)</b>       | <b>\$ (311,213)</b> | <b>\$ (98,910)</b> | <b>\$ 2,107,208</b>  | <b>\$ 2,410,349</b> | <b>\$ 2,200,922</b> |

## Sales Variance to Mid Year Update

Expressed in 000's

### Gross Sales:

|                                                                                    |           |                    |
|------------------------------------------------------------------------------------|-----------|--------------------|
| • Impact of trade inventories higher than mid year update (1)                      | \$ 15,036 |                    |
| • Lower demand versus mid year update (1) (2)                                      | (88,010)  |                    |
| OxyContin                                                                          |           | <u>\$ (72,974)</u> |
| • Butrans sales due to lower trade inventory (\$9 million)and demand (\$3 million) |           | (14,211)           |
| • Intermezzo due to lower trade inventory                                          |           | (3,554)            |
| • All other                                                                        |           | <u>(1,552)</u>     |
| Subtotal - Gross sales variance                                                    |           | (92,291)           |

### Deductions:

|                                                |  |               |
|------------------------------------------------|--|---------------|
| • Lower variable deductions due to lower sales |  | <u>20,425</u> |
|------------------------------------------------|--|---------------|

### **Net Branded Sales Variance**

\$ (71,866)

(1) Each of these factors is based on estimates provided by IMS and customers.

(2) Lower demand is estimated to be due to reported IMS demand net of VCBs and returns lower than the mid year update by \$12.1 million and IMS data error of \$75.9 million.

## Brand Profit and Loss Statements

Expressed in 000's

|                                 | September Year-to-Date |                          |                     | 2013 YTD Actual versus   |                     |                      | Full Year           |                     |                     |                    |
|---------------------------------|------------------------|--------------------------|---------------------|--------------------------|---------------------|----------------------|---------------------|---------------------|---------------------|--------------------|
|                                 | 2013 YTD Actual        | 2013 YTD Mid Year Update | 2013 YTD Budget     | 2013 YTD Mid Year Update | 2013 YTD Budget     | 2013 Mid Year Update | 2013 Budget         | 2012 Actual         | 2011 Actual         | 2010 Actual        |
| <b>OxyContin</b>                |                        |                          |                     |                          |                     |                      |                     |                     |                     |                    |
| Gross Sales                     | \$ 1,840,242           | \$ 1,913,216             | \$ 2,184,831        | \$ (72,974)              | \$ (344,589)        | \$ 2,553,108         | \$ 2,916,463        | \$ 2,777,064        | \$ 2,781,019        |                    |
| Net Sales                       | 1,336,954              | 1,398,884                | 1,614,740           | (61,930)                 | (277,786)           | 1,877,183            | 2,147,645           | 2,006,701           | 2,030,891           |                    |
| Gross Profit                    | 1,205,115              | 1,262,269                | 1,460,650           | (57,154)                 | (255,535)           | 1,700,116            | 1,957,518           | 1,822,882           | 1,838,411           |                    |
| S&P Expense                     | (60,509)               | (73,667)                 | (75,551)            | 13,158                   | 15,042              | (99,949)             | (100,238)           | (62,033)            | (50,758)            |                    |
| All Other                       | (136,781)              | (135,531)                | (133,019)           | (1,250)                  | (3,762)             | (189,574)            | (185,324)           | (182,300)           | (173,762)           |                    |
| <b>Product Operating Margin</b> | <b>\$ 1,007,825</b>    | <b>\$ 1,053,071</b>      | <b>\$ 1,252,080</b> | <b>\$ (45,246)</b>       | <b>\$ (244,255)</b> | <b>\$ 1,410,593</b>  | <b>\$ 1,671,956</b> | <b>\$ 1,578,549</b> | <b>\$ 1,613,891</b> |                    |
| <b>Butrans</b>                  |                        |                          |                     |                          |                     |                      |                     |                     |                     |                    |
| Gross Sales                     | \$ 100,772             | \$ 114,983               | \$ 114,983          | \$ (14,211)              | \$ (14,211)         | \$ 160,025           | \$ 160,025          | \$ 112,887          | \$ 73,531           | \$ -               |
| Net Sales                       | 81,918                 | 93,506                   | 93,175              | (11,588)                 | (11,257)            | 127,250              | 126,990             | 84,131              | 55,937              | -                  |
| Gross Profit                    | 74,076                 | 84,207                   | 82,528              | (10,131)                 | (8,452)             | 114,026              | 111,855             | 71,059              | 45,728              | (913)              |
| S&P Expense                     | (71,497)               | (73,047)                 | (75,261)            | 1,550                    | 3,764               | (99,181)             | (100,459)           | (105,912)           | (120,536)           | (6,743)            |
| All Other                       | (20,602)               | (27,072)                 | (27,153)            | 6,470                    | 6,551               | (36,069)             | (36,369)            | (24,307)            | (26,308)            | (9,123)            |
| <b>Product Operating Margin</b> | <b>\$ (18,023)</b>     | <b>\$ (15,912)</b>       | <b>\$ (19,886)</b>  | <b>\$ (2,111)</b>        | <b>\$ 1,863</b>     | <b>\$ (21,224)</b>   | <b>\$ (24,973)</b>  | <b>\$ (59,160)</b>  | <b>\$ (101,116)</b> | <b>\$ (16,779)</b> |
| <b>Intermezzo</b>               |                        |                          |                     |                          |                     |                      |                     |                     |                     |                    |
| Gross Sales                     | \$ 7,449               | \$ 11,003                | \$ 38,438           | \$ (3,554)               | \$ (30,989)         | \$ 13,892            | \$ 57,622           | \$ 16,556           | \$ -                | \$ -               |
| Net Sales                       | 9,312                  | 9,038                    | 33,464              | 274                      | (24,152)            | 10,371               | 44,046              | 5,582               | -                   | -                  |
| Gross Profit                    | 5,156                  | 4,602                    | 26,572              | 554                      | (21,416)            | 5,352                | 33,825              | 2,391               | -                   | -                  |
| S&P Expense                     | (43,580)               | (42,589)                 | (49,805)            | (991)                    | 6,225               | (45,701)             | (61,193)            | (78,573)            | (3,034)             | (1,591)            |
| All Other                       | 4,784                  | 4,873                    | 6,294               | (89)                     | (1,510)             | 4,148                | 7,849               | (3,236)             | -                   | -                  |
| <b>Product Operating Margin</b> | <b>\$ (33,640)</b>     | <b>\$ (33,114)</b>       | <b>\$ (16,939)</b>  | <b>\$ (526)</b>          | <b>\$ (16,701)</b>  | <b>\$ (36,201)</b>   | <b>\$ (19,519)</b>  | <b>\$ (79,418)</b>  | <b>\$ (3,034)</b>   | <b>\$ (1,591)</b>  |
| <b>Laxatives</b>                |                        |                          |                     |                          |                     |                      |                     |                     |                     |                    |
| Gross Sales                     | \$ 37,594              | \$ 36,964                | \$ 36,965           | \$ 630                   | \$ 629              | \$ 49,287            | \$ 49,287           | \$ 51,514           |                     |                    |
| Net Sales                       | 36,740                 | 36,163                   | 36,477              | 577                      | 263                 | 48,611               | 48,636              | 48,838              |                     |                    |
| Gross Profit                    | 26,763                 | 26,781                   | 27,120              | (18)                     | (357)               | 37,218               | 36,160              | 37,562              |                     |                    |
| S&P Expense                     | (12,469)               | (11,182)                 | (11,735)            | (1,287)                  | (734)               | (15,446)             | (15,646)            | (18,969)            |                     |                    |
| All Other                       | (600)                  | (975)                    | (975)               | 375                      | 375                 | (1,301)              | (1,300)             | (1,301)             |                     |                    |
| <b>Product Operating Margin</b> | <b>\$ 13,694</b>       | <b>\$ 14,624</b>         | <b>\$ 14,410</b>    | <b>\$ (930)</b>          | <b>\$ (716)</b>     | <b>\$ 20,471</b>     | <b>\$ 19,214</b>    | <b>\$ 17,292</b>    |                     |                    |

Note: All Other includes Pharma Fee, Legal Fees, R&D Support for the marketed product and an allocation of G&A.

General and Administrative Summary

Expressed in 000's

|                                            | September YTD     |                          |                   |                   | 2013 YTD Actual versus   |                   |                 | Full Year            |                   |                   | HEADCOUNT       |                      |               |             | Comments                                                                                                                                                                            |
|--------------------------------------------|-------------------|--------------------------|-------------------|-------------------|--------------------------|-------------------|-----------------|----------------------|-------------------|-------------------|-----------------|----------------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                            | 2013 YTD Actual   | 2013 YTD Mid Year Update | 2013 YTD Budget   | 2012 YTD Actual   | 2013 YTD Mid Year Update | 2013 YTD Budget   | 2012 YTD Actual | 2013 Mid Year Update | 2013 Budget       | 2012 Actual       | 2013 YTD Actual | 2013 Mid Year Update | Var to Budget | 2012 Actual |                                                                                                                                                                                     |
| Finance                                    | \$ 10,474         | \$ 10,317                | \$ 10,317         | \$ 10,166         | \$ 157                   | \$ 157            | \$ 308          | \$ 13,520            | \$ 13,520         | \$ 13,324         | 62              | 66                   | 4             | 62          | \$0.2 million unfavorable for timing of outside services.                                                                                                                           |
| Information Technology                     | 24,650            | 26,447                   | 26,995            | 24,285            | (1,797)                  | (2,345)           | 365             | 35,217               | 35,466            | 32,262            | 94              | 102                  | 8             | 96          | \$1.8 million favorable due to: \$0.8 million favorable open positions, \$0.6 million favorable timing of consulting and \$0.4 million favorable software and hardware maintenance. |
| Corporate Procurement                      | 2,505             | 2,670                    | 2,670             | 2,370             | (165)                    | (165)             | 135             | 3,500                | 3,500             | 3,215             | 13              | 15                   | 2             | 13          | \$0.2 million favorable due to two open positions.                                                                                                                                  |
| Insurance                                  | 2,043             | 2,380                    | 2,618             | 2,128             | (337)                    | (575)             | (85)            | 3,192                | 3,492             | 2,846             | -               | -                    | -             | -           | \$0.3 million favorable due to lower negotiated property premium rates, lower than anticipated business interruption insurance, and timing of clinical trial insurance.             |
| IPAP                                       | 2,718             | 2,778                    | 2,925             | 2,630             | (60)                     | (207)             | 88              | 3,704                | 3,900             | 3,747             | -               | -                    | -             | -           |                                                                                                                                                                                     |
| <b>Subtotal - Mahony</b>                   | <b>42,390</b>     | <b>44,592</b>            | <b>45,525</b>     | <b>41,579</b>     | <b>(2,202)</b>           | <b>(3,135)</b>    | <b>811</b>      | <b>59,133</b>        | <b>59,878</b>     | <b>55,394</b>     | <b>169</b>      | <b>183</b>           | <b>14</b>     | <b>171</b>  |                                                                                                                                                                                     |
| Human Resources                            | 4,738             | 4,989                    | 5,029             | 4,537             | (251)                    | (291)             | 201             | 6,546                | 6,587             | 5,900             | 24              | 24                   | -             | 23          | \$0.3 million favorable due to timing of new hire, training and consulting.                                                                                                         |
| EHS Corporate Administration Building      | 2,004             | 1,993                    | 1,974             | 1,728             | 11                       | 30                | 276             | 2,599                | 2,587             | 2,286             | 5               | 6                    | 1             | 6           |                                                                                                                                                                                     |
| Administration Building                    | 6,234             | 6,112                    | 6,266             | 6,030             | 122                      | (32)              | 204             | 8,132                | 8,322             | 8,156             | 34              | 34                   | -             | 34          | \$0.1 million unfavorable for higher duplication and higher postage.                                                                                                                |
| Stamford Facilities                        | 16,911            | 17,100                   | 17,132            | 16,422            | (189)                    | (221)             | 489             | 22,734               | 22,837            | 22,062            | -               | -                    | -             | -           | \$0.2 million favorable due to lower operating expenses as compared to the budget. This is trued up at year end.                                                                    |
| Facilities Allocation Out                  | (17,132)          | (17,133)                 | (17,133)          | (16,990)          | 1                        | 1                 | (142)           | (22,837)             | (22,837)          | (22,649)          | -               | -                    | -             | -           |                                                                                                                                                                                     |
| <b>Subtotal - Long</b>                     | <b>12,755</b>     | <b>13,061</b>            | <b>13,268</b>     | <b>11,727</b>     | <b>(306)</b>             | <b>(513)</b>      | <b>1,028</b>    | <b>17,174</b>        | <b>17,496</b>     | <b>15,755</b>     | <b>63</b>       | <b>64</b>            | <b>1</b>      | <b>63</b>   |                                                                                                                                                                                     |
| Public Affairs                             | 3,937             | 5,172                    | 5,172             | 3,333             | (1,235)                  | (1,235)           | 604             | 7,129                | 7,129             | 5,218             | 3               | 4                    | 1             | 4           | \$1.2 million favorable due to timing of various consulting projects and special promotion project payments.                                                                        |
| Federal Government Affairs                 | 3,214             | 3,253                    | 3,253             | 3,239             | (39)                     | (39)              | (25)            | 3,495                | 3,495             | 3,473             | 2               | 2                    | -             | 2           |                                                                                                                                                                                     |
| State Government Affairs                   | 7,578             | 8,918                    | 8,918             | 7,683             | (1,340)                  | (1,340)           | (105)           | 11,522               | 11,522            | 10,659            | 12              | 12                   | -             | 12          | \$1.3 million favorable due to timing of organizational grant payments versus a straight line budget assumption.                                                                    |
| <b>Subtotal - External Affairs</b>         | <b>14,729</b>     | <b>17,343</b>            | <b>17,343</b>     | <b>14,255</b>     | <b>(2,614)</b>           | <b>(2,614)</b>    | <b>474</b>      | <b>22,146</b>        | <b>22,146</b>     | <b>19,350</b>     | <b>17</b>       | <b>18</b>            | <b>1</b>      | <b>18</b>   |                                                                                                                                                                                     |
| Purdue Pharma Fund                         | 1,128             | 1,442                    | 1,442             | 846               | (314)                    | (314)             | 282             | 1,922                | 1,922             | 969               | -               | -                    | -             | -           | \$0.2 million unfavorable due to salary and related expense and records management expenses.                                                                                        |
| DEA Compliance                             | 20                | 25                       | 281               | 366               | (5)                      | (261)             | (346)           | 25                   | 362               | 448               | -               | 1                    | 1             | 1           | \$0.3 million favorable for timing of grants.<br>Moved to security.                                                                                                                 |
| Executive Administration                   | 5,562             | 5,518                    | 5,187             | 4,748             | 44                       | 375               | 814             | 7,334                | 6,832             | 6,712             | 6               | 6                    | -             | 5           |                                                                                                                                                                                     |
| General underspend                         | -                 | (541)                    | (676)             | -                 | 541                      | 676               | -               | (721)                | (901)             | -                 | -               | -                    | -             | -           |                                                                                                                                                                                     |
| <b>Subtotal - Executive Administration</b> | <b>5,562</b>      | <b>4,977</b>             | <b>4,511</b>      | <b>4,748</b>      | <b>585</b>               | <b>1,051</b>      | <b>814</b>      | <b>6,613</b>         | <b>5,931</b>      | <b>6,712</b>      | <b>6</b>        | <b>6</b>             | <b>-</b>      | <b>5</b>    |                                                                                                                                                                                     |
| Depreciation and Occupancy                 | 12,356            | 12,356                   | 12,356            | 12,916            | -                        | -                 | (560)           | 16,471               | 16,471            | 17,116            | -               | -                    | -             | -           |                                                                                                                                                                                     |
| Quality                                    | 5,992             | 6,655                    | 6,655             | 5,514             | (663)                    | (663)             | 478             | 8,757                | 8,757             | 7,438             | 34              | 35                   | 1             | 31          | \$0.7 million favorable for open positions, consulting and travel.                                                                                                                  |
| Security                                   | 4,143             | 4,427                    | 4,479             | 4,318             | (284)                    | (336)             | (175)           | 5,828                | 5,897             | 5,465             | 15              | 15                   | -             | 15          | \$0.3 million favorable for timing of grants and timing of new hire.                                                                                                                |
| Corporate Compliance                       | 2,437             | 2,789                    | 2,859             | 2,768             | (352)                    | (422)             | (331)           | 3,536                | 3,606             | 3,384             | 11              | 12                   | 1             | 11          | \$0.4 million favorable due to: \$0.1 million open positions, \$0.1 million reduced Axentis license fees, \$0.1 million consulting project spend to date.                           |
| Business Development                       | 2,121             | 2,607                    | 2,607             | 2,169             | (486)                    | (486)             | (48)            | 3,442                | 3,442             | 3,181             | 7               | 7                    | -             | 7           | \$0.5 million favorable due to minimal consulting project spend to date.                                                                                                            |
| Employee Benefits                          | (442)             | (790)                    | (942)             | 2,362             | 348                      | 500               | (2,804)         | (1,701)              | (1,447)           | 4,726             | -               | -                    | -             | -           | \$0.4 million unfavorable due to: \$0.1 million for higher medical expenses and \$0.3 million for higher retirement admin fees.                                                     |
| Fleet                                      | (579)             | (596)                    | 6                 | (626)             | 17                       | (585)             | 47              | (609)                | -                 | (349)             | -               | -                    | -             | -           |                                                                                                                                                                                     |
| <b>Subtotal - Other</b>                    | <b>26,028</b>     | <b>27,448</b>            | <b>28,020</b>     | <b>29,421</b>     | <b>(1,420)</b>           | <b>(1,992)</b>    | <b>(3,393)</b>  | <b>35,724</b>        | <b>36,726</b>     | <b>40,961</b>     | <b>67</b>       | <b>69</b>            | <b>2</b>      | <b>64</b>   |                                                                                                                                                                                     |
| <b>Total General and Administrative</b>    | <b>\$ 112,407</b> | <b>\$ 118,849</b>        | <b>\$ 120,626</b> | <b>\$ 112,102</b> | <b>\$ (6,442)</b>        | <b>\$ (8,219)</b> | <b>\$ 305</b>   | <b>\$ 155,762</b>    | <b>\$ 157,762</b> | <b>\$ 151,635</b> | <b>366</b>      | <b>385</b>           | <b>19</b>     | <b>365</b>  |                                                                                                                                                                                     |

**Redacted**

Research and Development

Expressed in 000's

|                                       | September YTD     |                          |                   |                   | 2013 YTD Actual versus   |                   |                  | Full Year            |                   |                   | HEADCOUNT       |                      |               |             | Comments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------|-------------------|--------------------------|-------------------|-------------------|--------------------------|-------------------|------------------|----------------------|-------------------|-------------------|-----------------|----------------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                       | 2013 YTD Actual   | 2013 YTD Mid Year Update | 2013 YTD Budget   | 2012 YTD Actual   | 2013 YTD Mid Year Update | 2013 YTD Budget   | 2012 YTD Actual  | 2013 Mid Year Update | 2013 Budget       | 2012 Actual       | 2013 YTD Actual | 2013 Mid Year Update | Var to Budget | 2012 Actual |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Clinical Program                      | \$ 91,970         | \$ 101,195               | \$ 152,213        | \$ 103,616        | \$(9,225)                | \$(60,243)        | \$(11,646)       | \$ 134,212           | \$ 191,025        | \$ 137,238        | -               | -                    | -             | -           | \$9.2 million favorability due to: OTR underspend \$3.3 million due to lower than expected CRO service and pass through costs in the pediatric studies. BUP underspend \$3.5 million due primarily to lower than expected CRO service and pass through costs in the pediatric PREA study BUP3031 coupled with lower than expected CRO service cost in the IQTC study BUP1025. ONU underspend of \$2.3 million due primarily to lower than expected CRO pass through costs incurred in the ONU cardiovascular data analysis effort coupled with lower than expected NDA compilation costs. |
| Non-Clinical                          | 30,175            | 33,105                   | 37,673            | 39,135            | (2,930)                  | (7,498)           | (8,960)          | 56,220               | 50,134            | 52,748            | 54              | 55                   | 1             | 50          | \$2.9 million underspend is primarily due to timing of outsourcing in VND (\$1.2 million), and BUP (\$0.9 million), and HYD (\$0.6 million). The latest estimate recognizes a full year reduction of \$9.8 million in outsourcing.                                                                                                                                                                                                                                                                                                                                                        |
| Medical Research                      | 21,483            | 25,387                   | 25,340            | 19,942            | (3,904)                  | (3,857)           | 1,541            | 34,180               | 33,455            | 27,394            | 72              | 78                   | 6             | 73          | \$3.9 million favorability primarily due to underspend on staff extenders and timing of consulting and software spends.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Discovery Research                    | 16,594            | 17,247                   | 18,468            | 15,705            | (653)                    | (1,874)           | 889              | 24,500               | 24,522            | 20,728            | 51              | 53                   | 2             | 50          | \$0.7 million favorability relates to reduced outsourcing for exploratory projects. The latest estimate recognizes a full year underspend for this work of \$2.0 million.                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Health Policy                         | 11,920            | 12,881                   | 12,552            | 13,021            | (961)                    | (632)             | (1,101)          | 16,572               | 16,502            | 16,693            | 41              | 41                   | -             | 40          | \$1.0 million favorable due to timing of special programs \$0.4 million, \$0.1 million in people costs, \$0.2 million in outside services / consulting, \$0.1 million in staff extenders and \$0.1 million in educational materials and \$0.1 million in other.                                                                                                                                                                                                                                                                                                                           |
| Risk Management                       | 9,570             | 12,079                   | 12,179            | 8,551             | (2,509)                  | (2,609)           | 1,019            | 16,146               | 16,246            | 12,050            | 14              | 14                   | -             | 14          | \$2.5 million underspend due to timing of studies & classwide REMS spend vs. budget phasing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Drug Safety                           | 6,411             | 7,991                    | 8,391             | 7,613             | (1,580)                  | (1,980)           | (1,202)          | 10,722               | 11,122            | 9,476             | 31              | 39                   | 8             | 33          | \$1.6 million underspend driven by \$0.6 million in lower adverse event processing, \$0.1 million staff extender expenses and \$0.9 million favorable in people and people related costs.                                                                                                                                                                                                                                                                                                                                                                                                 |
| Regulatory                            | 11,898            | 11,458                   | 12,318            | 7,752             | 440                      | (420)             | 4,146            | 15,043               | 15,423            | 10,560            | 26              | 27                   | 1             | 26          | \$0.4 million unfavorable driven phasing of submission processing expenses versus budget.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Tech Transfer                         | 2,801             | 3,058                    | 5,317             | 3,427             | (257)                    | (2,516)           | (626)            | 4,066                | 8,075             | 4,575             | -               | -                    | -             | -           | \$0.3 million underspend is due to timing of HYD, and TRPV1 batches.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Medical Affairs                       | 1,783             | 3,303                    | 3,103             | 576               | (1,520)                  | (1,320)           | 1,207            | 4,342                | 4,142             | 1,205             | 3               | 4                    | 1             | 3           | \$1.5 million favorability due to underspend relating to Investigator Initiated Studies and staff extenders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Shionogi Collaboration                | 1,899             | 1,898                    | 3,187             | 1,048             | 1                        | (1,288)           | 851              | 1,250                | 4,249             | 1,450             | -               | -                    | -             | -           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| R&D Innovation                        | 3,369             | 3,996                    | 3,966             | 386               | (627)                    | (597)             | 2,983            | 6,247                | 5,310             | 1,057             | 3               | 3                    | -             | 2           | \$0.6 million favorability due to timing of consulting spend related to exploratory projects.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Health Outcomes                       | 3,107             | 4,129                    | 4,216             | 631               | (1,022)                  | (1,109)           | 2,476            | 6,265                | 5,654             | 2,179             | 5               | 5                    | -             | 3           | \$1.0 million favorability due to outsidess services relating to advisory boards, various consulting projects and other of \$1.3 million offset by \$0.3 million in unfavorable people costs.                                                                                                                                                                                                                                                                                                                                                                                             |
| Project Management                    | 3,881             | 3,959                    | 3,959             | 3,300             | (78)                     | (78)              | 581              | 5,149                | 5,148             | 4,549             | 18              | 20                   | 2             | 208         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Outsource Management                  | 962               | 1,135                    | 1,136             | 1,064             | (173)                    | (174)             | (102)            | 1,488                | 1,488             | 1,314             | 6               | 6                    | -             | 6           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Stamford Occupancy and Depreciator    | 8,010             | 8,010                    | 8,010             | 7,060             | -                        | -                 | 950              | 10,678               | 10,678            | 9,412             | -               | -                    | -             | -           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Cranbury Occupancy                    | (413)             | (116)                    | (112)             | (358)             | (297)                    | (301)             | (55)             | (157)                | (151)             | (115)             | 15              | 15                   | -             | 14          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Underspend Estimate                   | -                 | (14,800)                 | (19,060)          | -                 | 14,800                   | 19,060            | -                | (19,676)             | (25,675)          | -                 | -               | -                    | -             | -           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Total Research and Development</b> | <b>\$ 225,420</b> | <b>\$ 235,915</b>        | <b>\$ 292,856</b> | <b>\$ 232,469</b> | <b>\$(10,495)</b>        | <b>\$(67,436)</b> | <b>\$(7,049)</b> | <b>\$ 327,247</b>    | <b>\$ 377,347</b> | <b>\$ 312,513</b> | <b>339</b>      | <b>360</b>           | <b>21</b>     | <b>334</b>  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

Other US

Expressed in 000's

|                                               | September YTD   |                          |                   | 2013 YTD Actual versus |                          |                 | Full Year       |                      |                   | Comments           |                                                                                                                                                                                                                                                                       |
|-----------------------------------------------|-----------------|--------------------------|-------------------|------------------------|--------------------------|-----------------|-----------------|----------------------|-------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                               | 2013 YTD Actual | 2013 YTD Mid Year Update | 2013 YTD Budget   | 2012 YTD Actual        | 2013 YTD Mid Year Update | 2013 YTD Budget | 2012 YTD Actual | 2013 Mid Year Update | 2013 Budget       |                    | 2012 Actual                                                                                                                                                                                                                                                           |
| <i>Other Income (Expense):</i>                |                 |                          |                   |                        |                          |                 |                 |                      |                   |                    |                                                                                                                                                                                                                                                                       |
| Purdue Pharma Tech                            | \$ 1,245        | \$ 1,262                 | \$ 1,262          | \$ 2,147               | \$ (17)                  | \$ (17)         | \$ (902)        | \$ 1,683             | \$ 1,683          | \$ 2,689           | Purdue Pharma Tech (PP Tech) provides EHS, security and other services to Purdue at cost plus markup. PP Tech is consolidated in these financials - its margin is shown here.                                                                                         |
| Amortization expense - Dilaudid               | (1,864)         | (1,864)                  | (1,864)           | (1,864)                | -                        | -               | -               | (2,486)              | (2,486)           | (2,485)            | Balance represents amortization of marketing rights of Dilaudid acquired in 2007 and 2008 for approximately \$100 million which is being amortized over its estimated useful life of 40 years.                                                                        |
| Reversal of use tax                           | 271             | -                        | -                 | 307                    | 271                      | 271             | (36)            | -                    | -                 | 307                | Sales and use taxes are recorded automatically when invoices are processed. When tax should not have been charged, the tax is not paid and the credit is captured here.                                                                                               |
| Trust expenses                                | (129)           | (75)                     | (75)              | (203)                  | (54)                     | (54)            | 74              | (100)                | (100)             | (328)              | All remaining settlements have been paid out from the Qualified Settlement Trust (QST). The balance of the QST is expected to be returned to Purdue after clearing probate court in 2014. Administrative costs are expected to be incurred in 2014 to close the fund. |
| Norwell rent income (Totowa)                  | 563             | 563                      | 563               | 562                    | -                        | -               | 1               | 750                  | 750               | 749                |                                                                                                                                                                                                                                                                       |
| Purchase discounts                            | 711             | 525                      | 525               | 535                    | 186                      | 186             | 176             | 700                  | 700               | 898                |                                                                                                                                                                                                                                                                       |
| Depreciation - Norwell & Other                | (159)           | (166)                    | (166)             | (155)                  | 7                        | 7               | (4)             | (220)                | (220)             | (290)              | Primarily represents depreciation on Norwell.                                                                                                                                                                                                                         |
| Depreciation savings                          | -               | 750                      | 750               | -                      | (750)                    | (750)           | -               | 1,000                | 1,000             | -                  | Budget expected favorability (underspend) here.                                                                                                                                                                                                                       |
| Intermezzo milestone amortization / write off | -               | -                        | -                 | (735)                  | -                        | -               | 735             | -                    | -                 | (20,000)           | 2012 Actual balance represents write off of two \$10 million milestone payments made upon the Orange Book listings of Intermezzo patents. Amounts were written off in 2012 based on declining sales projections.                                                      |
| Targeted headcount reduction                  | -               | 1,125                    | -                 | -                      | -                        | -               | -               | -                    | -                 | -                  |                                                                                                                                                                                                                                                                       |
| President's reserve                           | (908)           | (2,175)                  | (4,425)           | -                      | 1,267                    | 3,517           | (908)           | (2,900)              | (5,900)           | -                  | 2013 year to date actual represents professional fees paid to McKinsey in connection with identifying growth opportunities for OxyContin.                                                                                                                             |
| Miscellaneous                                 | 29              | (311)                    | (153)             | 24                     | 340                      | 182             | 5               | 1,471                | (30)              | 819                |                                                                                                                                                                                                                                                                       |
| <b>Net Other Income (Expense)</b>             | <b>\$ (241)</b> | <b>\$ (366)</b>          | <b>\$ (3,583)</b> | <b>\$ 618</b>          | <b>\$ 1,250</b>          | <b>\$ 3,342</b> | <b>\$ (859)</b> | <b>\$ (102)</b>      | <b>\$ (4,603)</b> | <b>\$ (17,641)</b> |                                                                                                                                                                                                                                                                       |

## Headcount Summary

|                            | <u>September 2013 Actual</u> | <u>2013 Mid Year Update</u> | <u>Variance to Mid Year Update</u> | <u>2013 Budget</u> | <u>2012 Actual</u> |
|----------------------------|------------------------------|-----------------------------|------------------------------------|--------------------|--------------------|
| G&A                        | 366                          | 385                         | 19                                 | 382                | 365                |
| R&D                        | 339                          | 360                         | 21                                 | 360                | 334                |
| Marketing / Sales Support  | 77                           | 81                          | 4                                  | 87                 | 77                 |
| Field Sales                | 657                          | 671                         | 14                                 | 673                | 625                |
| Total S&P                  | 734                          | 752                         | 18                                 | 760                | 702                |
| Totowa                     | 16                           | 18                          | 2                                  | 18                 | 18                 |
| Supply Chain Operations    | 52                           | 55                          | 3                                  | 60                 | 57                 |
| Wilson                     | 191                          | 202                         | 11                                 | 201                | 187                |
| Total Technical Operations | 259                          | 275                         | 16                                 | 279                | 262                |
| President's Reserve        | -                            | 1                           | 1                                  | 3                  | -                  |
| Other                      | 4                            | 4                           | -                                  | -                  | 3                  |
| Total Headcount            | <u>1,702</u>                 | <u>1,777</u>                | <u>75</u>                          | <u>1,784</u>       | <u>1,666</u>       |

To: John Stewart  
From: Ed Mahony  
CC: [REDACTED]  
Jon Lowne, [REDACTED] Executive Committee  
Date: October 10, 2013  
Subject: September year-to-date 2013 financial results

Attached are the September year-to-date 2013 Purdue financial statements. Actual results are compared to the 2013 mid-year update, 2013 budget and 2012 actual results<sup>1</sup>.

### **NET SALES**

Net Sales for the nine months ending September were \$1,498.9 million - \$98.9 million lower than the same period last year and \$71.9 million or 4.6% under the mid-year update, primarily due to lower OxyContin sales.

An updated full year 2013 sales estimate was presented to the Board last week which showed 2013 expected net sales of \$1,987 million which is \$120 million lower than the mid-year update, \$423 million lower than budget and \$213 million lower than 2012.

### **OxyContin**

OxyContin net sales for the nine months ending September total \$1,337.0 million - \$62.7 million below the mid-year update and \$115.7 million lower than the same period last year. The variance versus the mid-year update is due to:

- a. Estimated OxyContin demand running approximately \$73.9 million lower than the mid-year update:
  - a. IMS reported demand in scripts and tablets is running approximately in line with mid-year update;
  - b. IMS reported demand, which was relied on to build the mid-year update and budget, was recently determined to be overstated by approximately 5.5%<sup>2</sup>.
- b. The contraction in OxyContin trade inventory through August is lower than anticipated in the mid-year update by \$12.6 million.

OxyContin operating margin for the nine months ending September 30 was \$1,205 million – 90.1% of net sales. This is \$256 million below budget due to lower sales.

- a. The actual nine month operating margin ratio is 75.3%.

**Redacted**

<sup>2</sup> Internal analysis has shown that the IMS script data on which the budget and mid-year update were based is consistently overstated by around 5.5%. Since this analysis was completed, we have learned that another opioid tablet manufacturer has reported the same phenomena. IMS has acknowledged the error percentage and will be correcting their projection method going forward. The 2013 effect of this data error is to reduce forecasted OxyContin gross sales by \$110 million.

- b. Patient co-pay savings card expense is 1.4% versus 0.8% of gross sales in the budget. This change is primarily due to opening the eVoucher program to include patients over 65 covered by commercial insurance (eligibility and limits are being updated and may reduce costs in 2014).

### **Butrans**

Butrans net sales for the nine months ending September were \$81.9 million --- \$16.6 million above the same period last year but \$11.3 million below the original 2013 budget. The sales shortfall is driven by lower trade inventory (\$9 million) and prescriptions running below budget (\$2.3 million).

Butrans operating margin for the nine months ending September was a loss of \$18 million. This loss was in line with budget as margins lost due to lower sales are being offset by delays in the Butrans pediatric spending and other reductions in R&D support. The BBU P&L does not include new product development costs such as higher dose and smaller patch.

The Butrans 15mcg strength commenced shipping on October 2nd and to date Purdue has received \$3 million in stocking orders.

### **Intermezzo**

Intermezzo net sales in 2013 are estimated at \$10.4 million versus budget of \$44 million.

Intermezzo operating margin for the nine months ending September was a loss of \$33.6 million. At this point investment in Intermezzo includes; (1) tertiary sales calls by Analgesic sales force, (2) 5 primary sales calls/month/rep to core Intermezzo prescribers, and (3) limited non-rep promotion. For the balance of the year we estimate that sales will remain relatively flat (\$10-\$11 million annual run rate) and before allocations the operating margin will be breakeven.

**Redacted**

Transcept has expressed an interest in buying out Purdue's interest in Intermezzo. We expect an offer shortly.

**Operating expenses**

Total operating expenses were \$628.0 million:

[ EMBED Excel.Sheet.12 ]

1. G&A spend through September 30, 2013 was \$112.4 million which is:
  - a. Lower than the 2013 mid-year update by \$6.4 million primarily due to: (1) \$2.6 million lower spend in External Affairs; (2) \$1.8 million lower spend in IT and (3) \$2.0 favorable spend across other departments.
  - b. In line with 2012.

2.

**Redacted**

3. R&D spend through September 30, 2013 was \$10.6 million lower than the mid-year update:

[ EMBED Excel.Sheet.12 ]

**Butrans**

Spend through September 30, 2013 is \$10.7 million below the mid-year update primarily due to lower clinical/nonclinical spend (pediatric/higher strengths) and lower people cost.

**OxyContin (primarily pediatric)**

Spend through September 30, 2013 is \$8.5 million below the mid-year update due to continued slow enrollment in pediatrics studies and a corresponding lower people cost.

### **All Other**

All Other consists of Risk Management, Marketing Support, Drug Safety and all other project/non-project spend not identified above. 2013 September year-to-date spend is \$6.4 million above the mid-year-update due to people costs not being allocated to Butrans and OxyContin due to lower spending on those projects not being allocated to the above projects.

R&D spend through September 30, 2013 was \$7.1 million lower than 2012 due to lower Butrans and OxyContin spend, primarily due to lower Butrans higher strength and OxyContin pediatric programs.

4. S&P spend through September 30, 2013 was \$210.0 million, which is:

- a. \$10.5 million lower than the mid-year update due to:
  - i. Lower Butrans and OxyContin promotional spend (\$4.7 million).
  - ii. Lower people driven expenses (\$3.8 million) primarily due to lower Q2 sales bonus (\$1.9 million) and vacancies.
  - iii. All other (\$1.9 million).
- b. \$26.1 million lower than budget due to lower:
  - i. OxyContin and Butrans promotional spend (\$8.5 million).
  - ii. People driven expenses (\$6.6 million) primarily due to lower Q1 and Q2 sales bonus (\$3.0 million) and vacancies (3.2%) in the Field Force.
  - iii. Contract Sales Organization (\$6.0 million) primarily driven by termination effective May 14, 2013.
  - iv. All other (\$4.9 million).
- c. \$13.1 million lower than prior year due to:
  - i. Lower Intermezzo direct to consumer advertising and promotional spend (\$1.9 million).
  - ii. Lower spending in Contract Sales organization (\$23.7 million) due to a reduction from 275 representatives in first half of 2012 to 90 through May 2013.
  - iii. Higher people driven expenses (\$7.2 million) primarily due to higher Q1 and Q2 sales bonus (\$3.7 million) and lower vacancies.
  - iv. All Other (\$5.3 million).

### **Pre-tax earnings**

Full year pre-tax earnings of \$660.9 million are:

- a. \$42.5 million lower than the mid-year update due to lower gross profit (\$60.4 million) on lower sales, higher incentives (\$8.6 million) due to the Better Medicine Awards offset by lower operating expenses (\$19.0 million) and lower ex-US expense of \$10.5 million due to Germany now projecting to break even versus a budgeted full year loss of \$15 million. The improved results are due to not having to fund Pearl and not making milestone payments.
- b. \$87.1 million lower than budget due to lower gross profit (\$275.3 million) on lower sales and higher ex-US expenses (\$20.4 million), offset by lower operating expenses (\$89.2 million) and the gain on Infinity stock (\$124.6 million).

- c. \$58.4 million higher than 2012 primarily due to lower gross profit (\$92.8 million) on lower sales, lower ex-US royalty income (\$28.8 million) and higher ex-US expenses (\$44.8 million) offset by the gain on Infinity stock (\$124.6 million).

### **Non-Tax Distributions**

Year-to-date partner non-tax distributions were \$399.9 million, made up of \$216.7 million of Infinity shares and \$183.2 million in cash, of which \$10 million was re-invested in Rhodes.

### **Working Capital Highlights**

#### **Cash and Short Term Investments**

At the end of September, unrestricted cash and short term investments totaled \$868 million --- which is \$23 million higher than the mid-year update. This temporary higher-than-forecast cash balance is due to timing of payments. Actual cash payments during the month included tax payments of \$97 million, the branded prescription drug fee (“Healthcare Reform Fee”) of \$28 million and \$12 million of ex-USA funding (Brazil, Japan, Malaysia, Singapore, and Mexico).

#### **Accounts Receivable**

1. The rolling 3 month average days sales outstanding (“DSO”) was 34.6 days at September 30, 2013 which is 0.4 days lower than our target of 35 days, and unchanged from August 31, 2013. Invoice collections remain strong at 99.9 % within 10 days of the due date. Bad debt write-offs year to date 2013 total \$3,900.
2. Open deductions totaled \$495,813 at September 30, 2013 or .002% of the total receivables versus \$555,706 at December 31<sup>st</sup>, 2012.
3. In all respects, we believe accounts receivable collections are excellent. We continue to watch Super Valu (balance at September 30 of \$136,700) – as they are restructuring their business, selling assets and are experiencing declining sales.

#### **Accounts Payable**

1. Payables at September 30, 2013 totaled \$28.7 million versus \$21.8 million at August 31, 2013. The monthly increase was caused by the timing of the last check run in each month.
2. The June 30, 2013 rebates Day’s Payable Outstanding (“DPO”) was 53.06 versus 52.73 days at December 31, 2012 a 0.33 day increase. The DPO for all other payments was 38.88 days at June 30, 2013 versus 38.84 days at December 31, 2012 an increase of 0.04 days. Fluctuations in the DPO can occur due to the mix of payment types. The DPO is measured semi-annually.
3. Early payment discounts of \$816,807 or 98.0% of those available were earned through September 30, 2013.

#### **Inventory levels**

1. At the end of September, Purdue is carrying \$69.0 million in inventory net of reserves. This balance has increased over prior year-end and September 2012 by \$18.4 million and \$13.6 million, respectively.

- a. \$18.4 million higher than prior year-end due to:
  - i. Higher Oxycodone API (\$15.4 million) primarily driven by accelerated receipts from Rhodes Technology which positioned them to free up labor and equipment capacity for new product validations.
  - ii. Higher Morphine Sulfate API (\$1.3 million) primarily driven by depleted 2012 year end levels.
  - iii. Higher finished goods for Dilaudid (\$0.9 million) and Slow-Mag (\$0.9 million) due to timing of 3rd party receipts.
- b. \$13.6 million higher than September 2012 due to higher Oxycodone API (\$14.5 million) primarily driven by accelerated receipts from Rhodes Technology which positioned them to free up labor and equipment capacity for new product validations.

2. Oxycodone comprises \$38.9 million of the \$69.0 million total inventory. Details are provided in the table below:

| Oxycodone              | Sep-13        |               | Sep-12        | Y/E 2012      |
|------------------------|---------------|---------------|---------------|---------------|
|                        | kg            | million S's   | million S's   | million S's   |
| Raw                    | 7,113         | \$23.0        | \$8.5         | \$7.6         |
| WIP                    | 1,339         | \$4.3         | \$1.9         | \$2.1         |
| Bulk                   | 1,124         | \$3.6         | \$3.9         | \$4.4         |
| FG                     | 2,473         | \$8.0         | \$9.5         | \$9.0         |
| <b>Total Oxycodone</b> | <b>12,050</b> | <b>\$38.9</b> | <b>\$23.8</b> | <b>\$23.1</b> |

*Higher YTD WIP balance (\$4.3 million) driven by timing of packaging 40mg and 80mg batches as evidenced in the lower YTD finished goods (\$8.0 million).*

3. At the end of September, the average MOH inventory level for OxyContin finished goods is ~ 2.0 months (based on projected sales). Details are as follows:

OxyContin - Months on Hand Inventory  
(100 count bottles only)

|             |             |             |             |             |             |             |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| <u>10mg</u> | <u>15mg</u> | <u>20mg</u> | <u>30mg</u> | <u>40mg</u> | <u>60mg</u> | <u>80mg</u> |
| 2.2         | 1.9         | 2.5         | 2.0         | 1.3         | 3.4         | 1.4         |

4. The current months on hand of 2.0 is lower than prior year-end of 2.1 and the target of 2.5 months. The variance versus target is driven by the timing of production.

**Headcount**

At the end of September, Purdue's headcount was 1,702 versus the mid-year update of 1,752. The variance of 50 includes 36 actively recruited positions - 8 with offers outstanding and 28 being actively recruited.

|    | A                                    | B                      | C               | D               | E               | F | G                        | H                | I             | J             | K               |
|----|--------------------------------------|------------------------|-----------------|-----------------|-----------------|---|--------------------------|------------------|---------------|---------------|-----------------|
| 1  |                                      | Year-to-date September |                 |                 |                 |   | Variance 2013 actual vs. |                  |               |               |                 |
| 2  | (million)                            | Mid-Year               |                 |                 |                 |   | Mid-Year                 |                  |               | 2013 Mid-Year |                 |
| 3  | G&A                                  | Actual                 | Update          | Budget          | Prior year      |   | Update                   | 2013 Budget      | 2012 Actual   |               | Update          |
| 3  |                                      | \$ 112.4               | \$ 118.8        | \$ 120.6        | \$ 112.1        |   | \$ (6.4)                 | \$ (8.2)         | \$ 0.3        |               | \$ 155.7        |
| 4  |                                      | <b>Redacted</b>        |                 |                 |                 |   |                          |                  |               |               |                 |
| 5  | R&D                                  | 225.4                  | 235.9           | 292.9           | 232.5           |   | (10.5)                   | (67.5)           | (7.1)         |               | 327.2           |
| 6  | R&D Other - Milestones and Alliances | 10.5                   | 10.0            | 5.0             | 1.6             |   | 0.5                      | 5.5              | 8.9           |               | 11.0            |
| 7  | S&P                                  | 210.0                  | 220.5           | 236.1           | 223.1           |   | (10.5)                   | (26.1)           | (13.1)        |               | 288.3           |
| 8  | New Health Care Reform Pharma Fee    | 22.7                   | 23.9            | 23.9            | 23.0            |   | (1.2)                    | (1.2)            | (0.3)         |               | 31.8            |
| 9  | Other - US                           | 0.3                    | 0.4             | 3.6             | (0.6)           |   | (0.1)                    | (3.3)            | 0.9           |               | 0.4             |
| 10 | <b>Total</b>                         | <b>\$ 628.0</b>        | <b>\$ 647.4</b> | <b>\$ 717.2</b> | <b>\$ 622.1</b> |   | <b>\$ (19.4)</b>         | <b>\$ (89.2)</b> | <b>\$ 5.9</b> |               | <b>\$ 860.3</b> |